SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CC(=O)[O-],BURN,_ACETATE,NCT01413620,Phase 1,Recruiting,All,"6 Months to 85 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Shriners Hospitals for Children, Galveston, Texas, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,OVARIAN CANCER,_EXEMESTANE,NCT04460807,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy|Ospedale Oncologico IRCCS Bari, Bari, BA, Italy|Ospedale degli Infermi, Biella, BI, Italy|AULSS 1 Dolomiti - Ospedale ""Santa Maria del Prato"", Feltre, BL, Italy|Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi, Bologna, BO, Italy|ASST degli Spedali Civili di Brescia, Brescia, BS, Italy|Fondazione Poliambulanza, Brescia, BS, Italy|Ospedale di Manerbio, Manerbio, BS, Italy|AOU Cagliari, Policlinico Universitario, Cagliari, CA, Italy|Ospedale Policlinico ""SS. Annunziata"", Chieti, CH, Italy|Azienda Sanitaria Locale CN2, Alba, CN, Italy|Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy|Ospedale di Mondovì CN1, Mondovì, CN, Italy|Ospedale Sant Anna di Como, Como, CO, Italy|ARNAS Garibaldi, Catania, CT, Italy|Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy|ASL 3 Ospedale Villa Scassi, Genova, GE, Italy|IRCCS AOU San Martino - IST, Genova, GE, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, LC, Italy|Ospedale ""Vito Fazzi"", Lecce, LE, Italy|UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy|Presidio Ospedaliero Unico Av3, Macerata, MC, Italy|Istituto Europeo di Oncologia (IEO), Milano, MI, Italy|AOU Policlinico di Modena, Modena, MO, Italy|A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Palermo, PA, Italy|Ospedale ""Guglielmo da Saliceto"", Piacenza, PC, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy|CRO Centro di Riferimento Oncologico, Aviano, PN, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy|Azienda Ospedaliera Regionale San Carlo, Potenza, PZ, Italy|Ospedale ""degli Infermi"", Faenza, RA, Italy|Ospedale ""Umberto I"", Lugo, RA, Italy|Ospedale Santa Maria delle Croci, Ravenna, RA, Italy|Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy|Policlinico Umberto I, Università di Roma ""La Sapienza"", Roma, RM, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, RM, Italy|ASST Valtellina e Alto Lario, Sondrio, SO, Italy|Azienda Ospedaliero Universitaria di Sassari, Sassari, SS, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, TO, Italy|AO Ordine Mauriziano, Torino, TO, Italy|Azienda Ospedaliero-Universitaria Città della Salute e della Scienza - Ospedale Ostetrico Ginecologico Sant'Anna, Torino, TO, Italy|Presidio Ospedaliero S. Andrea, Vercelli, VC, Italy|Medical Oncology Division, Ente Ospedaliero Ospedali Galliera, Genova, Italy|Istituto Nazionale Tumori - IRCCS ""Fondazione G.Pascale"", Napoli, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy",4808616,C07J1/0011,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,OVARIAN CANCER,_LETROZOLE,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",4978672,C07D213/57,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,OVARIAN CANCER,_METFORMIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6288095.0,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,OVARIAN CANCER,_ASPIRIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6015577,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,OVARIAN CANCER,_OLAPARIB,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",7151102,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,FRONTOTEMPORAL DEMENTIA,_PREDNISONE,NCT04408625,Phase 1|Phase 2,Recruiting,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Memory and Aging Center, 350 Parnassus Ave, Suite 706, San Francisco, California, United States|Mayo Clinic, 4500 San Pablo Road,, Jacksonville, Florida, United States|Bioclinica Orlando, 100 West Gore Street, Suite 202, Orlando, Florida, United States|University of Pennsylvania, The Penn FTD Center, 3 West Gates, Philadelphia, Pennsylvania, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,FRONTOTEMPORAL DEMENTIA,_METHYLPREDNISOLONE,NCT04408625,Phase 1|Phase 2,Recruiting,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Memory and Aging Center, 350 Parnassus Ave, Suite 706, San Francisco, California, United States|Mayo Clinic, 4500 San Pablo Road,, Jacksonville, Florida, United States|Bioclinica Orlando, 100 West Gore Street, Suite 202, Orlando, Florida, United States|University of Pennsylvania, The Penn FTD Center, 3 West Gates, Philadelphia, Pennsylvania, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,FRONTOTEMPORAL DEMENTIA,_SIROLIMUS,NCT04408625,Phase 1|Phase 2,Recruiting,All,"30 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Memory and Aging Center, 350 Parnassus Ave, Suite 706, San Francisco, California, United States|Mayo Clinic, 4500 San Pablo Road,, Jacksonville, Florida, United States|Bioclinica Orlando, 100 West Gore Street, Suite 202, Orlando, Florida, United States|University of Pennsylvania, The Penn FTD Center, 3 West Gates, Philadelphia, Pennsylvania, United States",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NEOPLASMS,_DOCETAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NEOPLASMS,_PACLITAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,SOFT TISSUE SARCOMA,_DOCETAXEL,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SOFT TISSUE SARCOMA,_GEMCITABINE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N=C(N)NCCC[C@H](N)C(=O)O,SOFT TISSUE SARCOMA,_ARGININE,NCT03449901,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Medicine, Palo Alto, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,GASTRIC CANCER,_DOCETAXEL,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,GASTRIC CANCER,_CAPECITABINE,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,GASTRIC CANCER,_EPIRUBICIN,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4950738.0,A61K41/0042,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,GASTRIC CANCER,_LEUCOVORIN,NCT01924819,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Geelong Hospital, Geelong, Victoria, Australia|Austin Hospital, Melbourne, Victoria, Australia|Monash Medical Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St Vincent's Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,GASTRIC CANCER,_NIRAPARIB,NCT04178460,Phase 1,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-Sen University Cancer Center, Guangzhou, China|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China|The University of Hong Kong, Queen Mary Hospital, Hong Kong, China|Sir Run Shaw Hospital, School Of Medicine ,Zhejiang University, Zhejiang, China",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PANCREATIC CANCER,_NIRAPARIB,NCT03601923,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,OVARIAN CANCER,_ENZALUTAMIDE,NCT03464201,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Mar, Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|Hospital Madrid Sanchinarro (CIOCC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital de Navarra, Pamplona, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital La Fe, Valencia, Spain",7709517,C07D233/70,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,OVARIAN CANCER,_CYCLOPHOSPHAMIDE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",3987166,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,OVARIAN CANCER,_FLUDARABINE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",7547776,C07H19/16,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,NEOPLASMS,_CYCLOPHOSPHAMIDE,NCT03967223,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,NEOPLASMS,_FLUDARABINE,NCT03967223,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,PANCREATIC CANCER,_CYCLOPHOSPHAMIDE,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,PANCREATIC CANCER,_LEUCOVORIN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,PANCREATIC CANCER,_IRINOTECAN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,PANCREATIC CANCER,_ALDOXORUBICIN,NCT04390399,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States|Hoag memorial Presbyterian Hospital, Newport Beach, California, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.26,750.758,267.84,15.0,7.0,6.0,75.89,189.86,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,STOMACH NEOPLASMS,_CAPECITABINE,NCT03675737,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128), Orange, California, United States|University of California at Los Angeles (UCLA) ( Site 0124), Santa Monica, California, United States|University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113), Miami, Florida, United States|Greater Baltimore Medical Center ( Site 0102), Baltimore, Maryland, United States|Minnesota Oncology Hematology, PA ( Site 8000), Minneapolis, Minnesota, United States|University of Rochester ( Site 0122), Rochester, New York, United States|Cancer Treatment Centers of America - Philadelphia ( Site 0112), Philadelphia, Pennsylvania, United States|Allegheny General Hospital ( Site 0118), Pittsburgh, Pennsylvania, United States|Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8001), Roanoke, Virginia, United States|Wenatchee Valley Clinic [Wenatchee, WA] ( Site 0116), Wenatchee, Washington, United States|Instituto de Investigaciones Metabolicas ( Site 0312), Buenos Aires, Argentina|Fundacion Favaloro - Hospital Universitario ( Site 0302), Buenos Aires, Argentina|Centro Oncologico Riojano Integral ( Site 0313), La Rioja, Argentina|Liverpool Hospital ( Site 2301), Liverpool, New South Wales, Australia|Southern Medical Day Care Centre ( Site 2303), Wollongong, New South Wales, Australia|Box Hill Hospital ( Site 2300), Box Hill, Victoria, Australia|Instituto do Cancer do Ceara ( Site 0407), Fortaleza, Ceara, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0403), Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0401), Rio de Janeiro, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0404), Sao Paulo, Brazil|BC Cancer - Abbotsford ( Site 0206), Abbotsford, British Columbia, Canada|Sunnybrook Research Institute ( Site 0202), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0203), Toronto, Ontario, Canada|McGill University Health Centre ( Site 0208), Montreal, Quebec, Canada|Instituto Clinico Oncologico del Sur ( Site 0500), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0501), Santiago, Region M. De Santiago, Chile|Sociedad Oncovida S.A. ( Site 0508), Santiago, Region M. De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 0502), Santiago, Region M. De Santiago, Chile|Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421), Beijing, Beijing, China|Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China|Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital ( Site 2414), Fuzhou, Fujian, China|900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China|The First Affiliated Hospital of Xiamen University ( Site 2430), Xiamen, Fujian, China|Guangdong General Hospital ( Site 2431), Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital ( Site 2401), Harbin, Heilongjiang, China|Henan Cancer Hospital ( Site 2415), Zhengzhou, Henan, China|Hubei Cancer Hospital ( Site 2434), Wuhan, Hubei, China|Xiangya Hospital Central-South University ( Site 2419), Changsha, Hunan, China|The 81st Hospital of PLA ( Site 2413), Nanjing, Jiangsu, China|Jiangsu Cancer Hospital ( Site 2432), Nanjing, Jiangsu, China|Yancheng First People s Hospital ( Site 2426), Yancheng, Jiangsu, China|The First Hospital of Jilin University ( Site 2416), Chang chun, Jilin, China|The Affiliated Hospital of Qingdao University ( Site 2405), Qingdao, Shandong, China|Shanghai East Hospital ( Site 2403), Shanghai, Shanghai, China|Zhongshan Hospital affiliated to Fudan University ( Site 2407), Shanghai, Shanghai, China|1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428), XiAn, Shanxi, China|Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420), Urumqi, Xinjiang, China|Sir Run Run Show Hospital ( Site 2427), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 2417), Hangzhou, Zhejiang, China|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0608), Valledupar, Cesar, Colombia|Oncomedica S.A. ( Site 0606), Monteria, Cordoba, Colombia|Instituto Nacional de Cancerologia E.S.E ( Site 0605), Bogota, Distrito Capital De Bogota, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0604), Cali, Valle Del Cauca, Colombia|CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica|Policlinico San Bosco ( Site 3002), San Jose, Costa Rica|ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica|FN Ostrava ( Site 3105), Ostrava, Moravskoslezsky Kraj, Czechia|Fakultni Thomayerova Nemocnice [Prague, Czech Republic] ( Site 3101), Praha 4, Czechia|Rigshospitalet ( Site 3202), Copenhagen, Hovedstaden, Denmark|Aalborg University Hospital ( Site 3204), Aalborg, Nordjylland, Denmark|Odense Universitets Hospital ( Site 3201), Odense, Syddanmark, Denmark|CHU-Jean Minjoz ( Site 1002), Besancon, Doubs, France|C.H.R.U. de Brest - Hopital Morvan ( Site 1007), Brest, Finistere, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1004), Saint-Herblain, Loire-Atlantique, France|Centre Oscar Lambret ( Site 1003), Lille, Nord, France|CHU de Rouen ( Site 1006), Rouen, Seine-Maritime, France|Institut Gustave Roussy ( Site 1000), Villejuif, Val-de-Marne, France|CHU Hopital Saint Antoine ( Site 1001), Paris, France|Celan SA ( Site 0705), Guatemala, Guatemala|Oncomedica ( Site 0702), Guatemala, Guatemala|Grupo Angeles SA ( Site 0701), Guatemala, Guatemala|Private Clinic ( Site 0704), Guatemala, Guatemala|Centro Regional de Sub Especialidades Medicas SA ( Site 0703), Quetzaltenango, Guatemala|Prince of Wales Hospital ( Site 2503), Hong Kong, Hong Kong|Princess Margaret Hospital. ( Site 2502), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 2501), Hong Kong, Hong Kong|Bacs-Kiskun Megyei Korhaz ( Site 3306), Kecskemet, Bacs-Kiskun, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 3302), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Beaumont Hospital ( Site 2101), Dublin, Ireland|St. James s Hospital ( Site 1200), Dublin, Ireland|Tallaght University Hospital ( Site 1202), Dublin, Ireland|Meir Medical Center ( Site 1308), Kfar Saba, Central, Israel|Soroka University Medical Center ( Site 1305), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 1304), Ramat Gan, Tel Aviv, Israel|Edith Wolfson Medical Center ( Site 1307), Holon, Tell Abib, Israel|Sourasky Medical Center ( Site 1306), Tel Aviv, Tell Abib, Israel|Hadassah Ein Karem Jerusalem ( Site 1301), Jerusalem, Yerushalayim, Israel|Rambam Medical Center ( Site 1303), Haifa, Israel|Rabin Medical Center ( Site 1302), Petah Tikva, Israel|Istituto Europeo di Oncologia ( Site 1411), Milano, Lombardia, Italy|Istituto Oncologico Veneto ( Site 1412), Padova, Italy|Aichi Cancer Center Hospital ( Site 2619), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 2617), Kashiwa, Chiba, Japan|Hyogo Cancer Center ( Site 2604), Akashi, Hyogo, Japan|Kobe City Medical Center General Hospital ( Site 2603), Kobe, Hyogo, Japan|Ibaraki Prefectural Central Hospital ( Site 2610), Kasama, Ibaraki, Japan|Kagawa University Hospital ( Site 2615), Kita-gun, Kagawa, Japan|Kitasato University Hospital ( Site 2618), Sagamihara, Kanagawa, Japan|Kanagawa Cancer Center ( Site 2614), Yokohama, Kanagawa, Japan|Kansai Medical University Hospital ( Site 2608), Hirakata, Osaka, Japan|Kindai University Hospital ( Site 2616), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 2600), Suita, Osaka, Japan|Saitama Cancer Center ( Site 2601), Kitaadachi-gun, Saitama, Japan|National Hospital Organization Kyushu Cancer Center ( Site 2612), Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2611), Hiroshima, Japan|Kumamoto University Hospital ( Site 2602), Kumamoto, Japan|Niigata Cancer Center Hospital ( Site 2613), Niigata, Japan|Osaka International Cancer Institute ( Site 2607), Osaka, Japan|National Cancer Center Hospital ( Site 2606), Tokyo, Japan|Tokyo Metropolitan Komagome Hospital ( Site 2605), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2609), Tokyo, Japan|Seoul National University Hospital ( Site 2803), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2800), Seoul, Korea, Republic of|Asan Medical Center ( Site 2802), Seoul, Korea, Republic of|Samsung Medical Center ( Site 2801), Seoul, Korea, Republic of|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0808), Guadalajara, Jalisco, Mexico|Christus Muguerza Clinica Vidriera ( Site 0802), Monterrey, Nuevo Leon, Mexico|Medical Care and Research S.A. de C.V. ( Site 0809), Merida, Yucatan, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0806), Ciudad de Mexico, Mexico|Instituto Nacional de Cancerologia. ( Site 0804), Mexico City, Mexico|Auckland City Hospital ( Site 2700), Auckland, New Zealand|Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0908), Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas ( Site 0901), Lima, Peru|Hospital Nacional Arzobispo Loayza ( Site 0902), Lima, Peru|Clinica San Gabriel ( Site 0907), Lima, Peru|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1506), Wroclaw, Dolnoslaskie, Poland|Dolnoslaskie Centrum Onkologii we Wroclawiu ( Site 1504), Wroclaw, Dolnoslaskie, Poland|Szpital Uniwersytecki w Krakowie ( Site 1503), Krakow, Malopolskie, Poland|Magodent Szpital Elblaska ( Site 1509), Warszawa, Mazowieckie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1500), Warszawa, Mazowieckie, Poland|Przychodnia Lekarska Komed ( Site 1514), Konin, Wielkopolskie, Poland|Regionalny Szpital Specjalistyczny im Wl. Bieganskiego w Grudziadzu ( Site 1505), Grudziadz, Poland|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1608), Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|Blokhin National Medical Oncology ( Site 1604), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1614), Moscow, Moskva, Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 1609), Samara, Samarskaya Oblast, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 1616), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 1603), Saint Petersburg, Sankt-Peterburg, Russian Federation|Cancer Care Langenhoven Drive Oncology Centre ( Site 1708), Port Elizabeth, Eastern Cape, South Africa|Universitas Annex National Hospital ( Site 1701), Bloemfontein, Free State, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 1700), Johannesburg, Gauteng, South Africa|Wits Clinical Research ( Site 1707), Parktown-Johannesburg, Gauteng, South Africa|Tshwane District Hospital ( Site 1702), Pretoria, Gauteng, South Africa|The Oncology Centre Overport and Umhlanga ( Site 1705), Durban, Kwazulu-Natal, South Africa|Cancercare Rondebosch Oncology ( Site 1709), Cape Town, Western Cape, South Africa|Groote Schuur Hospital ( Site 1706), Cape Town, Western Cape, South Africa|Outeniqua Cancercare Oncology Unit ( Site 1704), George, Western Cape, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 1703), Kraaifontein, Western Cape, South Africa|Hospital Universitario General de Asturias ( Site 1802), Oviedo, Asturias, Spain|Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 1806), Badalona, Barcelona, Spain|Hospital Universitario Marques de Valdecilla ( Site 1804), Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid ( Site 1805), Pozuelo de Alarcon, Madrid, Spain|Hospital General Universitari Vall d Hebron ( Site 1801), Barcelona, Spain|Universitaetsspital Basel ( Site 1900), Basel, Basel-Stadt, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1907), Geneva, Geneve, Switzerland|Kantonsspital Graubuenden ( Site 1903), Chur, Grisons, Switzerland|Kantonsspital St. Gallen ( Site 1901), St. Gallen, Sankt Gallen, Switzerland|Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1905), Bellinzona, Ticino, Switzerland|Universitaetsspital Zuerich ( Site 1902), Zuerich, Zurich, Switzerland|Luzern Kantonsspital ( Site 1904), Luzern, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 2902), Kaohsiung, Taiwan|National Cheng Kung University Hospital ( Site 2901), Tainan, Taiwan|National Taiwan University Hospital ( Site 2900), Taipei, Taiwan|Mackay Memorial Hospital ( Site 2903), Taipei, Taiwan|Adana Sehir Hastanesi ( Site 2002), Adana, Turkey|Hacettepe University Medical Faculty ( Site 2017), Ankara, Turkey|Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006), Ankara, Turkey|Trakya Universitesi Tip Fakultesi ( Site 2015), Edirne, Turkey|Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000), Erzurum, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001), Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011), Izmir, Turkey|Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009), Malatya, Turkey|Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012), Sakarya, Turkey|City Clinical Hosp.4 of DCC ( Site 2201), Dnipro, Dnipropetrovska Oblast, Ukraine|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2200), Kryviy Rih, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2204), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 2208), Kharkiv, Kharkivska Oblast, Ukraine|Clinic of National Cancer Institute ( Site 2203), Kyiv, Kyivska Oblast, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2213), Kyiv, Kyivska Oblast, Ukraine|Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2205), Kyiv, Kyivska Oblast, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2210), Lviv, Lvivska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 2212), Odesa, Odeska Oblast, Ukraine|Medical Centre LLC Oncolife ( Site 2202), Zaporizhzhya, Zaporizka Oblast, Ukraine|South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 1205), Torquay, Devon, United Kingdom|Castle Hill Hospital ( Site 1201), Cottingham, East Riding Of Yorkshire, United Kingdom|University College London Hospital ( Site 1211), London, London, City Of, United Kingdom|St. Georges University Hospital NHS Foundation Trust ( Site 1204), London, London, City Of, United Kingdom",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,SOFT TISSUE SARCOMA,_EVEROLIMUS,NCT03114527,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,SOFT TISSUE SARCOMA,_RIBOCICLIB,NCT03114527,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",8324225,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,ADVANCED PANCREATIC CANCER,_GEMCITABINE,NCT04098081,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Medical Center, Baltimore, Maryland, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,ADVANCED PANCREATIC CANCER,_GALETERONE,NCT04098081,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Medical Center, Baltimore, Maryland, United States",WO-2008154382-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,GASTRIC CANCER,_PACLITAXEL,NCT03801668,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,PANCREATIC CANCER,_PACLITAXEL,NCT04054362,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts Health NHS Trust, London, London, Greater, United Kingdom",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,PANCREATIC CANCER,_PARICALCITOL,NCT04054362,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts Health NHS Trust, London, London, Greater, United Kingdom",5246925,C07C401/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,GASTROINTESTINAL STROMAL TUMORS,_PACLITAXEL,NCT03944304,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Korea, Republic of",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,MYELODYSPLASTIC SYNDROME,_ENTINOSTAT,NCT02936752,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,NEUROENDOCRINE TUMORS,_ENTINOSTAT,NCT03211988,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N=C(N)NCCC[C@H](N)C(=O)O,GASTRIC CANCER,_ARGININE,NCT01704664,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Medical University of Bialystok, Bialystok, Podlaskie, Poland",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
NC(=O)CC[C@H](N)C(=O)O,GASTRIC CANCER,_GLUTAMINE,NCT01704664,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Medical University of Bialystok, Bialystok, Podlaskie, Poland",5288703.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,PANCREATIC CANCER,_LIDOCAINE,NCT04048278,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Illnois at Chicago, Chicago, Illinois, United States",5234957.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,PANCREATIC CANCER,_LIDOCAINE_HYDROCHLORIDE,NCT04048278,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Illnois at Chicago, Chicago, Illinois, United States",4091090,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,POMPE DISEASE,_LIDOCAINE,NCT02240407,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical and Translational Research Building (CTRB), University of Florida, Gainesville, Florida, United States",5234957.0,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,POMPE DISEASE,_ACETAMINOPHEN,NCT02240407,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical and Translational Research Building (CTRB), University of Florida, Gainesville, Florida, United States",5972916.0,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,POMPE DISEASE,_DIPHENHYDRAMINE,NCT02240407,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical and Translational Research Building (CTRB), University of Florida, Gainesville, Florida, United States",8263647,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,CYSTIC FIBROSIS,_TEICOPLANIN,NCT04176328,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,BETA-THALASSEMIA,_SIROLIMUS,NCT03877809,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, Ferrara, Italy|Department of Growth and Reproduction Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR,_OCTREOTIDE,NCT03972488,Phase 3,Recruiting,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sunnybrook Health Sciences Centre, Toronto, Canada|BC Cancer Agency, Vancouver, Canada|CHU Paris Nord-Val de Seine, Clichy, France|Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot, Lyon, France|Institut du Cancer de Montpellier - Oncology, Montpellier, France|Institut Gustave Roussy, Villejuif, France|A.O.di Bologna Policl.S.Orsola, Bologna, Italy|Istituto Oncologico Romagnolo, Meldola, Italy|IRCCS fondazione Pascale - Oncology, Napoli, Italy|Seoul National University Bundang Hospital, Seongnam-Si, Korea, Republic of|Seoul National University Hospital - Department of Internal, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System - Medical Oncology, Seoul, Korea, Republic of|Erasmus Medisch Centrum, Rotterdam, Netherlands|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Bristol Haematology and Oncology Centre, Bristol, United Kingdom",5538739.0,A61K38/31,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)NCC(O)COc1cccc2ccccc12,GASTRIC CANCER,_PROPRANOLOL,NCT04005365,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xiangya Hospital Central South University, Changsha, Hunan, China",6500454,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,MYELODYSPLASTIC SYNDROME,_SERTRALINE,NCT02452983,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States",4962128,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,MUCOSITIS,_FOLIC_ACID,NCT03581773,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aarhus University Hospital, Department of oncology, Aarhus, Central Region Of Denmark, Denmark|Department of Oncology, Herlev Hospital, Herlev, Denmark|Department of Oncology, Odense University Hospital, Odense, Denmark",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,AMYOTROPHIC LATERAL SCLEROSIS,_BIOTIN,NCT03427086,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","American univeristy of Beirut medical center, Beirut, Lebanon",3946115.0,A23K20/158,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.17,244.31099999999998,78.43,3.0,3.0,2.0,24.92,60.05,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,OVARIAN CANCER,_ANLOTINIB,NCT03924882,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",8148532,C07D239/88,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,SOFT TISSUE SARCOMA,_ANLOTINIB,NCT03890068,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,GASTROINTESTINAL STROMAL TUMORS,_ANLOTINIB,NCT04106024,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,ALZHEIMER DISEASE,_PERINDOPRIL,NCT02085265,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary, Calgary, Alberta, Canada|University of Lethbridge, Lethbridge, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Parkwood Institute, London, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada",5162362,C07K5/0222,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,106.482679315797,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.56,368.4678,95.94,5.0,2.0,2.0,39.99,95.69,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,ALZHEIMER DISEASE,_TELMISARTAN,NCT02085265,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary, Calgary, Alberta, Canada|University of Lethbridge, Lethbridge, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Parkwood Institute, London, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada",5591762,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,PANCREATIC CANCER,_AZACITIDINE,NCT01845805,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",4058602,C07H19/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,STOMACH NEOPLASMS,_SUNITINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,STOMACH NEOPLASMS,_IMATINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",5521184,C07D409/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,STOMACH NEOPLASMS,_GEFITINIB,NCT03170180,Phase 2,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,GASTROINTESTINAL STROMAL TUMORS,_SUNITINIB,NCT03673501,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of California San Diego Medical Center, La Jolla, California, United States|UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States|Stanford Medicine, Stanford, California, United States|University of Colorado Hospital - Anschutz Cancer Pavillion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Audubon Hospital Campus, Louisville, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, United States|Montefiore Medical Center-Montefiore Medical Park, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University Center for Health and Healing, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert Hospital-Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Sanatorio Allende, Córdoba, Cordoba, Argentina|Instituto Medicao Especializado Alexander Fleming, Buenos Aires, Argentina|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Princess Alexandara Hospital, Woolloongabba, Australia|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Québec, Canada|Clinica San Carlos de Apoquindo Red Salud UC Christs, Santiago, Chile|Fakultni nemocnice v Motole, Prague, Czechia|Institut Bergonnié, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille Cedex, France|Centre Léon Bérard, Lyon, France|Hopital La Timone, Marseille, France|IPC, Marseille, France|IGR, Paris, France|CHU Poitiers-Hopital la Miletrie, Poitiers, France|ICO - Site René Gauducheau, Saint Herblain, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Technische Universitat Dresden, Dresden, Germany|West German Cancer Center, Essen, Germany|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Israel|Rabin Medical Cente, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy|stituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Universita degli Studi di Palermo, Palermo, Italy|Università Campus Bio-Medico di Roma, Rome, Italy|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Antoni van Leeuwenhoek, Amsterdam, Netherlands|The Netherlands Cancer Institute, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Oslo University Hospital, Oslo, Norway|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|National Cancer Centre, Singapore, Singapore|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncología,, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Karolinska universitetssjukhuset, Solna, Sweden|Centre Hospitalier Universitaire Vaudois, Fondation du Centre Pluridisciplinaire d'Oncologi, Lausanne, Switzerland|Universitaetsspital Zuerich, Klinik fuer Onkologie, Zurich, Switzerland|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Kaohsiung Chang Gung Memorial Hospital,, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Chen Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Royal Marsden Hospital - Fulham, London, United Kingdom|University College London Hospitals, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,PANCREATIC NEUROENDOCRINE TUMORS,_SUNITINIB,NCT02282059,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Other|Time Perspective: Prospective,"Oncology Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China|Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|SUN Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|The Affiliated Tumour Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Nanjing General Hospital of Nanjing Military Command/Hepatobiliary Surgery Department, Nanjing, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Digestive surgery Department, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shannxi, China|West China Hospital of Sichuan University/Hepatobiliary Pancreatic Surgery, Chengdu, Sichuan, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Oncology department, Hangzhou, Zhejiang, China|The PLA of 307 Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Medical University General Hospital/General Surgery, Tianjin, China",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,MALARIA,_RUXOLITINIB,NCT04456634,Phase 1,Recruiting,All,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Nucleus Network Brisbane, Brisbane, Queensland, Australia",7598257,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,MALARIA,_RUXOLITINIB_PHOSPHATE,NCT04456634,Phase 1,Recruiting,All,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Nucleus Network Brisbane, Brisbane, Queensland, Australia",US-20080312259-A1,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,60.0,32.7488,16.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,GASTRIC CANCER,_DOXORUBICIN,NCT04358341,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jian Xiao, Guangzhou, Guangdong, China",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,GASTRIC CANCER,_IRINOTECAN,NCT04358341,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jian Xiao, Guangzhou, Guangdong, China",6403569,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,OVARIAN CANCER,_DOXORUBICIN_HYDROCHLORIDE,NCT04337632,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hunan Cancer Hospital, Changsha, Hunan, China",4003996,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C([O-])[O-].[Ca+2],OSTEOPOROSIS,_CALCIUM_CARBONATE,NCT04550078,Not Applicable,Recruiting,Female,"50 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Zealand University Hospital, Køge, Denmark",5989588,A61K33/10,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,ULCERATIVE COLITIS,_CURCUMIN,NCT02277223,Phase 3,Recruiting,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Schneider Medical Center, Petach Tikva, Israel",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CN(C)C(=N)NC(=N)N,FAMILIAL ADENOMATOUS POLYPOSIS,_METFORMIN,NCT01725490,Phase 2,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of|Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,PREECLAMPSIA,_METFORMIN,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",6288095.0,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,PREECLAMPSIA,_ESOMEPRAZOLE,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5900424,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,ALZHEIMER DISEASE,_ICOSAPENT,NCT02719327,Phase 2|Phase 3,Recruiting,All,"50 Years to 75 Years   (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",4377526.0,C07C67/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,14.0,15.310375983079698,4159.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.53,302.45099999999996,37.3,2.0,1.0,0.0,35.93,101.07,13.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,ALZHEIMER DISEASE,_ICOSAPENT_ETHYL,NCT02719327,Phase 2|Phase 3,Recruiting,All,"50 Years to 75 Years   (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",8188146,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,AMYOTROPHIC LATERAL SCLEROSIS,_DARUNAVIR,NCT02437110,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5843946,C07D239/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,AMYOTROPHIC LATERAL SCLEROSIS,_DOLUTEGRAVIR,NCT02437110,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5905082,C07D411/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,AMYOTROPHIC LATERAL SCLEROSIS,_RITONAVIR,NCT02437110,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5541206,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,AMYOTROPHIC LATERAL SCLEROSIS,_TENOFOVIR_ALAFENAMIDE,NCT02437110,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5814639,C07D411/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.49,476.474,143.48,7.0,2.0,3.0,47.88,122.74,12.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,AMYOTROPHIC LATERAL SCLEROSIS,_TENOFOVIR,NCT02437110,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",6057305,C07F9/65616,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(O)CCCC[C@@H]1CCSS1,AMYOTROPHIC LATERAL SCLEROSIS,_LIPOIC_ACID,NCT04518540,Not Applicable,Recruiting,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",4100150.0,C07K14/565,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,NONALCOHOLIC FATTY LIVER DISEASE,_FRUCTOSE,NCT01930123,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Duke University Medical Center, Durham, North Carolina, United States",WO-2006138705-A1,A23L7/1963 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,180.1559,110.38,6.0,5.0,1.0,16.29,36.36,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=c1[nH]cc(F)c(=O)[nH]1,GASTRIC CANCER,_FLUOROURACIL,NCT04379596,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Santa Monica, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, São José do Rio Preto, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Verona, Italy|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Gdańsk, Poland|Research Site, Konin, Poland|Research Site, Warszawa, Poland|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,PREECLAMPSIA,_PRAVASTATIN,NCT03648970,Phase 2,Recruiting,Female,"15 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Sanglah General Hospital, Denpasar, Bali, Indonesia|Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia|Ramelan Naval Hospital, Surabaya, East Java, Indonesia|Dr. Soetomo Hospital, Surabaya, East Java, Indonesia|Adam Malik General Hospital, Medan, North Sumatra, Indonesia|Dr. Wahidin Sudirohusodo General Hospital, Makasar, South Sulawesi, Indonesia|Hasan Sadikin General Hospital, Bandung, West Java, Indonesia",5622985.0,4,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,ALZHEIMER DISEASE,_MONTELUKAST,NCT03991988,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States|Executive Park, Atlanta, Georgia, United States|Wesley Woods, Atlanta, Georgia, United States",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"HEPATITIS B, CHRONIC",_MIDAZOLAM,NCT02952924,Phase 1,Recruiting,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Acibadem City Clinic Tokuda Hospital Ead, Sofia, Bulgaria|Nanfang Hospital, Southern Medical University, Guangzhou, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|The University of Hong Kong; Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Korea University Guro Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine, Asan Medical Center, Digestive Disease Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Seoul National University College of Medicine, Liver Research Institute, Seoul, Korea, Republic of|Middlemore Hospital, Auckland, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand|National University Health System, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Taichung Veterans Gen Hosp, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital - Linkou Branch, Taipei, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand",8217033,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,OVARIAN CANCER,_ROSUVASTATIN,NCT03532139,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",RE37314,C07D239/42 ,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CIRRHOSIS,_SIMVASTATIN,NCT02968810,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Cedars Sinai Medical Center, Los Angeles, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Puerto Rico, San Juan, Puerto Rico",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,MILD COGNITIVE IMPAIRMENT,_CANDESARTAN,NCT02646982,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Emory University, Atlanta, Georgia, United States|Wesley Woods Center, Atlanta, Georgia, United States",5605919,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PERIPHERAL NEUROPATHY,_CANDESARTAN,NCT03688633,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CHU Limoges, Limoges, France",5605919,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CCC[C@H]1c1cccnc1,MILD COGNITIVE IMPAIRMENT,_NICOTINE,NCT02720445,Phase 2,Recruiting,All,"55 Years to 90 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perseverance Research Center, Scottsdale, Arizona, United States|Central Arkansas Veterans Healthcare System, North Little Rock, Arkansas, United States|USC Rancho Los Amigos, Downey, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Western Connecticut Medical Group, Danbury, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Augusta University Movement and Memory Disorders, Augusta, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Acadia Hospital, Bangor, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Donald S. Marks, MD, PC, Plymouth, Massachusetts, United States|Bronson Lakeview Hospital, Kalamazoo, Michigan, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|University at Buffalo (UBMD), Buffalo, New York, United States|Clarity Clinical Research, East Syracuse, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Integrative Clinical Trials, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Central States Research (formerly Tulsa Clinical Research), Tulsa, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|LeHigh Valley Hospital, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Glenn Biggs Institute at the University of Texas Health, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington / VA Puget Sound, Seattle, Washington, United States|University of Washington Memory and Brain Wellness Center, Seattle, Washington, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",5656255.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,WILSON DISEASE,_BUPROPION,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5358970,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,WILSON DISEASE,_BUPROPION_HYDROCHLORIDE,NCT04526210,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",RE33994,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,ALZHEIMER DISEASE,_DEXMEDETOMIDINE,NCT04205539,Phase 1,Enrolling by invitation,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Westwood Open MRI, Los Angeles, California, United States|Neurological Associates of West Los Angeles, Santa Monica, California, United States",5344840,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,ANALGESIA,_DEXMEDETOMIDINE,NCT04442906,Not Applicable,Recruiting,All,21 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Zagazig university, Zagazig, Egypt",5344840,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,ANALGESIA,_FENTANYL,NCT04442906,Not Applicable,Recruiting,All,21 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Zagazig university, Zagazig, Egypt",6169920,A61N1/303,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,WILSON DISEASE,_CELECOXIB,NCT04526197,Phase 1,Enrolling by invitation,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Trial Site, Austin, Texas, United States",5972986.0,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,PANCREATIC CANCER,_LOSARTAN,NCT03563248,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Cancer Center, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Newton Wellesley Hospital, Newton, Massachusetts, United States|New York University Langone Medical Center, New York, New York, United States",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,ALZHEIMER DISEASE,_DASATINIB,NCT04063124,Phase 1|Phase 2,Recruiting,All,65 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,ALZHEIMER DISEASE,_QUERCETIN,NCT04063124,Phase 1|Phase 2,Recruiting,All,65 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States",4211772,C07H17/07,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,25.232550976406003,3241.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.81,302.2357,127.45,7.0,5.0,3.0,28.54,76.86,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,GASTRIC CANCER,_REGORAFENIB,NCT03627728,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,"CARCINOMA, HEPATOCELLULAR",_REGORAFENIB,NCT03347292,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Hospital and Clinics, Los Angeles, California, United States|University of Florida Health Sciences Center, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,SOFT TISSUE SARCOMA,_TRAMETINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,SOFT TISSUE SARCOMA,_DABRAFENIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,SOFT TISSUE SARCOMA,_LAPATINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",6391874,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,SOFT TISSUE SARCOMA,_NILOTINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,SOFT TISSUE SARCOMA,_PALBOCICLIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",6936612,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,SOFT TISSUE SARCOMA,_OLAPARIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,SOFT TISSUE SARCOMA,_CAPMATINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",WO-2008064157-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,72.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,412.42800000000005,85.07,5.0,1.0,5.0,42.1,125.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,SOFT TISSUE SARCOMA,_CERITINIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",7153964,C07D239/48,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,SOFT TISSUE SARCOMA,_GLASDEGIB,NCT03784014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",8148401,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,45.471159572065105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.68,374.448,96.84,4.0,3.0,4.0,40.98,108.26,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,MYELODYSPLASTIC SYNDROME,_VENETOCLAX,NCT02942290,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States|University of Chicago /ID# 153673, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 153669, Baltimore, Maryland, United States|Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 153671, Saint Louis, Missouri, United States|Weill Cornell Medical College /ID# 155524, New York, New York, United States|Columbia University Medical Center /ID# 153661, New York, New York, United States|Oregon Health and Science University /ID# 152734, Portland, Oregon, United States|University of Pittsburgh MC /ID# 153662, Pittsburgh, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 152738, Nashville, Tennessee, United States|UT MD Anderson Cancer Center /ID# 153809, Houston, Texas, United States|Concord Repatriation & Gen Hos /ID# 154958, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst /ID# 222846, Darlinghurst, New South Wales, Australia|St George Hospital /ID# 154954, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 222410, Liverpool, New South Wales, Australia|Calvary Mater Newcastle /ID# 154957, Waratah, New South Wales, Australia|Princess Alexandra Hospital /ID# 154990, Woolloongabba, Queensland, Australia|Austin Hospital /ID# 154955, Heidelberg, Victoria, Australia|Alfred Health /ID# 154956, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 222847, Murdoch, Western Australia, Australia|Juravinski Cancer Clinic /ID# 152947, Hamilton, Ontario, Canada|CHU Hotel Dieu /ID# 153828, Nantes CEDEX 1, Pays-de-la-Loire, France|Hopital Saint-Louis /ID# 153827, Paris, France|Universitatsklinikum Mannheim /ID# 153140, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Duesseldorf /ID# 222576, Dusseldorf, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 153141, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gus /ID# 153958, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 153142, Leipzig, Sachsen, Germany|Universitaetsklinikum Halle (S /ID# 153760, Halle, Germany|Klinikum Rechts der Isar /ID# 153139, Munich, Germany|A.O.U. Policlinico S.Orsola-Malpighi /ID# 153763, Bologna, Emilia-Romagna, Italy|Azienda Policlinico Umberto I /ID# 153764, Rome, Lazio, Italy|Norfolk and Norwich Univ Hosp /ID# 156492, Norwich, Norfolk, United Kingdom|Heart of England NHS Foundation Trust /ID# 158810, Birmingham, United Kingdom|King's College Hospital NHS /ID# 156489, London, United Kingdom|Churchill Hospital /ID# 222567, Oxford, United Kingdom",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,ALZHEIMER DISEASE,_DAPAGLIFLOZIN,NCT03801642,Phase 1|Phase 2,Recruiting,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,NONALCOHOLIC STEATOHEPATITIS,_DAPAGLIFLOZIN,NCT03723252,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,CYSTIC FIBROSIS,_TRIMETHOPRIM,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5763449.0,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,CYSTIC FIBROSIS,_MINOCYCLINE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5908838,6,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,CYSTIC FIBROSIS,_MUPIROCIN,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",6013657.0,3,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,CYSTIC FIBROSIS,_CHLORHEXIDINE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",5538353,A45D34/04,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CYSTIC FIBROSIS,_CHLORHEXIDINE_GLUCONATE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",4199567,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,CYSTIC FIBROSIS,_SULFAMETHOXAZOLE,NCT03489629,Phase 2,Recruiting,All,"2 Years to 45 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|N.C. Memorial Hospital and N.C. Children's Hospital, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States",3983209,A61L15/64,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,AMYOTROPHIC LATERAL SCLEROSIS,_DEXTROMETHORPHAN,NCT03883581,Phase 1|Phase 2,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States",5980882,A61K47/6903,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,AMYOTROPHIC LATERAL SCLEROSIS,_QUINIDINE,NCT03883581,Phase 1|Phase 2,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phil Smith Neuroscience Institute at Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States",RE38115,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,15.540360171666698,1608.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.82,94.69,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,PANCREATIC CANCER,_WARFARIN,NCT03536208,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",3932656,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,PREECLAMPSIA,_SILDENAFIL,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5250534.0,C07D487/04,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,PREECLAMPSIA,_SILDENAFIL_CITRATE,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",WO-1999030688-A1,A61K9/19,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,CYSTIC FIBROSIS,_SILDENAFIL,NCT04039087,Phase 2|Phase 3,Recruiting,All,"9 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","National Jewish Health, Denver, Colorado, United States|Augusta University, Augusta, Georgia, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,MYELODYSPLASTIC SYNDROME,_PYRIMETHAMINE,NCT03057990,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",4062940.0,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,AMYOTROPHIC LATERAL SCLEROSIS,_CAPSAICIN,NCT02962050,,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|NIH,Observational Model: Cohort|Time Perspective: Prospective,"University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States",6239180,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,PRADER-WILLI SYNDROME,_CANNABIDIOL,NCT03458416,Phase 2,Recruiting,All,8 Years to 17 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Research and Innovation   MultiCare Health System, Tacoma, Washington, United States",10195159,0,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,GASTRIC CANCER,_OLANZAPINE,NCT03575637,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Cancer Hospital & Institute, Beijing, China",5229382.0,C07D495/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,AMYOTROPHIC LATERAL SCLEROSIS,_COLCHICINE,NCT03693781,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Centro Sla, University of Bari, Bari, Italy|Centro Sla, Istituto Auxologico Italiano, University of Milano, Milano, Milano, Italy|Irccs Carlo Besta, Milano, Italy|Irccs St. Raffaele Institute of Milano, Milano, Italy|Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U. Modena, Modena, Italy|Università della Campania Gianluigi Vanvitelli, Napoli, Italy|Centro Sla, Universita' Di Padova, Padova, Italy|Als Centre, ""C. Mondino"" National Neurological Institute, University of Pavia, Pavia, Italy|, Neuromuscular Omnicentre Centre, Rome, Catholic University, Rome, Roma, Italy|Centro Sla, Universita' Di Torino, Torino, Italy",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,CYSTIC FIBROSIS,_CEPHALEXIN,NCT04553419,Phase 3,Recruiting,All,3 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BC Children's Hospital, Vancouver, British Columbia, Canada",3931404,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,7.0,25.0682765559867,1218.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,347.389,112.73,5.0,3.0,3.0,32.52,88.97,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,PANCREATIC CANCER,_FENTANYL,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",6169920,A61N1/303,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,PANCREATIC CANCER,_BUPIVACAINE,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",8182835.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)c1cccc(C(C)C)c1O,PANCREATIC CANCER,_PROPOFOL,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",5714520,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,PANCREATIC CANCER,_ROCURONIUM,NCT03434678,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",5962536,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,CHOLECYSTITIS,_ONDANSETRON,NCT04468685,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","The National Hepatology and Tropical Research medicine institute, Cairo, Egypt",5344658,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,ANALGESIA,_BUPIVACAINE,NCT03922048,Phase 2,Recruiting,All,3 Years to 16 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Plano Surgical Hospital, Plano, Texas, United States",8182835.0,1,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,ALZHEIMER DISEASE,_GUANFACINE,NCT03116126,Phase 3,Recruiting,All,"45 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Imperial Memory Unit, Charing Cross Hospital, London, United Kingdom",5854290,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,39.2615864802152,71.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.28,246.093,78.97,3.0,3.0,1.0,21.75,69.63,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,GASTROPARESIS,_PIOGLITAZONE,NCT04300127,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",4687777,C07D213/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,GASTRIC CANCER,_BLEOMYCIN,NCT04139070,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Surgery, Zealand University Hospital, Køge, Denmark",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,PREECLAMPSIA,_OXYTOCIN,NCT02221830,Early Phase 1,Recruiting,Female,"13 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States",3943246,A61K38/095,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,PRADER-WILLI SYNDROME,_OXYTOCIN,NCT03114371,Not Applicable,Recruiting,All,3 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Centre de référence du syndrome de Prader-Willi Hôpital des Enfants, Toulouse, France",3943246,A61K38/095,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,GASTRIC CANCER,_NEOSTIGMINE,NCT04205097,Not Applicable,Recruiting,All,"19 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Gyeonggido, Korea, Republic of",4439427,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,GASTRIC CANCER,_SUGAMMADEX,NCT04205097,Not Applicable,Recruiting,All,"19 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Gyeonggido, Korea, Republic of",7265099,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc(CC(C)N)c(OC)cc1C,GASTROPARESIS,_DOM,NCT03810287,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Digestive Diseases, New Haven, Connecticut, United States",WO-1998042331-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,GASTROPARESIS,_DOMPERIDONE,NCT03810287,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Digestive Diseases, New Haven, Connecticut, United States",4066772,C07D235/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,19.5815109139818,755.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,425.911,67.92,3.0,2.0,5.0,45.61,119.37,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,HEPATITIS B INFECTION,_SOFOSBUVIR,NCT03312023,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Human Virology (IHV), University of Maryland Baltimore, Baltimore, Maryland, United States",7964580,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,HEPATITIS B INFECTION,_LEDIPASVIR,NCT03312023,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Human Virology (IHV), University of Maryland Baltimore, Baltimore, Maryland, United States",7964580,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,38.9987474075443,17.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,5.98,888.9999,174.64,6.0,4.0,10.0,97.49,235.47,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CS(=O)(=O)O.Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1,CHRONIC HEPATITIS B,_PRADEFOVIR_MESYLATE,NCT04543565,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Hospital of Jilin University, Changchun, Jilin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.81,519.896,114.38,6.0,1.0,4.0,39.16,104.06,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
Nc1ncnc2c1ncn2CCOC[P@@]1(=O)OCC[C@@H](c2cccc(Cl)c2)O1,CHRONIC HEPATITIS B,_PRADEFOVIR,NCT04543565,Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Hospital of Jilin University, Changchun, Jilin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.7,423.79,114.38,6.0,1.0,4.0,39.12,104.06,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
OCC(O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,IRON DEFICIENCY ANEMIA TREATMENT,_ISOMALT,NCT03610230,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tung Wah Hospital, Hong Kong, Hong Kong",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,IRON DEFICIENCY ANEMIA TREATMENT,_SUCROSE,NCT03610230,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tung Wah Hospital, Hong Kong, Hong Kong",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],IRON DEFICIENCY ANEMIA TREATMENT,_IRON_SUCROSE,NCT03610230,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tung Wah Hospital, Hong Kong, Hong Kong",6174442,A23L5/273,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,EOSINOPHILIC ESOPHAGITIS,_FAMOTIDINE,NCT04248712,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic, Jacksonville, Florida, United States",5075114,A61K9/5047,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,EOSINOPHILIC ESOPHAGITIS,_LORATADINE,NCT04248712,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic, Jacksonville, Florida, United States",6132758.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,NEOPLASMS,_CRIZOTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",7230098,C07D413/12,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,NEOPLASMS,_ALECTINIB,NCT03194893,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",9126931,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,PANCREATIC CANCER,_APATINIB,NCT04415385,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,COLORECTAL CANCER,_APATINIB,NCT04446091,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Zhejiang Province Cancer Hospital, Hangzhou, Zhejiang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,OVARIAN CANCER,_TOPOTECAN,NCT03763123,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|The first affiliated hospital,sun yat-sen university, Guangzhou, Guangdong, China|the Affiliated Cancer Hospital of Harbin Medical University, Harbin, Hei Longjiang, China|Hunan Cancer Hospital, Changsha, Hunan, China|Wuhan Union Hospital, Wuhan, Hunan, China",5004758,C07D491/22,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,PANCREATIC CANCER,_TALAZOPARIB,NCT03637491,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas, California, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States|University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Horizon Oncology Research, LLC, Lafayette, Indiana, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Institut Jules Bordet, Brussels, Belgium|UZ Gent, Gent, Belgium|Singapore National Eye Centre, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|SingHealth Investigational Medicine Unit, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",8012976,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,PANCREATIC CANCER,_BINIMETINIB,NCT03637491,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Highlands Oncology Group, Springdale, Arkansas, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas, California, United States|California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States|University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Horizon Oncology Research, LLC, Lafayette, Indiana, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Institut Jules Bordet, Brussels, Belgium|UZ Gent, Gent, Belgium|Singapore National Eye Centre, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|SingHealth Investigational Medicine Unit, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",7777050,C07D235/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,END STAGE RENAL DISEASE,_EMPAGLIFLOZIN,NCT03713190,Phase 2,Recruiting,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy",6303661,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,SOFT TISSUE SARCOMA,_PIRARUBICIN,NCT04126811,Phase 2,Recruiting,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China",4818818,C07H15/252,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,29.14228218238561,628.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,627.643,204.3,13.0,5.0,6.0,64.85,157.38,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1,AMYOTROPHIC LATERAL SCLEROSIS,_TOCOTRIENOL,NCT04140136,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Investigation Centre (CIC), Kuala Lumpur, Malaysia",US-20070293449-A1,A61K9/1272 ,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.68,382.5787,29.46,2.0,1.0,2.0,48.12,122.8,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,HIV INFECTION,_EPLERENONE,NCT02740179,Not Applicable,Recruiting,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",6410524,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,GASTROINTESTINAL STROMAL TUMORS,_AXITINIB,NCT04258956,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maria Sklodowska-Curie National Research Institue of Oncology, Warsaw, Poland",6534524,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,16.7231359986858,54.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.17,386.47,70.67,3.0,2.0,4.0,42.58,115.14,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
O=c1[nH]c(=O)n(C2CCCO2)cc1F,GASTRIC CANCER,_TEGAFUR,NCT03006705,Phase 3,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anhui Province Clinical Site, Anhui Province, China|Beijing Clinical Site1, Beijing, China|Beijing Clinical Site2, Beijing, China|Cuangdong Province Clinical Site, Cuangdong Province, China|Guangdong Province Clinical Site1, Guangdong, China|Guangdong Province Clinical Site2, Guangdong, China|Henan Province Clinical Site1, Henan, China|Henan Province Clinical Site2, Henan, China|Jiangsu Province Clinical Site1, Jiangsu Province, China|Jiangsu Province Clinical Site3, Jiangsu Province, China|Jiangsu Province Clinical Site4, Jiangsu Province, China|Jiangsu Province Clinical Site5, Jiangsu Province, China|Jiangxi Province Clinical Site2, Jiangxi, China|Jilin Province Clinical Site, Jilin, China|Shanghai Clinical Site2, Shanghai, China|Shanxi Province Clinical Site, Shanxi, China|Tianjin Clinical Site1, Tianjin, China|Tianjin Clinical Site2, Tianjin, China|Zhejiang Province Clinical Site, Zhejiang, China|Zhengjiang Province Clinical Site, Zhengjiang Province, China|Aichi Clinical Site1, Nagoya, Aichi, Japan|Aichi Clinical Site2, Nagoya, Aichi, Japan|Chiba Clinical Site, Kamogawa, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Ehime Clinicla Site, Matsuyama, Ehime, Japan|Gifu Clinical Site, Ōgaki, Gifu, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Takasaki, Gunma, Japan|Hiroshima Clinical Site, Fukuyama, Hiroshima, Japan|Hokkaido Clinical Site 3, Hakodate, Hokkaido, Japan|Hokkaido Clinical Site 1, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Ishikawa Clinical Site, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Miyagi Clinical Site, Osaki, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Okayama Clinical Site, Kurashiki, Okayama, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Osaka Clinical Site, Ōsaka-sayama, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Chiba Clinical Site, Chiba, Japan|Fukuoka Clinical Site 1, Fukuoka, Japan|Fukuoka Clinical Site 2, Fukuoka, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site1, Hiroshima, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site3, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Osaka Clinical Site1, Osaka, Japan|Osaka Clinical Site2, Osaka, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site4, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamagata Clinical Site, Yamagata, Japan|Busan Clinical Site1, Busan, Korea, Republic of|Busan Clinical Site2, Busan, Korea, Republic of|Busan Clinical Site3, Busan, Korea, Republic of|Daegu Clinical Site1, Daegu, Korea, Republic of|Daegu Clinical Site2, Daegu, Korea, Republic of|Daegu Clinical Site3, Daegu, Korea, Republic of|Daejeon Clinical Site 1, Daejeon, Korea, Republic of|Daejeon Clinical Site 2, Daejeon, Korea, Republic of|Gwangju Clinical Site, Gwangju, Korea, Republic of|Gyeonggi-do Clinical Site1, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site2, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site3, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site4, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site5, Gyeonggi-do, Korea, Republic of|Jeollabuk-do Clinical Site, Jeollabuk-do, Korea, Republic of|Seoul Clinical Site 8, Seoul, Korea, Republic of|Seoul Clinical Site 9, Seoul, Korea, Republic of|Seoul Clinical Site1, Seoul, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site7, Seoul, Korea, Republic of|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|New Taipei Clinical Site, New Taipei, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site2, Tainan, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site1, Taipei, Taiwan|Taipei Clinical Site2, Taipei, Taiwan",3948897,C07D405/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,29.897944516314503,918.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.09,200.169,58.64,3.0,1.0,2.0,17.52,44.5,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,SOFT TISSUE SARCOMA,_TRABECTEDIN,NCT02367924,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Other|Time Perspective: Prospective,"Dokusan GmbH und Co. KG; Praxisklinik Herne / Onkologie, Herne, Nordrhein-Westfalen, Germany|MVZ Marien-Hospital-Wesel GmbH, Wesel, Nordrhein-Westfalen, Germany|Onkologische Gemeinschaftspraxis Dr. med. Mohm & Dr. med. Prange-Krex, Dresden, Sachsen, Germany|Praxis Dr. med. Jens Uhlig, Naunhof, Sachsen, Germany|Praxis für Innere Medizin, Hämatologie u. Onkologie, Bremen, Germany",8895557,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,ALZHEIMER DISEASE,_DRONABINOL,NCT02792257,Phase 2,Recruiting,All,"60 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Miami Jewish Health, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States",6703418.0,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,"HEPATITIS B, CHRONIC",_RIBAVIRIN,NCT03759782,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada",6172046,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,OVARIAN CANCER,_ZAFIRLUKAST,NCT04339140,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",4859692,C07D249/18,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
FC(F)(F)C(F)(F)C(F)(F)F,HEPATOCELLULAR CARCINOMA|LIVER CANCER,_PERFLUTREN,NCT03199274,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",6723303,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
FS(F)(F)(F)(F)F,CIRRHOSIS,_SULFUR_HEXAFLUORIDE,NCT03407001,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"M D Anderson Cancer Center, Houston, Texas, United States",5686060,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,11.0,31.0150105751658,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,146.05,0.0,0.0,0.0,0.0,7.11,18.44,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,PSORIATIC ARTHRITIS,_TOFACITINIB,NCT03486457,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University/Rheumatology Department, Hefei, Anhui, China|Peking University First Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Army Medical University, PLA, Chongqing, Chongqing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China|The Third Hospital of Hebei Medical University, Rheumatology and Immunology Department, Shijiazhuang, Hebei, China|Rheumatology Department, The first Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Zhuzhou Central Hospital, Zhuzhou, Hunan, China|The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Department of Rheumatology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, China|Department of Rheumatology ,The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Department of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|Jiu Jiang No.1 People's Hospital, Jiujiang, Jiangxi, China|Pingxiang People's Hospital, Pingxiang, Jiangxi, China|The First hospital of Jilin University, Changchun, Jilin, China|Linyi People's Hospital, Linyi, Shandong, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Department of Rheumatology and Immunology,West China Hospital，Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Rheumatology and Immunology Department, Tianjin, Tianjin, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hosptial of Wenzhou Medical University, Wenzhou, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University, Beijing, China|Huashan Hospital, Fudan University, Shanghai, China|Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China",7301023,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,FAMILIAL ADENOMATOUS POLYPOSIS,_NICLOSAMIDE,NCT04296851,Phase 2,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",4283400,A23K10/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,319.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.49,327.12,95.15,4.0,2.0,2.0,28.47,80.51,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,FUNCTIONAL DYSPEPSIA,_KETOTIFEN,NCT02484248,Phase 3,Recruiting,All,8 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Children's Mercy Hospital, Kansas City, Missouri, United States",4232002,A61K9/0078,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0
O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1,PRIMARY SCLEROSING CHOLANGITIS,_CILOFEXOR,NCT03890120,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Institute For Liver Health, Chandler, Arizona, United States|The Institute for Liver Heath, Phoenix, Arizona, United States|Southern California Research Center, Coronado, California, United States|Altman Clinical and Translational Research Institute (Clinic), La Jolla, California, United States|Scripps Clinic/Green Hospital, La Jolla, California, United States|Ruane Clinical Research Group Inc., Los Angeles, California, United States|Stanford Hospital, Palo Alto, California, United States|California Liver Research Institute, Pasadena, California, United States|University of California, Davis Medical Center (study visits), Sacramento, California, United States|Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco, California, United States|University of California, San Francisco Liver Clinic, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|University of Colorado Denver and Hospital, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Advanced Research Institute, Inc, New Port Richey, Florida, United States|Advanced Medical Research Center, Port Orange, Florida, United States|Florida Research Institute, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center (outpatient clinic), Chicago, Illinois, United States|NorthShore University Healthsystem, Evanston, Illinois, United States|IU Health University Hospital, Indianapolis, Indiana, United States|University of Kansas Hospital, Kansas City, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|Michigan Medicine - University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Gastroenterology, PA, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research LLC, Jackson, Mississippi, United States|Saint Louis University, Gastroenterology & Hepatology, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Rutgers New Jersey Medical School - Doctors Office Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Northwell Health Center for Liver Diseases and Transplantation, Manhasset, New York, United States|NYU Langone Health, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The University of NC at Chapel Hill, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States|Carolinas Medical Center - Center for Liver Disease, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Holmes Hospital, Cincinnati, Ohio, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Rapid City Medical Center, LLP, Rapid City, South Dakota, United States|Gastro One, Germantown, Tennessee, United States|Methodist University Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Annette & Harold C. Simmons Transplant Institute @ Baylor University Medical Center at Dallas, Dallas, Texas, United States|Baylor Scott & White Medical Center at Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Spring Gastroenterology Associates, Humble, Texas, United States|Intermountain Medical Center - Transplant Services, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Verity Research Inc., Fairfax, Virginia, United States|Bon Secours Richmond Community Hospital, Richmond, Virginia, United States|Virginia Commonwealth University Clinical Research Services Unit, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Liver Institute Northwest, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Nepean Hospital, Penrith, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Coral Sea Clinical Research Institute - Mackay, Auchenflower, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Misericordiae Ltd, South Brisbane, Queensland, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Landeskrankenanstalten-Betriebsgesellscaft - KABEG, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria|Allgemeines Krankenhaus Wien, Vienna, Austria|Hôpital Erasme - ULB, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Algemeen Ziekenhuis Maria Middelares, Ghent, Belgium|Centre Hospitalier Universitaire de Liège Site Sart Tilman, Liege, Belgium|William Osler Health System - Brampton Civic Hospital, Brampton, Canada|University of Calgary Liver Unit - Heritage Medical Research Clinic (HMRC), Calgary, Canada|University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre (WMC), Edmonton, Canada|Queen Elizabeth II Health Sciences Centre, Nova Scotia Health Authority, Halifax, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Canada|McMaster University Medical Center, Hamilton, Canada|Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada|Chronic Viral Illness Service/McGill University Health Centre (MUHC), Montreal, Canada|Toronto General Hospital - Toronto Centre for Liver Disease (TCLD), Toronto, Canada|Toronto Liver Centre, Toronto, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, UBC Division of Gastroenterology, Vancouver, Canada|(G.I.R.I.) GI Research Institute, Vancouver, Canada|University of Manitoba/Health Sciences Centre, Winnipeg, Canada|Aalborg University Hospital, Aalborg, Denmark|Copenhagen University Hospital - Hvidovre, København Ø, Denmark|Helsinki University Hospital, Endoscopy Unit, Gastroenterology Outpatient clinic, Meilahden tomisairaala, Helsinki, Finland|Turku University Hospital, Gastroenterology Outpatient Clinic, Turku, Finland|Hôpital Saint-Eloi, Montpellier cedex 5, Herault, France|CHU Amiens-Picardie Hôpital Sud, Amiens, France|Hôpital Henri Mondor, Creteil, France|CHU Grenoble Alpes, Grenoble cedex 09, France|Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille, France|Hôpital Saint-Joseph, Marseille, Cedex 8, France|Hopital Saint Antoine, Paris, France|CHU Bordeaux-Hopital Haut-Leveque, Pessac, France|Hopital Robert Debré - Centre Hospitalier Universitaire de Reims, Reims, France|CHU de Strasbourg - Nouvel Hôpital Civil, Strasbourg, France|CHU de Toulouse Hopital Ranguiel, Toulouse cedex, France|CHU de Toulouse - Hopital Rangueil, Toulouse, France|Hopital Paul Brousse, Villejuif, France|GASTRO-Studien GbR, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Medizinische Hochscule Hannover, Hannover, Germany|Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Klinik für Innere Medizin II, Gastroenterologie und Hepatologie, Homburg, Germany|Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Germany|Universitätsmedizin Mannheim, II. Medizinische Klinik, Mannheim, Germany|Emek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Dipartimento Gastroenterologico e dei Trapianti, Ancona, Italy|Ca'Granda Ospedale Maggiore Policlinico UOC Gastroenterologia ed Epatologia, Milan, Italy|Medicina Interna 1, Novara, Italy|Azienda Ospedaliera Universitaria Policlinico P. Giaccone, Palermo, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy|U.O.C. Gatroenterologia, Rozzano, Italy|IRCCS Ospedale Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Chiba University Hospital, Chiba-shi, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan|Okayama University Hospital, Okayama, Japan|National University Corporation Tohoku University Tohoku University Hospital, Sendai, Japan|Osaka University Hospital, Suita, Japan|Juntendo University Hospital, Tokyo, Japan|Teikyo University Hospital, Tokyo, Japan|Ehime University Hospital, Tōon, Japan|Yamagata University Hospital, Yamagata, Japan|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Ramon y cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari Politecnic La Fe de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Universitatsspital Bern, Bern, Switzerland|Epatocentro Ticino SA, Lugano, Switzerland|Universitatsspital Zurich, Zurich, Switzerland|University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,5.36,586.85,108.92,7.0,2.0,6.0,56.81,148.43,7.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,PREECLAMPSIA,_SALSALATE,NCT03482440,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of Iowa, Iowa City, Iowa, United States|Pennsylvania State University, University Park, Pennsylvania, United States",3954533,C06B23/007,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,NON-ALCOHOLIC FATTY LIVER DISEASE,_SORBITOL,NCT04330326,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Koç University Hospital, Istanbul, Turkey",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.12,38.4,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,ALZHEIMER DISEASE,_GENISTEIN,NCT01982578,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitat de València, Valencia, Spain|Hospital General Universitario, Valencia, Spain",5213971,C12N15/76,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,FRIEDREICH ATAXIA,_RESVERATROL,NCT03933163,Phase 2,Recruiting,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal North Shore Hospital, St Leonards, New South Wales, Australia|University of Queensland Centre for Clinical Research, Herston, Queensland, Australia|Murdoch Children's Research Institute, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia",5747536,0,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,MAJOR DEPRESSIVE DISORDER,_BIA,NCT04137367,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Psychology, Oslo, Norway",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCCCCC/C=C/CCCCCCCC(=O)O,CYSTIC FIBROSIS,_OLEIC_ACID,NCT04531410,Not Applicable,Enrolling by invitation,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Università degli Studi di Milan, Milan, Italy|Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway|Poznan University of Medical Sciences, Poznań, Poland",3937674,C09D11/108,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,40.7072013799051,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.68,282.4614,37.3,2.0,1.0,0.0,37.64,87.4,15.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,CYSTIC FIBROSIS,_LINOLEIC_ACID,NCT04531410,Not Applicable,Enrolling by invitation,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Università degli Studi di Milan, Milan, Italy|Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway|Poznan University of Medical Sciences, Poznań, Poland",3932476,C07C231/02,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,NON ALCOHOLIC STEATOHEPATITIS,_HESPERIDIN,NCT03734510,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Nutrition and Food Technology Research Institute, Tehran, Iran (the Islamic Republic Of), Iran, Islamic Republic of",4078137,C07H17/07,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,22.012772336187602,842.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.27,610.5606,234.29,15.0,8.0,5.0,58.76,140.77,7.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0
CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O,NON-ALCOHOLIC FATTY LIVER DISEASE,_OBETICHOLIC_ACID,NCT03836937,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Hepatology, Dhaka, Bangladesh",7138390,C07C215/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,56.9703690014168,9.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.5,420.6252,77.76,4.0,3.0,4.0,49.74,118.35,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[N@+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,PANCREATIC CANCER,_METHYLNALTREXONE,NCT04083651,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Bausch Site 001, Omaha, Nebraska, United States",6559158,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,43.0,31.2778496478367,15.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.59,356.441,66.76,4.0,2.0,6.0,38.04,107.42,2.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,AMYOTROPHIC LATERAL SCLEROSIS,_FASUDIL,NCT03792490,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Center Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|University of Würzburg, Würzburg, Germany",4283400,A23K10/20,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,435.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.16,291.369,62.3,4.0,1.0,3.0,29.6,77.92,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,GASTRO ESOPHAGEAL REFLUX,_HYALURONIC_ACID,NCT04202692,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Diakonie Klinikum GmbH - Jung- Stilling Krankenhaus, Siegen, Nordrhein-Westfalen, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=[Si]([O-])O[Si]([O-])([O-])O[Si](=O)[O-].[Mg+2].[Mg+2],GASTRO ESOPHAGEAL REFLUX,_MAGNESIUM_TRISILICATE,NCT04202692,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Diakonie Klinikum GmbH - Jung- Stilling Krankenhaus, Siegen, Nordrhein-Westfalen, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.7,260.857,144.84,6.0,0.0,0.0,11.91,11.36,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1c(O)c(=O)ccn1C,AMYOTROPHIC LATERAL SCLEROSIS,_DEFERIPRONE,NCT03293069,Phase 2|Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hôpital Roger Salengro, CHU, Lille, France",7049328,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,58.810242510113106,75.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.6,139.1519,40.54,3.0,1.0,1.0,14.05,40.7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,OVARIAN CANCER,_BRIVANIB,NCT03895788,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jing Wang, Changsha, Hunan, China",US-20040072832-A1,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,20.1400439434074,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.32,370.384,84.67,4.0,2.0,4.0,37.82,110.02,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,GASTROPARESIS|DIABETES MELLITUS,_RELAMORELIN,NCT03420781,Phase 3,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pinnacle Research Group, Anniston, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|Simon Williamson Clinic, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|Synexus Clinical Research US, Inc., Fountain Hills, Arizona, United States|Central Arizona Medical Associates, Mesa, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Adobe Clinical Research LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|Preferred Clinical Research Partners, Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|HCP Clinical Research LLC, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Citrus Valley Gastroenterology Clinic, Covina, California, United States|Diagnamics Inc., Encinitas, California, United States|Fresno Clinical Research Center, Fresno, California, United States|VVCRD Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|Stanford Hospital, Palo Alto, California, United States|TriWest Research Associates, Poway, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Optimal Research California, San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Care Access Research, San Pablo, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Synexus Clinical Research, US, Santa Rosa, Santa Rosa, California, United States|Upland Clinical Research, Upland, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|New Hope Research Development, Whittier, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Synexus, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|Visionary Investigators Network, Aventura, Florida, United States|Gastro Florida, Clearwater, Florida, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Florida, College of Medicine Dept. of Gastroenterology, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Panax Clinical Research, LLC., Miami Lakes, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|Sanchez Clinical Research, Inc., Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Top Medical Research, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|Synexus, Pinellas Park, Florida, United States|University of South Florida, Tampa, Florida, United States|Gastro Florida, Tampa, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Synexus Clinical Research US, Inc ., Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Gastroenterology of Southern Indiana, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Integrated Clinical Trial Services Inc, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|Gastroenterology Associates of Hazard, Hazard, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Silverman, Bowie, Maryland, United States|Capital Diabetes and Endocrine Associates, Camp Springs, Maryland, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Coastal Research Associates, Inc., South Weymouth, Massachusetts, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Biocon Clinical Research, LLC, Caro, Michigan, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Troy Gastroenterology, PC dba Center for Digestive Health, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Minnesota Gastroenterology, P.A., Coon Rapids, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|National Diabetes and Obesity Research Institute - Gen1 Research, Biloxi, Mississippi, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc., Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Methodist Physicians Clinic Diabetes and Endocrine Specialists, Omaha, Nebraska, United States|Heartland Clinical Research, Inc', Omaha, Nebraska, United States|Synexus Clinical Research, Henderson, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Las Vegas Gastroenterology, Las Vegas, Nevada, United States|Clinical Research of South Nevada - CROSN, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology, Brick, New Jersey, United States|Synexus Clinical Research US, Inc., Bridgeton, New Jersey, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|USMA Clinical Research, LLC, Elizabeth, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|CHEAR Center LLC, Bronx, New York, United States|Trialspark - Silverman, Forest Hills, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Queens Hospital Center, Jamaica, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|NYU Winthrop Hospital, Clinical Trials Center, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, PA, Concord, North Carolina, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Vidant Multispeciality Clinic - Kinston, Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc., Cincinnati, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc. DBA New Venture Medical Research, Wadsworth, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Partners in Clinical Research, LLC, Cumberland, Rhode Island, United States|Care Access Research, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Medical Research South, Charleston, South Carolina, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Synexus Clinical Research, Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastroenterology Centers of the Midsouth, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Avant Research Associates,LLC, Austin, Texas, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|Texas Tech University Health Sciences, Center Division of Gastroenterology, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|DHAT Research Institute, Garland, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Pri-Med Care, Lewisville, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Southern Star Research Institute, LLC, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Dwayne O. Williams MD, Sugar Land, Texas, United States|Synexus Clinical Research US, Inc., Layton, Utah, United States|Synexus Clinical Research US, Inc., Murray, Utah, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Gastroenterology Consultants of Southwest Virginia, Inc., Roanoke, Virginia, United States|Cardinal Internal Medicine Associates, PC, Woodbridge, Virginia, United States|MultiCare Institute for Research & Innovation, Spokane, Washington, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Maffei Centro Medico-Investigacion Clinica Aplicada, C.a.b.a., Buenos Aires Province, Argentina|CIMEL, Lanús, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires Province, Argentina|DIM Clinica Privada, Ramos Mejia, Buenos Aires Province, Argentina|CIAD Moron, Moron, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Clinica Mayo de Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Sanatorio Guemes, Caba, Argentina|CIPREC, Ciudad Autonoma de Buenos Aires, Argentina|CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegian, Cordoba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Instituto Privado de Investigaciones Clínicas de Córdoba, Córdoba, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Sankt Stefan ob Stainz, Styria, Austria|Medizinische Universitat Innsbruck, Innsbruck, Tirol, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch', Vorarlberg, Austria|Klinikum Klagenfurt am WÃ¶rthersee, Klagenfurt, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Landeskrankenhaus Steyr, Steyr, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|CHC - Clinique Saint-Joseph, Liege, Belgium|Instituto de Estudos e Pesquisas Clinicas do Ceara IEP/CE - Oncology, Fortaleza, Ceara, Brazil|Hospital Universitário Walter Cantídio, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|Quanta Diagnóstico e Terapia, Curitiba, Parana, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, Rio Grande Do Sul, Brazil|NOOVA, Florianópolis, Santa Catarina, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clinica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica de Campinas, Campinas, Sao Paulo, Brazil|Clinica Espec Ima Brasil, Cerqueira Cesar - Sao Paulo, Sao Paulo, Brazil|Hospital Universitário João de Barros Barreto, Belém, Brazil|IPEC-Instituto de Pesquisa Clinica, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, Brazil|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|MHAT Ivan Rilski - 2003, Dupnitsa, Bulgaria|MHAT Dr. Tota Venkova AD, Gabrovo, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Sliven, MHAT ""Hadzhi Dimitar"", Sliven, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|Acibadem City Clinic Oncology Center, Sofia, Bulgaria|Medical centre Synexus Sofia EOOD, Sofia, Bulgaria|Medical Center Synexus Sofia, Stara Zagora, Bulgaria|MHAT Dobrich AD, Targovishte, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|Central Alberta Research Centre, Red Deer, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Eastern Health, St. John's, Newfoundland and Labrador, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Etobicoke, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellín, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion BIOS, Barranquilla, Atlantico, Colombia|Endocare Ltda., Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Medplus Medicina Prepagada, Bogota, Distrito Capital De Bogota, Colombia|Asociación Colombiana de Diabetes, Teusaquillo, Distrito Capital De Bogotá, Colombia|Clinica Meta, Villavicencio, Meta, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Gentofte Hospital, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Aalborg University Hospital, Aalborg, Denmark|Hôpital Haut Lévêque, Pessac, Gironde, France|CHRU Nancy, Vandœuvre-lès-Nancy, Grand Est, France|Hopital Louis Mourier, Colombes, France|Corbeil Essonnes, Corbeil Essonnes cedex, France|Grenoble, Grenoble, France|Hospices Civils de Lyon - Hôpital Edouard Herrriot, Lyon Cedex 03, France|CHU Nantes, Nantes Cedex 1, France|Hopital Charles Nicolle, Rouen Cedex, France|Centre de Recherche Clinique, Venissieux, France|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Wuertemberg, Germany|Praxis Dr. Etzrodt-Walter und Kollegen, Ulm, Baden-WÃ¼rttemberg, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Diabetologische Schwerpunktpraxis, Bad Berleburg, Germany|Diabetespraxis Prenzlauer, Berlin, Germany|Emovis GmbH, Berlin, Germany|Synexus Berlin Clinical Research Centre, Berlin, Germany|Synexus Clinical Research GmbH, Frankfurt am MAin, Germany|Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|KRH Klinikum Siloah, Hannover, Germany|Diabetesinstitut Heidelberg c-o St. Josefskrankenhaus, Heidelberg, Germany|SMO.MD GmbH, Magdeburg, Germany|Klinikum Bogenhausen, Munich, Germany|First Department of Medicine, University of Szeged, Szeged, CsonfrÃ¡d, Hungary|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Synexus Budapest DRS, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|SYNEXUS Magyarorszag Kft Debrecen A.S., Debrecen, Hungary|Synexus Magyarország kft. Gyula DRS, Gyula, Hungary|BKS Research Kft Synexus AS, Hatvan, Hungary|Medifarma-98, Nyíregyháza, Hungary|Clinfan Szolgáltató Kft, Szekszard, Hungary|Synexus Magyarorszag Kft, Zalaegerszeg, Hungary|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|Anu Hospitals, Vijayawada, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Apollo Hospitals International Limited - Diabetologist, Ahmedabad, Gujarat, India|Surat Institute of Digestive Sciences Hospitals, Surat, Gujarat, India|Victoria Hospital Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|Lifecare Clinic and Research Centre - Internal Med/Diabetology, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Mysore Medical College & Research Institute, Mysore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|Chopda Medicare & Research Centre Pvt.Ltd, Magnum Heart Institute, Nashik, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|University Hospital - Internal Medicine, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S.P.Medical College & Group of Hospitals Bikaner, Bikaner, Rajasthan, India|S.R. Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Madras Medical College & Rajiv Gandhi Govt. General Hospital, Chennai, Tamil Nadu, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|M. V Hospital & Research Centre, Lucknow, Uttar Prandesh, India|IPGME&R and SSKM Hospital, Kolkata, West Bengal, India|M. S. Ramaiah medical College and Hospitals, Bangalore, India|Sir Ganga Ram Hospital, Delhi, India|Soroka University Medical Center, Beer Sheba, Israel|Bnei-Zion MC, Haifa, Israel|The E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Holy Family Hospital, Nazareth, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gastroenterology Institute, Tel Aviv, Israel|IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy|Azienda Ospedaliera Rilievo Nazionale Alta Specialita (ARNAS) Garibaldi, Catania, Sicily, Italy|Ospedale Cardinal Massaia, Asti, Italy|University of Bari, Bari, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|AO Universitaria San Martino - IRCCS, Genova, Italy|Universita degli Studi di Napoli Federico II, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IRCCS S.Matteo Hospital Foundation, University of Pavia, Pavia, Italy|University of Pisa - Cisanello Hospital, Pisa, Italy|Policlinico Gemelli, Divisione di Endocrinologia e Malattie del Metabolismo, Rome, Italy|Gruppo Humanitas - Humanitas Research Hospital, Rozzano-Milano, Italy|Universita' Di Salerno- Aou Ruggi D'aragona, Salerno, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Clinical Institute Beato Matteo, Vigevano, Italy|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ogorelova Jelena GP, Kraslava, Kraslavas Nov., Latvia|Polana-D, LLC, Daugavpils, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Riga Health Centre, Riga, Latvia|Siguldas Hospital, Sigulda, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Clinicos Asociados BOCM SC, Mexico City, Ciudad De Mexico, Mexico|Mentrials SA DE CV, Mexico City, Distrito Federal, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Morales Vargas Centro de Investigación S.C. (Consultorio ane, Colonia Centro, Guanajuato, Mexico|Centro de Investigación y Atención de Diabetes - Endocrinología y Nutrición, Durango, Guillermina, Mexico|Centro de Diabetes de Pachuca, Pachuca, Hidalgo, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, S.C., Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C., Guadalajara, Jalisco, Mexico|Centro de Atención e Investigación en Factores de Riesgo Car, Mexico, Mexico DF, Mexico|Instituto de Diabetes Obesidad y Nutricion SC, Cuautla, Morelos, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. José E. González"" UANL, Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Tlalpan, Mexico|Centro Especializado en Investigacion Clinica S.C., Boca del Rio, Veracruz, Mexico|Centro de Desarrollo Biomédico S.C.P, Mérida, Yucatán, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Investigación Médica Sonora, S.C., Hermosillo, Mexico|Centro Medico Christus Muguerza Sur, Nuevo Leon, Mexico|Oncologico Potosino, San Luis Potosi, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, Mexico|West Visayas State University Medical Center, IloIlo City, IloIlo, Philippines|St. Luke's Medical Center, Quezon City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Manila Doctors Hospital, Ermita, Manila, Metropolitan Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metropolitan Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|Synexus Polska Sp.z o.o., Pomorskie, Gdansk, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Lesser Poland, Poland|Zamość, Zamość, Lublin, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Oddzial Gastroenterologii Mazowieckie Centrum Rehabilitacji Stocer sp. Z o.o., Pruszków, Masovian, Poland|NZOZ Vita Diabetica - Malgorzata Buraczyk, Bialystok, Podlaski, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Szpital Uniwestytetu Medycznego w Bialymstoku, Białystok, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Synexus Polska sp.z.o.o oddzial Czestochowa, Czestochowa, Poland|Silmedic Sp z o o, Katowice, Poland|DRS Katowice, Katowice, Poland|DRS Leipzig, Leipzig, Poland|Synexus Polska Sp. z o.o. Oddzial w Lodzi, Lodz, Poland|Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie, Lublin, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Synexus Polska Sp. z o.o.Oddzial w Poznaniu, Poznan, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Powiatowe Centrum Medyczne w Wolowie Sp. z o.o., Wołów, Poland|DRS Wroclaw, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|ClinTrial Medical Center, Pulmonology Department, Dobrosloveni, Oltenia, Romania|Sana Medical Center, Bucharest, Romania|Cabinet Medical De Nutritie Si Boli Metabolice Dr. Nicoleta, Bucharest, Romania|University Emergency Militare Central Dr.Carol Davila, Bucharest, Romania|National Institute of Endocrinology, Bucharest, Romania|Societatea Civila Medicala, Bucharest, Romania|AMES Research Center SRL, Calarasi, Romania|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|State Budgetary Healthcare Institution Of Arkhangelsk Region Suvorova 1, Arkhangelsk, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Millitary-medical Academy, department of hospital therapy, Saint-Petersburg, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation|GUZ Saratov City Clinical Hospital 9, Saratov, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|King Fahad Specialist Hospital - Dammam, Dammam, Al Muraikabat, Saudi Arabia|Hayyal Jamia Hospital, Jeddah, Saudi Arabia|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Pretoria, Gauteng, South Africa|Soweto CTC, Soweto, Gauteng, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Jakaranda Hospital, Pretoria, South Africa|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario De Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Limited Liability Company ""Medical Center ""Salutem"", Vinnitsa, Vinnyts'ka Oblast', Ukraine|Municipal Institution City Hospital No. 7, Zaporizhzhia, Zaporizhzhia Region, Ukraine|Municipal nonprofit entity ""Chernigiv city hospital #2"" of Chernigiv municipal council, therapeutic department, Chernihiv, Ukraine|Regional muniRegional municipal institution ""Chernivtsi's regional clinical hospital"", gastroenterological department, Higher state educational establishment of Ukraine ""Bukovinian state medical university"", department of internal medicine and infectious, Chernivtsi, Ukraine|Regional Public Organization ""Chernivtsi Regional Endocrinology Center"", Chernivtsi, Ukraine|Kryvyi Rih City Hospital #3 of Dnipropetrovsk Regional Council, Dnipropetrovsk Region, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|SU"" Clinic of medical academy"" of SI ""Dnepropetrovsk medical cacadamy of MoH of Ukraine"", Dnipro, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal nonprofit entity of Kharkiv municipal council, Kharkiv, Ukraine|L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv municipal clinical endocrinological center, Kyiv, Ukraine|Limited Liability Company ""Medical and Diagnostic Center ""ADONIS Plus"", outpatient department, c. Kyiv, Kyiv, Ukraine|Medical Centre ""Edelveis Mediks"", LLC, Kyiv, Ukraine|Medical Centre ""Medbud-Clinic"", LLC, Kyiv, Ukraine|Kyiv Railway Clinical Hospital No-2 of Branch of Healthcare Center of the PJSC Ukrainian Railway , Endocrynology Department, Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit, Kyiv, Ukraine|Institute of Endocrinology and Metabolism im. V. P. Komisarenka NAMS Ukraine, Kyiv, Ukraine|City Hospital #1, department of endocrinology, c. Mykolayiv, Mykolaiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Communal Institution ""Odesa Regional Clinical Hospital"", Out-patient department, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Municipal Institution of Sumy Regional Council Sumy Regional Clinical Hospital, Sumy, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Medical Center of the Limited Liability Company ""Health Clinic"", nt oMedical Clinical Research Center, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|Municipal nonprofit entity ""Vinnytsia's city clinical hospital #1"", gastroenterological department, Vinnytsia National Pirogov Memorial Medical University, department of propedeutics of internal medicine, c. Vinnytsia, Vinnytsia, Ukraine|DRRI-Vinnytsia National Pirogov Memorial Medical University, Vinnytsya, Ukraine|6th City Clinical Hospital, c. Zaporizhzhia, Zaporizhzhia, Ukraine|Municipal Institution-Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine|Biomedical Research Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Kaman Court, Blackpool, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Synexus Lancashire Dedicated Research Centre, Chorley, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Synexus Hexham Dedicated Research Centre, Hardwick, United Kingdom|Synexus North Tees Clinical Research Centre, Hardwick, United Kingdom|Synexus Merseyside Dedicated Research Centre, Liverpool, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Wingate Institute of Neurogastroenterology and Barts Health Trust and the Royal London Hospital, London, United Kingdom|University College London Hospita, London, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Royal Victoria Infirmary: Clinical Research Facility, Newcastle upon Tyne, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,MYELODYSPLASTIC SYNDROME,_IMETELSTAT,NCT02598661,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|CBCC Global Research, Inc, Bakersfield, California, United States|UCLA Ronald Regan Medical Center, Los Angeles, California, United States|Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Franciscan Health, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, New York, New York, United States|Columbia Presbyterian, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic Taussig Cancer, Cleveland, Ohio, United States|The Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States|Prairie lakes Healthcare system, Inc, Watertown, South Dakota, United States|Tennessee Oncology at Centennial Medical Center, Nashville, Tennessee, United States|Texas Oncology/Methodist Charlton Cancer Center, Dallas, Texas, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|ZNA Middelheim, Antwerpen, Belgium|ZNA Stuivenberg- Middelheim, Antwerpen, Belgium|AZ Klina, Brasschaat, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|GZA Ziekenhuizen - Campus Sint, Wilrijk, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montréal, Quebec, Canada|University of Alberta Hospital - Hematology Research, Edmonton, Canada|Sunnybrook Health Sciences Centre, Toronto, Canada|Fakultni nemocnice Brno, Brno, Brno-město, Czechia|FN Hradec Kralove, Hradec Králové, Czechia|FN Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|CHU de Grenoble - Hôpital Albe, La Tronche, Isère, France|CHRU Nancy Brabois, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France|CHU de Poitiers, Poitiers, Vienne, France|CHU d'Angers, Angers, France|CHRU de Lille - Hopital Claude Huriez - Maladies du Sang, Lille, France|CHU de Limoges, Hopital Dupuytren, Limoges, France|CHU de Nice Hopital de l Archet, Nice, France|Hopital Saint-Louis, Paris Cedex 10, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France|CHU Bretonneau, Tours Cedex, France|University Hospital Freiburg, Freiburg, Baden-Württemberg, Germany|Fachärztliche Gemeinschaftspraxis mit Schwerpunkt, Dresden, Sachsen, Germany|University Hospital Leipzig, Leipzig, Sachsen, Germany|Studienzentrum für Hämatologie, Onkologie,Diabetologie, Endoskopie und Fußambulanz, Aschaffenburg, Germany|University Hospital Bonn, Bonn, Germany|Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Duesseldorf, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Johannes Gutenberg Universität, Mainz, Germany|Klinikum rechts der Isar an der Technischen Universität München, München, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Kaplan Medical Center, Reẖovot, Hagalil Saint, Israel|The Edith Wolfson Medical Center, H̱olon, HaMerkaz, Israel|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Ha'Emek Medical Center, Afula, HaZafon, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Tel-Aviv, Israel|The Chaim Sheba Medical Center, Tel HaShomer, Tel-Aviv, Israel|Carmel MC, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Istituto Clinico Humanitas Rozzano, IRCCS, Rozzano, Milano, Italy|Irccs Crob, Rionero In Vulture, Potenza, Italy|AOU Ospedali Riuniti Umberto I G.M. Lancisi G. Salesi, Ancona, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|A.O. Ospedale Niguarda Ca' Granda, Milano, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|A.O. Ospedali Riuniti Marche Nord Presidio Ospedaliero S. Salvatore di Pesaro-Stabilim. di Muraglia, Pesaro, Italy|Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria, Reggio Calabria, Italy|A.O. Universitaria Policlinico Tor Vergata, Roma, Italy|AO S. Andrea, Università degli Studi di Roma La Sapienza, Roma, Italy|Ospedale di Circolo, PO Varese, Varese, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei Uni, Seoul, Korea, Republic of|Meander Medisch Centrum, Amersfoort, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Radboud Umcn, Nijmegen, Netherlands|Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Russian Federation|City Clinical Hospital, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|FGU-Russian Research Institut, Saint Petersburg, Russian Federation|Oncologic Dispensary No.2, Sochi, Russian Federation|H.U.Pta.del Mar, Cadiz, Cádiz, Spain|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|Hospital Universitario Doctor, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.2,4610.18,1587.05,74.0,45.0,35.0,442.86,1045.35,95.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]2N)[C@H](O)[C@@H]1O,CYSTIC FIBROSIS,_ELX-02,NCT04135495,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Long Beach Memorial, Long Beach, California, United States|Stanford School of Medicine, Palo Alto, California, United States|National Jewish Health, Denver, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.5,482.531,262.38,14.0,10.0,3.0,48.09,109.01,6.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,CIRRHOSIS,_CATECHIN,NCT03278925,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"MedStar Georgetown University Hospital, Washington, District of Columbia, United States",4094969,A01N25/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,24.0,35.9103883036612,1741.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,PANCREATIC CANCER,_SECRETIN,NCT03404661,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Control|Time Perspective: Prospective,"Mayo Clinic in Florida, Jacksonville, Florida, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,METASTATIC MELANOMA,_NIRAPARIB,NCT03925350,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Pacific Medical Center Research Institute, San Francisco, California, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,GRAFT VS HOST DISEASE,_CYCLOPHOSPHAMIDE,NCT03357159,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chaim Sheba Medical Center, Ramat Gan, Israel",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC MELANOMA,_CYCLOPHOSPHAMIDE,NCT03475134,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHUV Oncology Department, Lausanne, Vaud, Switzerland",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC MELANOMA,_FLUDARABINE,NCT03475134,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHUV Oncology Department, Lausanne, Vaud, Switzerland",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,SICKLE CELL DISEASE,_CYCLOPHOSPHAMIDE,NCT03121001,Phase 2,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago, Chicago, Illinois, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,SICKLE CELL DISEASE,_FLUDARABINE,NCT03121001,Phase 2,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago, Chicago, Illinois, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,SICKLE CELL DISEASE,_MYCOPHENOLATE_MOFETIL,NCT03121001,Phase 2,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago, Chicago, Illinois, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,SICKLE CELL DISEASE,_SIROLIMUS,NCT03121001,Phase 2,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago, Chicago, Illinois, United States",5212155,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,SICKLE CELL DISEASE,_METHOTREXATE,NCT02766465,Phase 2,Recruiting,All,"15 Years to 40 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital at Oakland, Oakland, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Gainsville, Gainesville, Florida, United States|Foundation for Sickle Cell Research/Florida Sickle Inc., Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center/Albert Einstein School of Medicine, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Cohen Children's Medical Center, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health Sciences University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States|University of Texas/MD Anderson CRC, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,SICKLE CELL DISEASE,_TACROLIMUS,NCT02766465,Phase 2,Recruiting,All,"15 Years to 40 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital at Oakland, Oakland, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Gainsville, Gainesville, Florida, United States|Foundation for Sickle Cell Research/Florida Sickle Inc., Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center/Albert Einstein School of Medicine, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Cohen Children's Medical Center, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health Sciences University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States|University of Texas/MD Anderson CRC, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,SICKLE CELL DISEASE,_BUSULFAN,NCT02766465,Phase 2,Recruiting,All,"15 Years to 40 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital at Oakland, Oakland, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Gainsville, Gainesville, Florida, United States|Foundation for Sickle Cell Research/Florida Sickle Inc., Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center/Albert Einstein School of Medicine, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Cohen Children's Medical Center, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health Sciences University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States|University of Texas/MD Anderson CRC, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",5430057,2,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,SICKLE CELL DISEASE,_MELPHALAN,NCT02766465,Phase 2,Recruiting,All,"15 Years to 40 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital at Oakland, Oakland, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Gainsville, Gainesville, Florida, United States|Foundation for Sickle Cell Research/Florida Sickle Inc., Hollywood, Florida, United States|University of Miami, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center/Albert Einstein School of Medicine, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Cohen Children's Medical Center, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health Sciences University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States|University of Texas/MD Anderson CRC, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",8410077,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,HEMATOLOGICAL MALIGNANCY,_TACROLIMUS,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5260301,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,HEMATOLOGICAL MALIGNANCY,_BUSULFAN,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5430057,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,HEMATOLOGICAL MALIGNANCY,_MYCOPHENOLATE_MOFETIL,NCT01349101,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,GRAFT VS HOST DISEASE,_FLUDARABINE,NCT03263767,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nantes Uh, Nantes, France",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,GRAFT VS HOST DISEASE,_CLOFARABINE,NCT03263767,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nantes Uh, Nantes, France",5661136,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,STAPHYLOCOCCUS AUREUS BACTEREMIA,_DAPTOMYCIN,NCT03138733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6701 Airport Boulevard, Mobile, Alabama, United States|eStudy Site - Chula Vista - PPDS, Chula Vista, California, United States|eStudy Site - La Mesa - PPDS, La Mesa, California, United States|Yaneicy, Coral Gables, Florida, United States|Triple O Medical Services Inc, West Palm Beach, Florida, United States|Allina Health System DBA Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mercury Street Medical Group, Butte, Montana, United States|eStudy Site - Las Vegas - PPDS, Las Vegas, Nevada, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|3820 Olentangy River Road, Columbus, Ohio, United States|Hospital Nuestra Senora de la Misericordia, Córdoba, Argentina|Rawson Hospital, Córdoba, Argentina|Mayo Private Sanatorium, Córdoba, Argentina|Hospital Cordoba, Córdoba, Argentina|Medical Institute Platense SA, La Plata, Argentina|Zonal General Hospital for Acute Diseases ""Dr. Carlos Bocalandro"", Loma Hermosa, Argentina|British Sanatorium SA, Rosario, Argentina|Provincial Hospital ""Dr. Jose Maria Cullen"", Santa Fe, Argentina|Santa Casa of Belo Horizonte, Clinical Research Center/Critical Care Medicine/Internal Medicine, Belo Horizonte, Brazil|Hospital do Trabalhador, Curitiba, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Base Hospital of Sao Jose do Rio Preto, São José Do Rio Preto, Brazil|Multiprofile Hospital for Active Treatment ""Puls"", Intensive Care Unit, Blagoevgrad, Bulgaria|University Multiprofile Hospital for Active Treatment ""Eurohospital Plovdiv"", Plovdiv, Intensive Care Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment ""Dr. Ivan Seliminski"", Sliven, Anesthesiology and Intensive Care Department, Sliven, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N.I. Pirogov"", Sofia, Clinic of Purulent-Septic Surgery, Sofia, Bulgaria|JSC Rustavi Central Hospital, Rustavi, Georgia|LTD High Technology Medical Center University Clinic, Tbilisi, Georgia|LTD Acad. O. Gudushauri National Medical Center, Tbilisi, Georgia|LTD Academician G. Chapidze Emergency Cardiology Center, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia|LTD Central University Clinic After Academic N. Kipshidze, Tbilisi, Georgia|LTD N 5 Clinikal Hospital, Tbilisi, Georgia|Greifswald University Hospital, Anaesthesiology; Emergency Medicine, Greifswald, Germany|University Hospital Schleswig-Holstein, Clinic of Anesthesiology and Operative Intensive Care Medicine, Kiel, Germany|University Hospital Regensburg, Department of Infectious Diseases, Regensburg, Germany|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|The Baruch Padeh Medical Center, Poriyya 'Illit, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Sieff Medical Center, Safed, Israel|Sourasky Medical Center, Tel Aviv, Israel|Local Healthcare Company Papa Giovanni XXIII (ASST Papa Giovanni XXIII), Department of Infectious Diseases, Bergamo, Italy|Polyclinic S. Orsola-Malpighi, Department of Organ Impairment and Transplants, Operative Unit of Infectious Diseases, Bologna, Italy|University Polyclinic Hospital of Modena, Department of Infectious Diseases, Modena, Italy|University of Milan-Bicocca- S.Gerardo Hospital, Monza, Italy|Integrated University Health Authority of Trieste, Trieste, Italy|St. Joseph Belgorod Regional Clinical Hospital, Belgorod, Russian Federation|Territorial Clinical Hospital #2, Krasnodar, Russian Federation|O.M. Filatov City Clinical Hospital #15, Moscow, Russian Federation|Vinogradov Moscow Municipal Hospital, Department of Surgery #14, Moscow, Russian Federation|N.I. Pirogov City Clinical Hospital #1, Moscow, Russian Federation|Federal State Budget Institution ""Central Clinical Hospital with Polyclinic"" under the Presidential Executive Office of Russian Federation, Moscow, Russian Federation|L.A. Vorokhobov City Clinical Hospital #67, Moscow, Russian Federation|City Hospital #33, Nizhny Novgorod, Russian Federation|Pyatigorsk City Clinical Hospital, Pyatigorsk, Russian Federation|Railway Clinical Hospital under OAO Russian Railways, Saint Petersburg, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa|Hospital del Mar, Department of Intensive Care, Barcelona, Spain|University Hospital de Elche, Infectious Diseases Unit, Elche, Spain|General University Hospital Gregorio Maranon, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Ramon y Cajal, Department of Infectious Diseases, Madrid, Spain|La Paz University Hospital, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Mutua de Terrassa, Unit of Infectious Diseases, Terrassa, Spain|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Public Non-Profit Enterprise: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council, Kharkiv, Ukraine|City Clinical Hospital #3, Zaporizhzhya, Ukraine",6468967.0,A61K38/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1,STAPHYLOCOCCUS AUREUS BACTEREMIA,_CEFTOBIPROLE,NCT03138733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6701 Airport Boulevard, Mobile, Alabama, United States|eStudy Site - Chula Vista - PPDS, Chula Vista, California, United States|eStudy Site - La Mesa - PPDS, La Mesa, California, United States|Yaneicy, Coral Gables, Florida, United States|Triple O Medical Services Inc, West Palm Beach, Florida, United States|Allina Health System DBA Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mercury Street Medical Group, Butte, Montana, United States|eStudy Site - Las Vegas - PPDS, Las Vegas, Nevada, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|3820 Olentangy River Road, Columbus, Ohio, United States|Hospital Nuestra Senora de la Misericordia, Córdoba, Argentina|Rawson Hospital, Córdoba, Argentina|Mayo Private Sanatorium, Córdoba, Argentina|Hospital Cordoba, Córdoba, Argentina|Medical Institute Platense SA, La Plata, Argentina|Zonal General Hospital for Acute Diseases ""Dr. Carlos Bocalandro"", Loma Hermosa, Argentina|British Sanatorium SA, Rosario, Argentina|Provincial Hospital ""Dr. Jose Maria Cullen"", Santa Fe, Argentina|Santa Casa of Belo Horizonte, Clinical Research Center/Critical Care Medicine/Internal Medicine, Belo Horizonte, Brazil|Hospital do Trabalhador, Curitiba, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Base Hospital of Sao Jose do Rio Preto, São José Do Rio Preto, Brazil|Multiprofile Hospital for Active Treatment ""Puls"", Intensive Care Unit, Blagoevgrad, Bulgaria|University Multiprofile Hospital for Active Treatment ""Eurohospital Plovdiv"", Plovdiv, Intensive Care Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment ""Dr. Ivan Seliminski"", Sliven, Anesthesiology and Intensive Care Department, Sliven, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N.I. Pirogov"", Sofia, Clinic of Purulent-Septic Surgery, Sofia, Bulgaria|JSC Rustavi Central Hospital, Rustavi, Georgia|LTD High Technology Medical Center University Clinic, Tbilisi, Georgia|LTD Acad. O. Gudushauri National Medical Center, Tbilisi, Georgia|LTD Academician G. Chapidze Emergency Cardiology Center, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia|LTD Central University Clinic After Academic N. Kipshidze, Tbilisi, Georgia|LTD N 5 Clinikal Hospital, Tbilisi, Georgia|Greifswald University Hospital, Anaesthesiology; Emergency Medicine, Greifswald, Germany|University Hospital Schleswig-Holstein, Clinic of Anesthesiology and Operative Intensive Care Medicine, Kiel, Germany|University Hospital Regensburg, Department of Infectious Diseases, Regensburg, Germany|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|The Baruch Padeh Medical Center, Poriyya 'Illit, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Sieff Medical Center, Safed, Israel|Sourasky Medical Center, Tel Aviv, Israel|Local Healthcare Company Papa Giovanni XXIII (ASST Papa Giovanni XXIII), Department of Infectious Diseases, Bergamo, Italy|Polyclinic S. Orsola-Malpighi, Department of Organ Impairment and Transplants, Operative Unit of Infectious Diseases, Bologna, Italy|University Polyclinic Hospital of Modena, Department of Infectious Diseases, Modena, Italy|University of Milan-Bicocca- S.Gerardo Hospital, Monza, Italy|Integrated University Health Authority of Trieste, Trieste, Italy|St. Joseph Belgorod Regional Clinical Hospital, Belgorod, Russian Federation|Territorial Clinical Hospital #2, Krasnodar, Russian Federation|O.M. Filatov City Clinical Hospital #15, Moscow, Russian Federation|Vinogradov Moscow Municipal Hospital, Department of Surgery #14, Moscow, Russian Federation|N.I. Pirogov City Clinical Hospital #1, Moscow, Russian Federation|Federal State Budget Institution ""Central Clinical Hospital with Polyclinic"" under the Presidential Executive Office of Russian Federation, Moscow, Russian Federation|L.A. Vorokhobov City Clinical Hospital #67, Moscow, Russian Federation|City Hospital #33, Nizhny Novgorod, Russian Federation|Pyatigorsk City Clinical Hospital, Pyatigorsk, Russian Federation|Railway Clinical Hospital under OAO Russian Railways, Saint Petersburg, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa|Hospital del Mar, Department of Intensive Care, Barcelona, Spain|University Hospital de Elche, Infectious Diseases Unit, Elche, Spain|General University Hospital Gregorio Maranon, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Ramon y Cajal, Department of Infectious Diseases, Madrid, Spain|La Paz University Hospital, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Mutua de Terrassa, Unit of Infectious Diseases, Terrassa, Spain|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Public Non-Profit Enterprise: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council, Kharkiv, Ukraine|City Clinical Hospital #3, Zaporizhzhya, Ukraine",5981519,C07F9/572,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,65.0,23.0312737427873,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.3,534.57,203.44,11.0,5.0,5.0,51.22,131.04,6.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,PNEUMONIA VENTILATOR ASSOCIATED,_AMIKACIN,NCT03149640,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Service de Réanimation Chirurgicale, Angers, France|Service de Réanimation Médicale - CH d'Angoulême, Angoulême, France|Service de Réanimation Polyvalente, Argenteuil, France|Service de Réanimation - CH Beauvais, Beauvais, France|Service de Réanimation Médicale - Hôpital Louis Mourier, Colombes, France|Service de Réanimation, Dijon, France|Service de Réanimation Médicale - CHD Les Oudairies, La Roche-sur-Yon, France|Service de Réanimation, Le Mans, France|Service de Réanimation Médicale - Hôpital La Croix-Rousse, Lyon, France|Service de Réanimation Médicale - CH de Montauban, Montauban, France|Service de Réanimation, Mulhouse, France|Service de Réanimation Médicale, Orléans, France|Service de Réanimation Médicale - Hôpital Pitié Salpêtrière, Paris, France|Service de Réanimation Médicale - CHU La Milétrie, Poitiers, France|Service de Réanimation Médicale, Poitiers, France|Service de Réanimation Médicale - CHU Pontchaillou, Rennes, France|Service de Réanimation Médicale - CHU Rouen, Rouen, France|Service de Réanimation Médicale - Hôpital Charles Nicolle, Rouen, France|Service de Réanimation - NHC, Strasbourg, France|Service de Réanimation Médicale - Hôpital de Hautepierre, Strasbourg, France|Service de Réanimation médicale, Hôpital Trousseau, Tours, France",7718189.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,TUBERCULOUS MENINGITIS,_LINEZOLID,NCT03898635,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Retrospective,"Infectious department of Huashan Hospital, Fudan University, Shanghai, China",5688792,C07D413/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,TRANSPLANTATION INFECTION|CYTOMEGALOVIRUS INFECTIONS,_GANCICLOVIR,NCT03699254,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario de A Coruña, A Coruña, Spain|Hospital Universitario Vall D'Hebron, Barcelona, Spain|Hospital Univesitario Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain",5378475,A61K9/5073,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,TRANSPLANTATION INFECTION|CYTOMEGALOVIRUS INFECTIONS,_VALGANCICLOVIR,NCT03699254,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario de A Coruña, A Coruña, Spain|Hospital Universitario Vall D'Hebron, Barcelona, Spain|Hospital Univesitario Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain",6083953,C07D473/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
S=P(N1CC1)(N1CC1)N1CC1,SICKLE CELL DISEASE,_THIOTEPA,NCT04362293,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",4766149,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,SICKLE CELL DISEASE,_AZATHIOPRINE,NCT04362293,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",4452794,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,SICKLE CELL DISEASE,_PLERIXAFOR,NCT04362293,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",RE42152,C07D401/14 ,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
NC(=O)NO,SICKLE CELL DISEASE,_HYDROXYUREA,NCT04362293,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,METASTATIC MELANOMA,_MELPHALAN,NCT01920516,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, Pesaro, PU, Italy",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,GRAFT VS HOST DISEASE,_DEXAMETHASONE,NCT00391170,Phase 2,Recruiting,All,"12 Years to 110 Years   (Child, Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",6284804,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
NC(=O)c1cccnc1,SICKLE CELL DISEASE,_NICOTINAMIDE,NCT04055818,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States",3931207,C07D207/44,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
NC(=O)c1cccnc1,PREECLAMPSIA,_NICOTINAMIDE,NCT03419364,Phase 2,Recruiting,Female,18 Years to 55 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC at Chapel Hill, Chapel Hill, North Carolina, United States",3931207,C07D207/44,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CORONAVIRUS INFECTION,_RUXOLITINIB,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CORONAVIRUS INFECTION,_SIMVASTATIN,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,ATOPIC DERMATITIS,_CHOLECALCIFEROL,NCT02537509,Phase 2,Recruiting,All,"15 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU d'Angers, Angers, France|Hôpital Saint André, Bordeaux, France|Hôpital Morvan, Brest, France|Hôpital Femme-Mère-Enfant - Hospices Civils de Lyon, Bron, France|Hôpital Trousseau, Chambray Les Tours, France|CHD Vendée, La Roche sur Yon, France|Centre Hospitalier, Le Mans, France|Hôpital Claude Huriez, Lille, France|CHU de Nantes - Hôtel Dieu, Nantes, France|APHP - Hôpital Tenon, Paris, France|Centre Hospitalier, Perigueux, France|Hôpital Laënnec, Quimper, France|Hôpital Pontchaillou, Rennes, France|CHR St Brieuc, Saint Brieuc, France|Centre Hospitalier, Valence, France|Centre Hospitalier, Valenciennes, France",5994329.0,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
NNC(=O)c1ccncc1,TUBERCULOUS MENINGITIS,_ISONIAZID,NCT03787940,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Beijing Chest Hospital affiliated to Capital Medical University, Beijing, China|Jiamusi Infectious Disease Hospital, Jiamusi, China|Jiangxi Provincial Chest Hospital, Nanchang, China|Zunyi Medical College affiliated Hospital, Zunyi, China",3944522,C08G73/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,INFECTIVE ENDOCARDITIS,_DEXMEDETOMIDINE,NCT02698930,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",5344840,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,PLASMODIUM FALCIPARUM MALARIA (DRUG RESISTANT),_IMATINIB,NCT03697668,Phase 2,Unknown status,Male,18 Years to 55 Years   (Adult),Industry|Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"A Tuc, Hương Hóa, Quang Tri, Vietnam",5521184,C07D409/04,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,METASTATIC MELANOMA,_COBIMETINIB,NCT04109456,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MD Anderson, Houston, Texas, United States",7803839,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,GRAFT VS HOST DISEASE,_IBRUTINIB,NCT04235036,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northside Hospital, Atlanta, Georgia, United States",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CRYPTOCOCCAL MENINGITIS,_FLUCONAZOLE,NCT03945448,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"infectious Disease Institute Kampala,Uganda, Kampala, Uganda",4404216.0,C07D249/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,INVASIVE ASPERGILLOSIS,_POSACONAZOLE,NCT04218851,Phase 2,Recruiting,All,"2 Years to 18 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rady Children's Hospital-San Diego ( Site 1401), San Diego, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 1402), Chicago, Illinois, United States|Washington University ( Site 1403), Saint Louis, Missouri, United States|General Hospital of Thessaloniki ""Ippokrateio"" ( Site 1050), Thessaloniki, Greece|Chaim Sheba Medical Center ( Site 1126), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 1128), Tel Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 1125), Haifa, Israel|Seoul National University Hospital ( Site 1326), Seoul, Korea, Republic of|The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 1325), Seoul, Korea, Republic of|Instituto Nacional de Enfermedades Neoplásicas ( Site 1251), Lima, Peru|Dmitry Rogachev National Research Center ( Site 1275), Moscow, Moskva, Russian Federation|Institute of Invasive Mycosis ( Site 1282), Saint Petersburg, Sankt-Peterburg, Russian Federation|Institute of Child Hematology and Transpl n.a.R.M.Gorbacheva ( Site 1281), Saint Petersburg, Sankt-Peterburg, Russian Federation",5703079,C07D249/08,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,FUNGAL INFECTION,_CASPOFUNGIN,NCT03857399,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Affiliated Concord Hospital of Fujian Medical University, Fuzhou, Fujian, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Tongji Hospital of Shanghai, Shanghai, Shanghai, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China",5378804,C07K7/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,21.618513727181202,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.17,1093.3131,412.03,18.0,16.0,4.0,117.52,278.78,23.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,INVASIVE PULMONARY ASPERGILLOSIS,_VORICONAZOLE,NCT03672292,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UC Davis Medical Center 4150 V St Ste G500, Sacramento, California, United States|Emory University Hospital 1364 Clifton Road NE, Atlanta, Georgia, United States|University of Chicago 5841 S. Maryland Avenue MC 5065, Chicago, Illinois, United States|St. Vincent Hospital Indianapolis 8402 Harcourt Rd Suite 806, Indianapolis, Indiana, United States|Brigham Womens Hospital INF 75 Francis Street PBB-A4, Boston, Massachusetts, United States|University of Michigan UH south F4005; 1500 E. Medical Center Drive SPC 5378, Ann Arbor, Michigan, United States|Wayne State University 3990 John R Detroit 48201 Site Supplies/Lab Kits Harper university Hospital 3990 John R # 5904, 5 Hudson, Detroit, Michigan, United States|UNIVERSITY OF MINNESOTA PHYSICIANS Mayo Memorial Building 420 Delaware St SE, Minneapolis, Minnesota, United States|Washington University School of Medicine Division of Infectious Disease 660 S Euclid Ave, Box 8051, Saint Louis, Missouri, United States|Duke University PO BOX 102359, Durham, North Carolina, United States|Wake Forest Baptist Medical Center 1 Medical Center Blvd., Winston-Salem, North Carolina, United States|Lowcountry Infectious Diseases P.A. 1938 Charlie Hall Blvd, Charleston, South Carolina, United States|Memorial Hermann Hospital Texas Medical Center Clinical Research Unit, Houston, Texas, United States|Hematology Department AZ Sint-Jan Brugge - Oostende AV Campus Brugge Ruddershove 10 8000, Brugge, Belgium|Hopital Erasme, Bruxelles, Belgium|Institut Jules Bordet Departement des Maladies Infectieuses Boulevard de Waterloo 121, 1000 Bruxelles, Bruxelles, Belgium|UZ Leuven campus Gasthuisberg Hematology Department Herestraat 49 B - 3000, Leuven, Belgium|Universitätsklinikum Bonn, Medizinische Klinik III Venusberg-Campus 1, Gebäude 20, Bonn, Germany|Universitaetsklinikum Koeln, Klinisches Studienzentrum 2 für Infektiologie, Klinik I für Innere Medizin Kerpener Str. 62, Bettenhaus Ebene 15 Raum 64, Köln, Germany|Universitätsklinikum Magdeburg A.ö.R., Zentrum für Innere Medizin, Universitätsklinik für Hämatologie und Onkologie Leipziger Str. 44, Magdeburg, Germany|Universitätsmedizin Mainz, III. Medizinische Klinik und Poliklinik Studienzentrale, Geb. 302, 2.OG, Mainz, Germany|Universitaetsmedizin Rostock, Medizinische Klinik III , Hämatologie, Onkologie, Palliativmedizin am Zentrum für Innere Medizin Ernst-Heydemann-Strasse 6, Rostock, Germany|Coral García Hospital Universitario Virgen de las Nieves. UGC Hematologia y Hemoterapia Avda. de las Fuerzas Armadas, 2., Granada, Spain|Aurora Rodríguez Ródenas Hospital Clínico de Valencia.Fundación Investigación Clínico de Valencia Instituto de Investigación Sanitaria INCLIVA .Pabellón Materno-Infantil, Planta 8ª (Ensayos clínicos) Si, Valencia, Spain",5116844,C07D233/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,MALARIA IN PREGNANCY,_SULFADOXINE,NCT03998839,,Enrolling by invitation,All,up to 5 Years   (Child),Other,Observational Model: Ecologic or Community|Time Perspective: Prospective,"Kenge District, Community Setting, Kenge, Kwango, Congo, The Democratic Republic of the|Mananjary District, Community Setting, Mananjary, Fianarantsoa, Madagascar|Nhamatanda District, Community Setting, Nhamatanda, Sofala, Mozambique|Ohaukwu District, Community Setting, Selected Communities In Ohaukwu District, Ebonyi, Nigeria",4041160,1,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,CORONAVIRUS INFECTION,_IVERMECTIN,NCT04431466,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil|Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil",6103248,A01N53/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,MALARIA,_IVERMECTIN,NCT03967054,Phase 3,Recruiting,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Institut de Recherche en Sciences de la Sante, Diebougou, Sud-Ouest, Burkina Faso",6103248,A01N53/00,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,CORONAVIRUS INFECTIONS,_IVERMECTIN,NCT04384458,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil",6103248,A01N53/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,MYCOBACTERIUM AVIUM COMPLEX,_CLOFAZIMINE,NCT02968212,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","National Jewish Health, Denver, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|University of Chicago, Chicago, Illinois, United States|National Heart, Lung and Blood Institute, Bethesda, Maryland, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Texas Health Science Center, Tyler, Texas, United States",4100271,A61K47/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,28.4523296166245,195.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.39,473.39599999999996,39.99,4.0,1.0,5.0,51.52,142.55,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0
CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1,CORONA VIRUS INFECTION,_CAMOSTAT,NCT04321096,Phase 1|Phase 2,Recruiting,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",4990537,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,19.515801145814,104.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.88,398.4125,134.81,6.0,3.0,2.0,41.92,117.77,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1,COVID-19|SARS-COV-2,_PYRIDOSTIGMINE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",3931205,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],COVID-19|SARS-COV-2,_PYRIDOSTIGMINE_BROMIDE,NCT04343963,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",5298504,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,COVID-19,_NITAZOXANIDE,NCT04463264,Phase 2|Phase 3,Recruiting,All,18 Years to 59 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina",5387598,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,9.856465225158619,123.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.14,307.282,114.11,5.0,1.0,2.0,27.54,73.89,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,CORONAVIRUS INFECTION,_COLCHICINE,NCT04363437,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maimonides Medical Center, Brooklyn, New York, United States",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,CORONA VIRUS INFECTION,_COLCHICINE,NCT04322682,Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|Yuma Regional Medical Center Cancer Center, Yuma, Arizona, United States|Centric Health Resources Inc., Bakersfield, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Rancho Research Institute, Downey, California, United States|University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|South Florida Research Organization, Medley, Florida, United States|Miami Center for Advanced Cardiology, Miami Beach, Florida, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|New York University School of Medecine, New York, New York, United States|Baylor Scott & White Research Institute - Pharmacy, Dallas, Texas, United States|University of Texas(UT) Southwestern Medical Center, Dallas, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo, São Paulo, Sao Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Tread Research, Tygerberg Hospital, Cape Town, South Africa|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,CIRRHOSIS,_CARVEDILOL,NCT01212250,Not Applicable,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,SICKLE CELL DISEASE,_MOMETASONE,NCT03758950,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mount Sinai St Luke's, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",5394868,A61M15/0065,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
O=S(=O)(O)CCS,SICKLE CELL DISEASE,_MESNA,NCT03263559,Phase 2,Recruiting,All,"5 Years to 45 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Colorado - Denver/Children's Hospital of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Riley Children's Hospital at IU Health, Indianapolis, Indiana, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Helen Devos Children's at Spectrum Health, Grand Rapids, Michigan, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Center, Buffalo, New York, United States|Northwell Health/Monter Cancer Center, Lake Success, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|The Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc(CC(C)N)c(OC)cc1C,HEMOPHILIA A,_DOM,NCT03818763,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",WO-1998042331-A1,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,COVID-19,_MARAVIROC,NCT04441385,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain",6586430,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,SICKLE CELL DISEASE,_RIOCIGUAT,NCT02633397,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Howard University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Illinois, Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Albert Einstein University/ Montefiore Medical Center, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|UNC Comprehensive Sickle Cell Center, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|UPMC Division of Hematology and Oncology, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States",6743798,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,COVID-19,_PRAZOSIN,NCT04365257,Phase 2,Recruiting,All,"45 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States",4130647.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,17.380233680363,616.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.93,383.4011,106.95,7.0,1.0,4.0,40.49,104.5,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,MICROBIAL COLONIZATION,_RIFAXIMIN,NCT03529825,Early Phase 1,Recruiting,All,"2 Years to 21 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States",6861053,6,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,SICKLE CELL DISEASE,_PENTOSTATIN,NCT03077542,Phase 1|Phase 2,Recruiting,All,"2 Years to 80 Years   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",4151347,C07H19/052,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,13.831906199305902,1542.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.0,268.2691,112.13,7.0,4.0,3.0,26.34,64.98,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,COVID-19,_BARICITINIB,NCT04321993,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,ANKYLOSING SPONDYLITIS,_MELOXICAM,NCT04480359,Phase 2|Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China",6184220,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,22.47274071336161,1458.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.28,351.401,99.6,5.0,2.0,3.0,34.25,88.62,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1,MALARIA,_PERMETHRIN,NCT04102592,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Bugoye Level III Health Centre, Bugoye, Kasese, Uganda",3944666,C07F9/4078,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,16.000328548840802,523.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.24,391.288,35.53,1.0,0.0,3.0,39.43,114.28,7.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1nc(F)cnc1O,CORONAVIRUS INFECTION,_FAVIPIRAVIR,NCT04373733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.49,157.10399999999996,89.1,4.0,2.0,1.0,12.12,33.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,CYTOMEGALOVIRUS INFECTION,_LETERMOVIR,NCT03728426,Phase 2,Recruiting,All,"12 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,19.0,34.99045154931313,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.58,572.561,77.84,8.0,1.0,5.0,55.0,147.44,7.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cccc(N2CCN(C3=Nc4c(F)cccc4[C@H](CC(=O)O)N3c3cc(C(F)(F)F)ccc3OC)CC2)c1,CYTOMEGALOVIRUS (CMV) INFECTION,_LETERMOVIR,NCT03940586,Phase 2,Recruiting,All,up to 17 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"City of Hope Comprehensive Cancer Center ( Site 0251), Duarte, California, United States|Children's Hospital of Orange County ( Site 0241), Orange, California, United States|University of California San Francisco ( Site 0245), San Francisco, California, United States|University Of Chicago School Of Medicine ( Site 0253), Chicago, Illinois, United States|Boston Children's Hospital ( Site 0243), Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center ( Site 0254), New York, New York, United States|Duke University Health System ( Site 0252), Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center ( Site 0244), Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC ( Site 0258), Pittsburgh, Pennsylvania, United States|Children's Medical Center ( Site 0257), Dallas, Texas, United States|Seattle Childrens Hospital ( Site 0248), Seattle, Washington, United States|The Children s Hospital at Westmead ( Site 0185), Westmead, New South Wales, Australia|Lady Cilento Children s Hospital ( Site 0182), South Brisbane, Queensland, Australia|Royal Childrens Hospital Melbourne ( Site 0181), Parkville, Victoria, Australia|Instituto De Cancerologia S.A. ( Site 0213), Medellin, Antioquia, Colombia|Fundacion Valle del Lili ( Site 0212), Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0211), Cali, Valle Del Cauca, Colombia|Universitaetsklinikum Frankfurt ( Site 0112), Frankfurt, Hessen, Germany|Universitaetsklinikum Muenster ( Site 0114), Muenster, Nordrhein-Westfalen, Germany|Charite Universitaetsmedizin Berlin - Campus-Virchow-Klinikum ( Site 0113), Berlin, Germany|Universitatsklinikum Hamburg-Eppendorf ( Site 0111), Hamburg, Germany|Schneider Children's Medical Center ( Site 0122), Petah Tikva, HaMerkaz, Israel|Pediatric Hemato Oncology Safra Children's Hospital, Sheba Medical Center ( Site 0123), Ramat Gan, Tel Aviv, Israel|Rambam Medical Center ( Site 0121), Haifa, Israel|Saitama Children's Medical Center ( Site 0202), Saitama, Japan|Nuevo Hospital Civil Dr Juan I Menchaca ( Site 0223), Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0222), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Pediatria ( Site 0224), Mexico City, Mexico|Hospital Infantil de Mexico ( Site 0221), Mexico City, Mexico|Hospital Infantil Universitario Nino Jesus ( Site 0151), Madrid, Spain|Hospital Universitario La Paz ( Site 0153), Madrid, Spain|Acibadem Adana Hastanesi ( Site 0162), Adana, Turkey|Akdeniz University Faculty of Medicine ( Site 0161), Antalya, Turkey|Ege Univ.Tip Fakultesi Cocuk Has ( Site 0163), Izmir, Turkey",,,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,19.0,34.99045154931313,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.58,572.561,77.84,8.0,1.0,5.0,55.0,147.44,7.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,NEWLY DIAGNOSED MULTIPLE MYELOMA,_PREDNISONE,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",6488960,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,NEWLY DIAGNOSED MULTIPLE MYELOMA,_MELPHALAN,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8410077,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,NEWLY DIAGNOSED MULTIPLE MYELOMA,_CARFILZOMIB,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,DIFFUSE LARGE B CELL LYMPHOMA,_PREDNISONE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",6488960,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,DIFFUSE LARGE B CELL LYMPHOMA,_CYCLOPHOSPHAMIDE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,DIFFUSE LARGE B CELL LYMPHOMA,_GEMCITABINE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,DIFFUSE LARGE B CELL LYMPHOMA,_EPIRUBICIN,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",4950738.0,A61K41/0042,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,DIFFUSE LARGE B CELL LYMPHOMA,_VINDESINE,NCT02767674,Phase 3,Recruiting,All,70 Years to 90 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Medical College of HUST, Wuhan, Hubei, China|The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), NanJing, Jiangsu, China|QiLu Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Sudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,DIFFUSE LARGE B CELL LYMPHOMA,_METHOTREXATE,NCT04214626,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,DIFFUSE LARGE B CELL LYMPHOMA,_LENALIDOMIDE,NCT04214626,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_METHOTREXATE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_VINCRISTINE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6723338,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,_DEXAMETHASONE,NCT01376427,Not Applicable,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,PERIPHERAL T CELL LYMPHOMA,_METHOTREXATE,NCT03321890,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,ACUTE MYELOID LEUKEMIA,_TACROLIMUS,NCT03467386,Phase 1,Recruiting,All,"16 Years to 60 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,SEVERE APLASTIC ANEMIA,_TACROLIMUS,NCT02918292,Phase 2,Recruiting,All,"up to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center Oakland, Oakland, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Indiana University Medical Center/ Riley Hospital for Children, Indianapolis, Indiana, United States|University of Louisville/Kosair Children's Hospital, Louisville, Kentucky, United States|Johns Hopkins Unversity, Baltimore, Maryland, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute/Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State College of Medicine/The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Children's Hospital of Wisconsin/Midwest Children's Cancer, Milwaukee, Wisconsin, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,SEVERE APLASTIC ANEMIA,_MYCOPHENOLATE_MOFETIL,NCT02918292,Phase 2,Recruiting,All,"up to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center Oakland, Oakland, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Indiana University Medical Center/ Riley Hospital for Children, Indianapolis, Indiana, United States|University of Louisville/Kosair Children's Hospital, Louisville, Kentucky, United States|Johns Hopkins Unversity, Baltimore, Maryland, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute/Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State College of Medicine/The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Children's Hospital of Wisconsin/Midwest Children's Cancer, Milwaukee, Wisconsin, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,LYMPHOMA,_BUSULFAN,NCT03151876,Phase 2,Recruiting,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing cancer hospital, Beijing, Beijing, China|Peking university third hospital, Beijing, Beijing, China|The first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China|Southwest Hospital, Chongqing, Chongqing, China|General Hospital of Lanzhou military command, Lanzhou, Gansu, China|Henan cancer hospital, Zhengzhou, Henan, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu province hospital, Nanjing, Jiangsu, China|Rui jin hospital Shanghai jiao tong University, Shanghai, Shanghai, China|Tong Ren Hospital, Shanghai, Shanghai, China|Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Southwest Medical University, Nanchong, Sichuan, China|Blood diseases hospital, Chinese academy of medica, Tianjin, Tianjing, China|The first affiliated hospital of Xinjiang medical Universtiy, Ürümqi, Xinjiang, China|Kunming General Hospital of Chengdu Military Area, Kunming, Yunnan, China",5430057,2,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,LYMPHOMA,_CLADRIBINE,NCT03151876,Phase 2,Recruiting,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing cancer hospital, Beijing, Beijing, China|Peking university third hospital, Beijing, Beijing, China|The first affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China|Southwest Hospital, Chongqing, Chongqing, China|General Hospital of Lanzhou military command, Lanzhou, Gansu, China|Henan cancer hospital, Zhengzhou, Henan, China|The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu province hospital, Nanjing, Jiangsu, China|Rui jin hospital Shanghai jiao tong University, Shanghai, Shanghai, China|Tong Ren Hospital, Shanghai, Shanghai, China|Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Southwest Medical University, Nanchong, Sichuan, China|Blood diseases hospital, Chinese academy of medica, Tianjin, Tianjing, China|The first affiliated hospital of Xinjiang medical Universtiy, Ürümqi, Xinjiang, China|Kunming General Hospital of Chengdu Military Area, Kunming, Yunnan, China",7888328.0,7,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,PERIPHERAL T CELL LYMPHOMA,_FLUDARABINE,NCT04083495,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,PERIPHERAL T CELL LYMPHOMA,_BENDAMUSTINE,NCT04083495,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,OVARIAN CANCER,_PALBOCICLIB,NCT03936270,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil|AC Camargo Cancer Center, São Paulo, Brazil|Hospital Beneficência Portuguesa, São Paulo, Brazil|Hospital Pérola Byington, São Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil",6936612,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,MULTIPLE MYELOMA,_VINORELBINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,MULTIPLE MYELOMA,_GEMCITABINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,DIFFUSE LARGE B-CELL LYMPHOMA,_VINORELBINE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,DIFFUSE LARGE B-CELL LYMPHOMA,_MITOXANTRONE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",3977953,C12C3/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,DIFFUSE LARGE B-CELL LYMPHOMA,_DEXAMETHASONE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,DIFFUSE LARGE B-CELL LYMPHOMA,_THALIDOMIDE,NCT02733380,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China",6235756,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,DIFFUSE LARGE B-CELL LYMPHOMA,_GEMCITABINE,NCT04182204,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|The Cancer Institute at St Francis Hospital, East Hills, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Millennium Oncology, Houston, Texas, United States|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Centre Henri Becquerel; Service Hématologie, Rouen, France|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Cork University Hospital, Cork, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,DIFFUSE LARGE B-CELL LYMPHOMA,_VEDOTIN,NCT04182204,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|The Cancer Institute at St Francis Hospital, East Hills, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Millennium Oncology, Houston, Texas, United States|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|Centre Henri Becquerel; Service Hématologie, Rouen, France|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Cork University Hospital, Cork, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,NK/T CELL LYMPHOMA,_GEMCITABINE,NCT04230330,Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Centre Singapore, Singapore, Singapore",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,NK/T CELL LYMPHOMA,_DEXAMETHASONE,NCT04230330,Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Centre Singapore, Singapore, Singapore",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,ACUTE MYELOID LEUKEMIA,_ENTINOSTAT,NCT01305499,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale School of Medicine, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",WO-2004058234-A2,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,ACUTE LYMPHOBLASTIC LEUKEMIA,_METHYLPREDNISOLONE,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_ACETAMINOPHEN,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_DIPHENHYDRAMINE,NCT03913559,Phase 2,Recruiting,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",8263647,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,MULTIPLE MYELOMA,_METHYLPREDNISOLONE,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,MULTIPLE MYELOMA,_RUXOLITINIB,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,ACUTE MYELOID LEUKEMIA,_MYCOPHENOLATE_MOFETIL,NCT02782546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,SEVERE APLASTIC ANEMIA,_SIROLIMUS,NCT02979873,Phase 2,Recruiting,All,"2 Years to 99 Years   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",5212155,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,ACUTE LYMPHOBLASTIC LEUKEMIA,_CLADRIBINE,NCT03318419,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",7888328.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,DIFFUSE LARGE B CELL LYMPHOMA,_CYTARABINE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",5455044,A61K9/127,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,DIFFUSE LARGE B CELL LYMPHOMA,_MELPHALAN,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,DIFFUSE LARGE B CELL LYMPHOMA,_ETOPOSIDE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4701327,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=NN(CCCl)C(=O)NCCCl,DIFFUSE LARGE B CELL LYMPHOMA,_CARMUSTINE,NCT03072771,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4028410,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,MYELODYSPLASTIC SYNDROME,_CYTARABINE,NCT03412266,Phase 2,Recruiting,All,"1 Year to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Institute of Hematology,Beijing, Beijing, Beijing, China",5455044,A61K9/127,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,ACUTE MYELOID LEUKEMIA,_ELTROMBOPAG,NCT03603795,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CHU ANGERS - Maladies du sang, Angers, France|CH de la Côte Basque - Hématologie, Bayonne, France|CHU Estaing, Clermont-Ferrand, France|CHU Grenoble - Hématologie Clinique, Grenoble, France|Institut Paoli-Calmettes - Hématologie 2, Marseille, France|Hôpital Saint-Eloi - Hématologie Clinique, Montpellier, France|HOPITAL E. MULLER - Hématologie, Mulhouse, France|CHU HOTEL DIEU - Hématologie Clinique, Nantes, France|CHU Caremeau, Nîmes, France|CHU La Milétrie - Hématologie Clinique, Poitiers, France|CHU Pontchaillou, Rennes, France|CHU Hautepierre - Hématologie, Strasbourg, France|Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie, Toulouse, France|Sponsor FILO, Tours, France|CHU de Brabois, Vandœuvre-lès-Nancy, France",6280959,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,SEVERE APLASTIC ANEMIA,_ELTROMBOPAG,NCT04304820,Phase 2,Recruiting,All,"3 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",6280959,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,ACUTE MYELOID LEUKEMIA,_MELPHALAN,NCT02771197,Phase 2,Recruiting,All,"18 Years to 78 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States",8410077,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,MULTIPLE MYELOMA,_HYDROXYCHLOROQUINE,NCT04163107,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo, Norway|St. Olavs Hospital, Department of Hematology, Trondheim, Norway",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,MULTIPLE MYELOMA,_ACETAMINOPHEN,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,MULTIPLE MYELOMA,_DIPHENHYDRAMINE,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8263647,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,MULTIPLE MYELOMA,_MONTELUKAST,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CNNCc1ccc(C(=O)NC(C)C)cc1,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,_PROCARBAZINE,NCT03495960,Phase 2,Recruiting,All,70 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aarhus University Hospital, Aarhus, Denmark|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Bari IRCCS Istituto Tumori, Bari, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, Meldola, Italy|Milano, IRCCS Ospedale San Raffaele, Milan, Italy|Milano - Îstituto Besta, Milan, Italy|Milano Niguarda, Milan, Italy|Modena, Policlinico Universitario, Modena, Italy|Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi, Pescara, Italy|Piacenza, Piacenza, Italy|Ravenna - Ospedale di Ravenna - IRST, Ravenna, Italy|Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy|Roma - Unicampus-Bio, Roma, Italy|S. Giovanni Rotondo - Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy|Siena - Azienda Ospedaliera Universitaria Senese, Siena, Italy|Terni - Ospedale di Terni, Terni, Italy|Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, Torino, Italy|Tricase - Ospedale ""Card. G. Panico"", Tricase, Italy|Udine, Azienda Ospedaliera Universitaria, Udine, Italy|Basel - Universitätsspital, Basel, Switzerland|IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Bern - Inselspital, Bern, Switzerland|St. Gallen - Kantonsspital, Saint Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland",3993072,A61M31/002,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0
Cn1nnc2c(C(N)=O)ncn2c1=O,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,_TEMOZOLOMIDE,NCT03495960,Phase 2,Recruiting,All,70 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aarhus University Hospital, Aarhus, Denmark|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Bari IRCCS Istituto Tumori, Bari, Italy|ASST Spedali Civili di Brescia, Brescia, Italy|Meldola, IRST - ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI, Meldola, Italy|Milano, IRCCS Ospedale San Raffaele, Milan, Italy|Milano - Îstituto Besta, Milan, Italy|Milano Niguarda, Milan, Italy|Modena, Policlinico Universitario, Modena, Italy|Pescara, Presidio Ospedaliero UOS dipartimentale centro di diagnosi e terapia Linfomi, Pescara, Italy|Piacenza, Piacenza, Italy|Ravenna - Ospedale di Ravenna - IRST, Ravenna, Italy|Reggio Emilia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy|Roma - Unicampus-Bio, Roma, Italy|S. Giovanni Rotondo - Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy|Siena - Azienda Ospedaliera Universitaria Senese, Siena, Italy|Terni - Ospedale di Terni, Terni, Italy|Torino neurooncologia - AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, Torino, Italy|Tricase - Ospedale ""Card. G. Panico"", Tricase, Italy|Udine, Azienda Ospedaliera Universitaria, Udine, Italy|Basel - Universitätsspital, Basel, Switzerland|IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Bern - Inselspital, Bern, Switzerland|St. Gallen - Kantonsspital, Saint Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland",5260291,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=P1(NCCCl)OCCCN1CCCl,DIFFUSE LARGE B CELL LYMPHOMA,_IFOSFAMIDE,NCT03736616,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Swedish Cancer Institute, Seattle, Washington, United States",5252341,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,DIFFUSE LARGE B CELL LYMPHOMA,_ACALABRUTINIB,NCT03736616,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Swedish Cancer Institute, Seattle, Washington, United States",7459554,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,LYMPHOMA,_DEXAMETHASONE,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",6284804,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,LYMPHOMA,_IBRUTINIB,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",7514444,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=S(=O)(O)CCS,LYMPHOMA,_MESNA,NCT02436707,Phase 2,Recruiting,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,WALDENSTRÖM MACROGLOBULINEMIA,_DEXAMETHASONE,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,WALDENSTRÖM MACROGLOBULINEMIA,_ZANUBRUTINIB,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.836054128421528,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,471.561,102.48,4.0,2.0,5.0,51.75,146.25,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,SICKLE CELL DISEASE|SICKLE CELL ANEMIA,_BIOTIN,NCT04476277,Early Phase 1,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",3946115.0,A23K20/158,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.17,244.31099999999998,78.43,3.0,3.0,2.0,24.92,60.05,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,PERIPHERAL T CELL LYMPHOMA,_AZACITIDINE,NCT04480125,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, China",4058602,C07H19/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,MANTLE CELL LYMPHOMA,_LENALIDOMIDE,NCT04109872,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Retrospective,"Hospital Universitario Virgen Macarena, Sevilla, Spain",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,DIFFUSE LARGE B-CELL LYMPHOMA,_LENALIDOMIDE,NCT04404283,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St Louis, Saint Louis, Missouri, United States",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,NON HODGKIN LYMPHOMA,_LENALIDOMIDE,NCT02180711,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Innovative Clinical Research, Whittier, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Center, Louisville, Kentucky, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Clinical Research Alliance, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",5635517.0,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,NON HODGKIN LYMPHOMA,_ACALABRUTINIB,NCT02180711,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Innovative Clinical Research, Whittier, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Center, Louisville, Kentucky, United States|University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Clinical Research Alliance, Lake Success, New York, United States|Weill Cornell Medical College, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",7459554,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,_POMALIDOMIDE,NCT04191616,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Cincinnati, Ohio, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Hamburg, Germany|Research Site, Tubingen, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Ancona, Italy|Research Site, Brescia, Italy|Research Site, Lecce, Italy|Research Site, Roma, Italy",5635517,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,LYMPHOMA,_RUXOLITINIB,NCT02974647,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,HODGKIN LYMPHOMA,_RUXOLITINIB,NCT03681561,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois Cancer Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Wisconsin, Madison, Wisconsin, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,MANTLE CELL LYMPHOMA,_DOXORUBICIN_HYDROCHLORIDE,NCT03710772,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4003996,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_ASPIRIN,NCT04160546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Català d´oncologia Badalona (ICO), Badalona, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen de La Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_PONATINIB,NCT04160546,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Català d´oncologia Badalona (ICO), Badalona, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen de La Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",8114874,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,ACUTE LYMPHOBLASTIC LEUKEMIA,_PENTOXIFYLLINE,NCT02451774,Phase 2|Phase 3,Recruiting,All,"1 Year to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Civil de Guadalajara ""Dr. Juan I. Menchaca"", Guadalajara, Jalisco, Mexico",4189469,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,LYMPHOMA,_SIMVASTATIN,NCT04514029,Early Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,DIFFUSE LARGE B CELL LYMPHOMA,_BORTEZOMIB,NCT03129828,Phase 1|Phase 2,Recruiting,All,"61 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany",6083903.0,C07K5/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,DIFFUSE LARGE B CELL LYMPHOMA,_IBRUTINIB,NCT03129828,Phase 1|Phase 2,Recruiting,All,"61 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,ACUTE MYELOID LEUKEMIA,_BORTEZOMIB,NCT04173585,Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Heidelberg, Internal Medicine V, Heidelberg, Baden-Württemberg, Germany",6083903.0,C07K5/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,ACUTE MYELOID LEUKEMIA,_DASATINIB,NCT02013648,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitätsklinik für Innere Medizin V, Innsbruck, Austria|Krankenhaus der Barmherzigen Schwestern, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Universitätsklinik der PMU, Salzburg, Austria|Hanuschkrankenhaus, Wien, Austria|MVZ Osthessen, Fulda, Hessen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany|Helios Klinikum Bad Saarow, Klinik für Hämatologie, Bad Saarow, Germany|Klinikum am Urban, Berlin, Germany|Klinikum Neukölln, Berlin, Germany|Charité Universitätsmedizin Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Medizinische Klinik und Poliklinik III, Bonn, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Klinikum Bremen Mitte gGmbH, Bremen, Germany|Klinikum Darmstadt Medizinische Klinik V, Darmstadt, Germany|St. Johannes Hospital, Dortmund, Germany|Universitätsklinikum Medizinische Klinik und Poliklinik, Düsseldorf, Germany|Klinikum Esslingen, Esslingen, Germany|Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Wilhelm-Anton-Hospital gGmbH, Goch, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Hanau GmbH, Hanau, Germany|Klinikum Region Hannover GmbH, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK-Kliniken GmbH, Heilbronn, Germany|Marienhospital Klinikum der Ruhr-Universität, Herne, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|Gemeinschaftspraxis Hämato-Onkologie im Caritas Krankenhaus, Lebach, Germany|Klinikum Lippe GmbH, Lemgo, Germany|Märkische Kliniken GmbH, Lüdenscheid, Germany|Univ-Klinikum der Otto-von Guericke-Universität, Magdeburg, Germany|III. Medizinische Klinik und Poliklinik Universitätsmedizin der Johannes Gutenberg-Universität, Mainz, Germany|Johannes Wesling Klinikum, Minden, Germany|Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany|Klinikum rechts der Isar der TU, München, Germany|Ortenau Klinikum, Offenburg, Germany|PIUS Hospital, Oldenburg, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Klinikum Passau, Passau, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Caritasklinkum Saarbrücken St. Theresia, Saarbrücken, Germany|Klinikum Stuttgart, Stuttgart, Germany|Vinzenz von Paul Kliniken gGmbH Marienhospital, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier, Germany|Medizinische Universitätsklinik, Tübingen, Germany|Universitätsklinikum Ulm Zentrum für Innere Medizin, Ulm, Germany|Schwarzwald-Baar Klinikum, Villingen Schwenningen, Germany|Kliniken Essen Süd, Werden, Germany|HELIOS Klinikum, Wuppertal, Germany",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"MYELOID LEUKEMIA, CHRONIC",_DASATINIB,NCT02890784,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uniklinik der RWTH Aachen, Aachen, Germany|Gesundheitszentrum St. Marien GmbH, Amberg, Germany|Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany|OnkoBer, Berlin, Germany|Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany|Universitätsklinikum Bonn, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Bremen, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Gemeinschaftspraxis Mohm/Prange-Krex, Dresden, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|Helios St. Johannes Klinik Duisburg, Duisburg, Germany|Gemeinschaftspraxis Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Katholisches Karl-Leisner Klinikum, Goch, Germany|MVZ Onkologische Kooperation Harz, Goslar, Germany|ConMed GmbH, Göttingen, Germany|Hämato-Onkologische Gemeinschaftspraxis Halberstadt, Halberstadt, Germany|Universitätsklinikum Halle/S., Halle, Germany|Asklepios MVZ Onkologie, Hamburg, Germany|MediProjekt GbR, Hannover, Germany|St. Bernward Krankenhaus Hildesheim, Hildesheim, Germany|Universitätsklinikum Jena, Jena, Germany|Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR, Kaiserslautern, Germany|Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany|St. Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany|Onkologische Gemeinschaftspraxis, Kassel, Germany|Klinikum Kassel, Kassel, Germany|Städtisches Krankenhaus Kiel GmbH, Kiel, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|InVo Institut für Versorgungsforschung, Koblenz, Germany|MVZ Hämatologie und Onkologie, Krefeld, Germany|Onkologische Schwerpunktpraxis, Kronach, Germany|Onkologisches Zentrum, Lebach, Germany|Studienzentrum UnterEms, Leer, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin Mannheim, Mannheim, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany|Rotkreuzklinikum München, München, Germany|Gemeinschaftspraxis Hämatologie/ Onkologie, München, Germany|Universitätsklinikum Münster, Münster, Germany|Hämatologisch-onkologische Schwerpunktpraxis, Neustadt Am Rübenberge, Germany|Klinikum Passau, Passau, Germany|Kreiskliniken Reutlingen GmbH, Reutlingen, Germany|Universitätsmedizin Rostock, Rostock, Germany|Klinikum Südstadt Rostock, Rostock, Germany|Hämatologie-Onkologie Stolberg, Stolberg, Germany|Klinikum Mutterhaus der, Trier, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany|Rems-Murr-Klinik Winnenden, Winnenden, Germany",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,MULTIPLE MYELOMA,_TRAMETINIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,MULTIPLE MYELOMA,_DABRAFENIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,ACUTE LYMPHOBLASTIC LEUKEMIA,_IDELALISIB,NCT03742323,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario A Coruña, A Coruña, Spain|Hospital ICO Badalona, Badalona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital ICO Hospitalet, Hospitalet de Llobregat, Spain|Hospital 12 de Octubre, Madrid, Spain|H. Morales Meseguer, Murcia, Spain|H. Virgen de la Victoria, Mála, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Marques de Valdecilla, Santander, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Clínico Valencia, Valencia, Spain|Hospital Universitario y Politécnico la Fe, Valencia, Spain",6800620,C07D473/38,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,MANTLE CELL LYMPHOMA,_VENETOCLAX,NCT03523975,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Michgan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,DIFFUSE LARGE B CELL LYMPHOMA,_COPANLISIB,NCT04263584,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Halle, Halle (Saale), Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital Muenster, Muenster, Germany|Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany|Hospital Stuttgart - Stuttgart Cancer Center, Stuttgart, Germany|University Hospital Ulm, Ulm, Germany",7511041,C07D471/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,MANTLE CELL LYMPHOMA,_CARFILZOMIB,NCT03891355,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C. Ematologia, Alessandria, Italy|Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O., Bolzano, Italy|ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy|Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia, Genova, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy|IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia, Pavia, Italy|Ospedale Guglielmo da Saliceto - U.O.Ematologia, Piacenza, Italy|Ospedale delle Croci - Ematologia, Ravenna, Italy|Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia, Reggio Emilia, Italy|Policlinico Umberto I - Università ""La Sapienza"" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione, Roma, Italy|AOU Senese - U.O.C. Ematologia, Siena, Italy|A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy|A.O. C. Panico - U.O.C Ematologia e Trapianto, Tricase, Italy|Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy|Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - SOC Clinica Ematologica, Udine, Italy|AOU Integrata di Verona - U.O. Ematologia, Verona, Italy",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,MULTIPLE MYELOMA,_CARFILZOMIB,NCT03989414,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Colorado Blood Cancer Institute, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta - Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Charles University General Hospital, Praha 2, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Hopital Claude Huriez CHRU Lille, Lille cedex, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse Cedex 9, France|CHRU Hopital Bretonneau, Tours cedex, France|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Hopsital Germans Trias I Pujol, Badalona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,MULTIPLE MYELOMA,_CC-220,NCT02773030,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Winthrop Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital Weil Cornell Medical College, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Prisma Health Cancer Institute, Greenville, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McGill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|CHRU Hopital Claude Huriez, Lile Cedax, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU La Miletrie, Poitiers Cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia, Rome, Italy|Osp. S.Giovanni Battista Le Molinette, Torino, Italy|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Nagoya City University Hospital, Nagoya, Japan|Tohoku University Hospital, Sendai, Japan|VU University Medical Center, Amsterdam, Netherlands|Maastricht University Medical Center, Maastrich, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Val d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Genesis Care, Oxford, United Kingdom|The Institut of Cancer Research, Sutton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",WO-2014025958-A2,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,449.50699999999995,88.18,6.0,1.0,5.0,47.73,122.29,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,MANTLE CELL LYMPHOMA,_IXAZOMIB,NCT03616782,Phase 2,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kosin University Gospel Hospital, Busan, Western, Korea, Republic of",7442830,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,THALASSEMIA,_THALIDOMIDE,NCT03651102,Phase 2|Phase 3,Recruiting,All,"18 Months to 50 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Blood Diseases Clinic, Peshawar, Khyber Pakhtukhwa, Pakistan",6235756,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,NON-HODGKIN'S LYMPHOMA,_IBRUTINIB,NCT03198026,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,PERIPHERAL T CELL LYMPHOMA,_DUVELISIB,NCT03372057,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|University of California - Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Ohio State Univeristy, Columbia, Ohio, United States|Toledo Cancer Center, Toledo, Ohio, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor Research Institute - Charles Sammons Cancer Center, Dallas, Texas, United States|Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV, Halle, Sachsen-Anhalt, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo, Bergamo, Italy|A.O.di Bologna Policl.S.Orsola, Bologna, Italy|Ieo, Irccs, Milano, Italy|Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Italy|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",8193182,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,HODGKIN LYMPHOMA,_DECITABINE,NCT03250962,Phase 2,Recruiting,All,"12 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China",5654333,1,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,NON HODGKIN LYMPHOMA,_DECITABINE,NCT04337606,Phase 1|Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,DIFFUSE LARGE B CELL LYMPHOMA,_BENDAMUSTINE,NCT02753062,Phase 2,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,MULTIPLE MYELOMA,_BENDAMUSTINE,NCT04083898,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_BENDAMUSTINE,NCT02763319,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"MorphoSys Research Site, Anaheim, California, United States|MorphoSys Research Site, Bakersfield, California, United States|Morphosys Research Site, Burbank, California, United States|Morphosys Research Site, Fresno, California, United States|MorphoSys Research Site, Los Angeles, California, United States|MorphoSys Research Site, Whittier, California, United States|MorphoSys Research Site, Plainville, Connecticut, United States|MorphoSys Research Site, Skokie, Illinois, United States|MorphoSys Research Site, Detroit, Michigan, United States|MorphoSys Research Site, Rochester, Minnesota, United States|MorphoSys Research Site, Hattiesburg, Mississippi, United States|Morphosys Research site, Jackson, Mississippi, United States|Morphosys Research Site, Morristown, New Jersey, United States|MorphoSys Research Site, New York, New York, United States|MorphoSys Research Site, Stony Brook, New York, United States|MorphoSys Research Site, Oklahoma City, Oklahoma, United States|MorphoSys Research Site, Knoxville, Tennessee, United States|Morphosys Research Site, Lubbock, Texas, United States|MorphoSys Research Site, Adelaide, Australia|MorphoSys Research Site, Albury, Australia|MorphoSys Research Site, Bedford Park, Australia|MorphoSys Research Site, Box Hill, Australia|MorphoSys Research Site, Concord, Australia|MorphoSys Research Site, Frankston, Australia|MorphoSys Research SIte, Garran, Australia|MorphoSys Research Site, Geelong, Australia|MorphoSys Research Site, Gosford, Australia|MorphoSys Research Site, Nedlands, Australia|MorphoSys Research Site, South Brisbane, Australia|MorphoSys Research Site, St. Albans, Australia|MorphoSys Research Site, Innsbruck, Austria|Morphosys Research Site, Edmonton, Alberta, Canada|MorphoSys Research Site, Winnipeg, Manitoba, Canada|MorphoSys Research Site, Saint John, New Brunswick, Canada|Morphosys Research Site, Saint John's, Newfoundland and Labrador, Canada|MorphoSys Research Site, Kingston, Ontario, Canada|MorphoSys Research Site, Greenfield Park, Quebec, Canada|Morphosys Research Site, Montréal, Quebec, Canada|MorphoSys Research Site, Saskatoon, Canada|MorphoSys Research Site, Zagreb, Croatia|MorphoSys Research Site, Hradec Kralove, Czechia|Morphosys Research site, Olomouc, Czechia|Morphosys Research Site, Prague, Czechia|MorphoSys Research Site, Prague, Czechia|MorphoSys Research Site, Oulu, Finland|MorphoSys Research Site, Tampere, Finland|MorphoSys Research Site, Grenoble, France|MorphoSys Research Site, Le Mans, France|MorphoSys Research Site, Aachen, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Berlin, Germany|MorphoSys Research Site, Düsseldorf, Germany|MorphoSys Research Site, Giessen, Germany|Morphosys Research Site, Homburg, Germany|MorphoSys Research Site, Leipzig, Germany|MorphoSys Research Site, Mainz, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Munich, Germany|MorphoSys Research Site, Mutlangen, Germany|Morphosys Research Site, Münster, Germany|MorphoSys Research Site, Rostock, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys Research Site, Stuttgart, Germany|MorphoSys, Traunstein, Germany|MorphoSys, Budapest, Hungary|MorphoSys Research Site, Debrecen, Hungary|MorphoSys Research Site, Győr, Hungary|MorphoSys, Szeged, Hungary|MorphoSys Research Site, Haifa, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Jerusalem, Israel|MorphoSys Research Site, Kfar Saba, Israel|MorphoSys Research Site, Tel Aviv, Israel|MorphoSys Research Site, Alessandria, Italy|MorphoSys Research Site, Bologna, Italy|MorphoSys Research Site, Campobasso, Italy|MorphoSys Research Site, Cona, Italy|MorphoSys Research Site, Genova, Italy|MorphoSys Research Site, Lecce, Italy|MorphoSys Research Site, Meldola, Italy|MorphoSys Research Site, Monza, Italy|MorphoSys Research Site, Napoli, Italy|Morphosys Research Site, Novara, Italy|MorphoSys Research Site, Orbassano, Italy|MorphoSys Research Site, Parma, Italy|MorphoSys Research Site, Pavia, Italy|MorphoSys Research Site, Pisa, Italy|MorphoSys Research Site, Ravenna, Italy|MorphoSys Research Site, Reggio Emilia, Italy|MorphoSys Research Site, Rimini, Italy|MorphoSys Research Site, Rome, Italy|MorphoSys Research Site, Rome, Italy|Morphosys Research Site, Terni, Italy|MorphoSys Research Site, Turin, Italy|Morphosys Research Site, Turin, Italy|MorphoSys Research Site, Busan, Korea, Republic of|MorphoSys Research Site, Goyang-si, Korea, Republic of|MorphoSys Research Site, Incheon, Korea, Republic of|MorphoSys Research Site, Jeonju, Korea, Republic of|MorphoSys Research Site, Seongnam, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Seoul, Korea, Republic of|MorphoSys Research Site, Ulsan, Korea, Republic of|MorphoSys Research Site, Addington, New Zealand|MorphoSys Research Site, Auckland, New Zealand|MorphoSys Research Site, Grafton, New Zealand|Morphosys Research Site, Bydgoszcz, Poland|MorphoSys Research Site, Gdynia, Poland|MorphoSys Research Site, Kraków, Poland|MorphoSys Research Site, Legnica, Poland|MorphoSys Research Site, Lodz, Poland|MorphoSys Research Site, Lublin, Poland|Morphosys Research Site, Warszawa, Poland|MorphoSys Research Site, Wrocław, Poland|MorphoSys Research Site, Braga, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Coimbra, Portugal|MorphoSys Research Site, Matosinhos, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Porto, Portugal|MorphoSys Research Site, Pragal, Portugal|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Bucharest, Romania|MorphoSys Research Site, Iaşi, Romania|MorphoSys Research Site, Belgrade, Serbia|MorphoSys Research Site, Kragujevac, Serbia|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Singapore, Singapore|MorphoSys Research Site, Cadiz, Spain|MorphoSys Research Site, Girona, Spain|MorphoSys Research Site, L'Hospitalet De Llobregat, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Madrid, Spain|MorphoSys Research Site, Palma de Mallorca, Spain|MorphoSys Research Site, Pamplona, Spain|MorphoSys Research Site, Pozuelo De Alarcón, Spain|MorphoSys, Sabadell, Spain|MorphoSys Research Site, Salamanca, Spain|MorphoSys Research Site, Valencia, Spain|Morphosys Research Site, Chang Hua, Taiwan|Morphosys Research Site, Hualien City, Taiwan|Morphosys Research Site, Taichung City, Taiwan|MorphoSys Research Site, Adana, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Ankara, Turkey|MorphoSys Research Site, Bornova, Turkey|MorphoSys Research Site, Gaziantep, Turkey|MorphoSys Research Site, İzmir, Turkey|MorphoSys Research Site, Manisa, Turkey|MorphoSys Research Site, Samsun, Turkey|Morphosys Research Site, Birmingham, United Kingdom|MorphoSys Research Site, Leeds, United Kingdom|MorphoSys Research Site, Southend on Sea, United Kingdom",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,"LYMPHOMA, T-CELL, CUTANEOUS",_DOXYCYCLINE,NCT03116659,Early Phase 1,Recruiting,All,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States",5789395.0,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,16.0,23.1298383950389,2.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,"LYMPHOMA, T-CELL, CUTANEOUS",_IMIQUIMOD,NCT03116659,Early Phase 1,Recruiting,All,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James J Peters Bronx Veterans Affairs Medical Center, Bronx, New York, United States",4689338,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCC(CCC)C(=O)O,ACUTE MYELOID LEUKEMIA,_VALPROIC_ACID,NCT01369368,Phase 1|Phase 2,Unknown status,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haukeland University Hospital, Bergen, Norway",6419953.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,CHRONIC LYMPHOCYTIC LEUKEMIA,_LAMIVUDINE,NCT03528941,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Other|Time Perspective: Retrospective,"AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione, Cona, Ferrara, Italy|AOU Consorziale Policlinico - UO Ematologia con Trapianto, Bari, Italy|ASST degli Ospedali Civili di Brescia - UO Ematologia, Brescia, Italy|AO Brotzu, Presidio Ospedaliero A.Businco - SC Ematologia e CTMO, Cagliari, Italy|CTC U.O. di Ematologia con Trapianto di midollo osseo - Catania, Catania, Italy|AO di Catanzaro ""Pugliese - Ciaccio"", Presidio Ospedaliero ""Ciaccio - De Lellis"" - Ematologia, Catanzaro, Italy|IRCCS AOU San Martino - UO Ematologia e Trapianti, Genova, Italy|ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, Italy|Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico - Ematologia, Milano, Italy|IRCCS Ospedale San Raffaele - Unità neoplasie linfocitarie B, Milano, Italy|AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy|Fondazione IRCCS Policlinico San Matteo - OU Ematologia, Pavia, Italy|AOU Pisana - UO Ematologia Universitaria, Pisa, Italy|AOU Policlinico Tor Vergata - UOC Trapianto cellule staminali, Roma, Italy|Fondazione Policlinico Universitario A. Gemelli IRCCS - Area Ematologica, Roma, Italy|Policlinico Universitario Campus Bio Medico - UOC Ematologia e Trapianto di cellule staminali, Roma, Italy|AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia, Torino, Italy",5905082,C07D411/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,MULTIPLE MYELOMA,_PLERIXAFOR,NCT03406091,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy",RE42152,C07D401/14 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,LYMPHOMA,_ETOPOSIDE_PHOSPHATE,NCT02106988,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,ACUTE MYELOID LEUKEMIA,_PIOGLITAZONE,NCT02942758,Phase 2,Unknown status,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Regensburg, Regensburg, Germany",4687777,C07D213/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,CHRONIC MYELOID LEUKEMIA,_PIOGLITAZONE,NCT02889003,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de Versailles, Le Chesnay, France|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|CHU de Nantes, Nantes, France|CHU de Rennes, Rennes, France",4687777,C07D213/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
CN(C)/N=N/c1[nH]cnc1C(N)=O,HODGKIN LYMPHOMA,_DACARBAZINE,NCT03033914,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",4722834,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,28.0,22.965563974619602,1554.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.32,182.187,99.73,5.0,2.0,1.0,17.78,49.71,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],CENTRAL NERVOUS SYSTEM LYMPHOMA,_SODIUM_THIOSULFATE,NCT00293475,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CENTRAL NERVOUS SYSTEM LYMPHOMA,_MANNITOL,NCT00293475,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",3932678,A23L27/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,MYASTHENIA GRAVIS,_ALBUTEROL,NCT03914638,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Neurology, Aalborg University Hospital, Aalborg, Denmark|Neurology, Aarhus University Hospital, Aarhus, Denmark",5775321,B65D83/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,SICKLE CELL DISEASE,_DRONABINOL,NCT03978156,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Yale New Haven Hospital Smilow Cancer Center, New Haven, Connecticut, United States",6703418.0,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,CHRONIC LYMPHOCYTIC LEUKEMIA,_UMBRALISIB,NCT04016805,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TG Therapeutics Investigational Trial Site, Boston, Massachusetts, United States|TG Therapeutics Investigational Trial Site, Hackensack, New Jersey, United States|TG Therapeutics Investigational Trial Site, New York, New York, United States",US-20140011819-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,27.13813425327001,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.2,571.56,105.15,7.0,1.0,6.0,56.6,163.22,6.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,ACUTE MYELOID LEUKEMIA,_RIBAVIRIN,NCT03760666,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",6172046,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHRONIC MYELOID LEUKEMIA,_BOSUTINIB,NCT03831776,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aalborg university hospital, Aalborg, Denmark|Aarhus ..., Aarhus, Denmark|Copenhagen ..., Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Comprehensive Cancer Center, Hematology, Helsinki, Finland|Haukeland Universitetssjukehus, Bergen, Norway|Oslo Universitetssykehus, Oslo, Norway|Stavanger Universitetssjukehus, Stavanger, Norway|Universitetssykehuset Nord Norge, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Göteborg ...., Göteborg, Sweden|Universitetssjukhuset Linköping, Linköping, Sweden|Skåne University Hospital, Lund, Sweden|Karolinska Universitetssjukhus, Stockholm, Sweden|Sundsvall ..., Sundsvall, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|University Hospital, Uppsala, Sweden|Universitetssjukhuset Örebro, Örebro, Sweden",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHRONIC MYELOGENOUS LEUKEMIA,_BOSUTINIB,NCT02501330,,Recruiting,All,"Child, Adult, Older Adult",Industry,Observational Model: Case-Only|Time Perspective: Prospective,"Shibuya-ku, Japan",6002008,C07D401/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,20.600012320581502,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.87,530.446,82.88,8.0,1.0,4.0,56.14,142.12,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,MULTIPLE MYELOMA,_RIMIDUCID,NCT03288493,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of California Davis, Davis, California, United States|University of California San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wayne State - Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,DIFFUSE LARGE B-CELL LYMPHOMA,_TUCIDINOSTAT,NCT04231448,Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University Cancer Hospital, Beijing, Beijing, China|Shanghai JiaoTong University School of Medicine，Ruijin Hospital, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,UVEITIS,_BARICITINIB,NCT04088409,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France|Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France|GH Necker - Enfants Malades, Paris Cedex 15, France|CHU Poitiers - Hopital Jean Bernard, Poitiers Cedex, France|Asklepios Klinik Sankt Augustin, Saint Augustin, Nordrhein-Westfalen, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany|Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini, Genova, Liguria, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Meyer, Firenze, Italy|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Cambridge Clinical Research Facility, Cambridge, Cambridgeshire, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Royal Victoria Infirmary, Newcastle, N'castle-upon-tyne, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Bristol Royal Hospital for Children, Bristol, United Kingdom|Alder Hey Children's Hospital, Liverpool, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, London, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,"CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE",_RADOTINIB,NCT03722420,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital(北京大学人民医院), Beijing, China",US-20080096899-A1,A61P35/00 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,42.0542516273434,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.77,530.515,110.51,7.0,2.0,5.0,52.47,150.32,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,ACUTE MYELOID LEUKEMIA,_GLASDEGIB,NCT04051996,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Yale Cancer Center/Smilow, New Haven, Connecticut, United States",8148401,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,45.471159572065105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.68,374.44800000000004,96.84,4.0,3.0,4.0,40.98,108.26,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,IMMUNE THROMBOCYTOPENIA,_DANAZOL,NCT04481282,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",4055562,C07J71/0063,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,IMMUNE THROMBOCYTOPENIA,_TERBUTALINE,NCT04481282,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",3937838,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,PERIPHERAL T CELL LYMPHOMA,_FENRETINIDE,NCT02495415,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas, Southwestern, Dallas, Texas, United States",4190594,C07D213/87,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",_TENALISIB,NCT04204057,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Multiprofile Hospital for Active Treatment ""Dr Georgi Stranski"" Ltd.,, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv Ivan Rilski"" Ltd, Sofia, Bulgaria|Ltd. M.Zodelava Hematology Centre, Tbilisi, Georgia|Medivest - Institute of Hematology and Transfusiology, Tbilisi, Georgia|Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzow, Poland|Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus, Łódź, Poland",US-20140364447-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,415.42800000000005,92.79,6.0,2.0,5.0,41.59,116.09,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,SICKLE CELL DISEASE,_VOXELOTOR,NCT04247594,Phase 2,Recruiting,All,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Guy's Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Homerton University, London, United Kingdom|King's College Hospital, London, United Kingdom|Royal London Hospital, Barts Health NHS Trust, London, United Kingdom",9018210,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,27.95950635536661,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.02,337.379,77.24,5.0,1.0,3.0,35.37,106.25,6.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ERDAFITINIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,45.0,24.31261422205795,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,446.555,77.33,7.0,1.0,4.0,51.0,139.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ENASIDENIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,6.111008439598348,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,473.38300000000004,108.74,8.0,3.0,3.0,41.41,118.37,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,ACUTE MYELOID LEUKEMIA,_ENASIDENIB,NCT04075747,Phase 1,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Stanford University School of Medicine- Standford Cancer Institute, Palo Alto, California, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,6.111008439598348,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,473.38300000000004,108.74,8.0,3.0,3.0,41.41,118.37,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,DIFFUSE LARGE B CELL LYMPHOMA,_ZANUBRUTINIB,NCT04460248,Phase 2,Recruiting,All,75 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.836054128421528,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,471.561,102.48,4.0,2.0,5.0,51.75,146.25,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,BRAIN TUMOR,_LETROZOLE,NCT03122197,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Cincinnati, Cincinnati, Ohio, United States",4978672,C07D213/57,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PARKINSON'S DISEASE,_PREDNISONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,PARKINSON'S DISEASE,_METHYLPREDNISOLONE,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,PARKINSON'S DISEASE,_SIROLIMUS,NCT04127578,Phase 1|Phase 2,Recruiting,All,"35 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PPD, 100 West Gore Street, Suite 202, Orlando, Florida, United States|Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States|Mount Sinai Beth Israel, 10 Union Square East, Suite 5H, New York, New York, United States|NYU Langone Health, The Marlene and Paolo Fresco institute for Parkinson's and Movement Disorders, 222 East 41st Street, 13th Floor, New York, New York, United States|Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street, New York, New York, United States",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PANCREATIC ADENOCARCINOMA,_NIRAPARIB,NCT03404960,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States",8859562,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,OVARIAN NEOPLASMS,_NIRAPARIB,NCT03955471,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Solvang, California, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Maplewood, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Harrison, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Willow Grove, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States",8859562,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC RENAL CELL CARCINOMA,_CYCLOPHOSPHAMIDE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC RENAL CELL CARCINOMA,_FLUDARABINE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,RHABDOMYOSARCOMA,_CYCLOPHOSPHAMIDE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,RHABDOMYOSARCOMA,_VINCRISTINE,NCT04388839,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States",6723338,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,RETINOBLASTOMA,_CYCLOPHOSPHAMIDE,NCT02870907,Phase 2,Recruiting,All,2 Months to 10 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chr Felix Guyon, Saint-Denis, La Réunion, France|Hopital Nord Chu Amiens, Amiens, France|Chu Angers, Angers, France|Hopital Jean Minioz, Besancon, France|Chu R; Pellegrin, Bordeaux, France|Chu Morvan, Brest, France|CHU CAEN, Caen, France|Chu Estaing, Clermont Ferrand, France|Chu Bocage, Dijon, France|Chu de Grenoble, Grenoble, France|Centre Oscar Lambret, Lille, France|Chu Limoges, Limoges, France|Centre Leon Berard, Lyon, France|Hopital D'Enfants La Timone, Marseille, France|Hopital Arnaud de Villeneuve, Montpellier, France|Chu Nantes, Nantes, France|Chu de Nice, Nice, France|Institut Curie, Paris, France|Chu de Poitiers, Poitiers, France|Chur de Reims, Reims, France|Chu de Rennes, Rennes, France|Chu de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Hoptial Hautepierre, Strasbourg, France|Chu Toulouse, Toulouse, France|Chu Tours, Tours, France|Chu Nancy, Vandoeuvre Les Nancy, France",3987166,7,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
S=P(N1CC1)(N1CC1)N1CC1,RETINOBLASTOMA,_THIOTEPA,NCT02870907,Phase 2,Recruiting,All,2 Months to 10 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chr Felix Guyon, Saint-Denis, La Réunion, France|Hopital Nord Chu Amiens, Amiens, France|Chu Angers, Angers, France|Hopital Jean Minioz, Besancon, France|Chu R; Pellegrin, Bordeaux, France|Chu Morvan, Brest, France|CHU CAEN, Caen, France|Chu Estaing, Clermont Ferrand, France|Chu Bocage, Dijon, France|Chu de Grenoble, Grenoble, France|Centre Oscar Lambret, Lille, France|Chu Limoges, Limoges, France|Centre Leon Berard, Lyon, France|Hopital D'Enfants La Timone, Marseille, France|Hopital Arnaud de Villeneuve, Montpellier, France|Chu Nantes, Nantes, France|Chu de Nice, Nice, France|Institut Curie, Paris, France|Chu de Poitiers, Poitiers, France|Chur de Reims, Reims, France|Chu de Rennes, Rennes, France|Chu de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Hoptial Hautepierre, Strasbourg, France|Chu Toulouse, Toulouse, France|Chu Tours, Tours, France|Chu Nancy, Vandoeuvre Les Nancy, France",4766149,7,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,OSTEOSARCOMA,_CYCLOPHOSPHAMIDE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,OSTEOSARCOMA,_METHOTREXATE,NCT03063983,Phase 2,Recruiting,All,"up to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,GLIOBLASTOMA,_CAPECITABINE,NCT02669173,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4966891,C07H19/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,"CARCINOMA, RENAL CELL",_EVEROLIMUS,NCT04195750,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama - Birmingham ( Site 1538), Birmingham, Alabama, United States|St Joseph Heritage Healthcare ( Site 1531), Santa Rosa, California, United States|University Of Colorado ( Site 1540), Aurora, Colorado, United States|UCHealth Highlands Ranch Hospital ( Site 1560), Highlands Ranch, Colorado, United States|Sibley Memorial Hospital ( Site 1559), Washington, District of Columbia, United States|Northwest Georgia Oncology Centers PC ( Site 1520), Marietta, Georgia, United States|The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States|Dana Farber Cancer Institute ( Site 1505), Boston, Massachusetts, United States|Henry Ford Cancer Center ( Site 1511), Detroit, Michigan, United States|Hattiesburg Clinic ( Site 1509), Hattiesburg, Mississippi, United States|St. Vincent Frontier Cancer Center ( Site 1549), Billings, Montana, United States|University of Rochester Medical Center ( Site 1543), Rochester, New York, United States|University of North Carolina at Chapel Hill ( Site 1537), Chapel Hill, North Carolina, United States|Oncology Hematology Care, Inc. ( Site 1524), Cincinnati, Ohio, United States|Cleveland Clinic ( Site 1504), Cleveland, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523), Tulsa, Oklahoma, United States|Oregon Health & Science University ( Site 1553), Portland, Oregon, United States|Abramson Cancer Center ( Site 1525), Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center ( Site 1506), Philadelphia, Pennsylvania, United States|Medical University of South Carolina ( Site 1518), Charleston, South Carolina, United States|Henry Joyce Cancer Clinic ( Site 1544), Nashville, Tennessee, United States|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 1653), Sao Paulo, Brazil|Sociedad de Investigaciones Medicas Limitadas ( Site 0004), Temuco, Araucania, Chile|Sociedad Medica Aren y Bachero Limitada ( Site 0003), Santiago, Region M. De Santiago, Chile|Fundacion Centro de Investigacion Clinica CIC ( Site 1703), Medellin, Antioquia, Colombia|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1709), Valledupar, Cesar, Colombia|Administradora Country SA - Clinica del Country ( Site 1701), Bogota, Distrito Capital De Bogota, Colombia|Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1702), Bogota, Distrito Capital De Bogota, Colombia|Oncologos del Occidente S.A. ( Site 1708), Pereira, Risaralda, Colombia|Masarykuv onkologicky ustav ( Site 0105), Brno, Brno-mesto, Czechia|Fakultni nemocnice Ostrava ( Site 0103), Ostrava, Moravskoslezsky Kraj, Czechia|Fakultni nemocnice Hradec Kralove ( Site 0106), Hradec Kralove, Czechia|Fakultni nemocnice Olomouc ( Site 0104), Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady ( Site 0102), Praha 10, Czechia|Herlev Hospital ( Site 0251), Herlev, Hovedstaden, Denmark|Aarhus University Hospital Skejby ( Site 0250), Aarhus, Midtjylland, Denmark|Tampereen yliopistollinen sairaala ( Site 0300), Tampere, Pirkanmaa, Finland|Kuopion Yliopistollinen Sairaala ( Site 0304), Kuopio, Pohjois-Savo, Finland|HYKS. ( Site 0302), Helsinki, Uusimaa, Finland|TYKS T-sairaala Syopatautien pkl ( Site 0301), Turku, Varsinais-Suomi, Finland|HUS Hopital Hautepierre ( Site 0350), Strasbourg, Bas-Rhin, France|Centre Francois Baclesse ( Site 0360), Caen, Calvados, France|CHU Besancon - Hopital Jean Minjoz ( Site 0351), Besancon, Doubs, France|Institut de Cancerologie du Gard - CHU Caremeau ( Site 0352), Nimes, Gard, France|Centre Hospitalier Lyon Sud ( Site 0354), Pierre Benite, Rhone, France|Gustave Roussy ( Site 0353), Villejuif, Val-de-Marne, France|Universitaetsklinikum Jena ( Site 0402), Jena, Thuringen, Germany|Prince of Wales Hospital ( Site 1050), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 1051), Hong Kong, Hong Kong|Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0502), Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Onkologiai Intezet ( Site 0503), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0504), Debrecen, Hungary|Medical Oncology Ospedale San Donato ( Site 0609), Arezzo, Italy|Policlinico S. Orsola-Malpighi ( Site 0606), Bologna, Italy|Fondazione Salvatore Maugeri IRCCS ( Site 0600), Pavia, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0607), Roma, Italy|Azienda Ospedaliera Santa Maria ( Site 0602), Terni, Italy|Azienda Ospedaliera Universitaria di Verona ( Site 0605), Verona, Italy|National Cancer Center Hospital East ( Site 1001), Kashiwa, Chiba, Japan|National Cancer Center Hospital ( Site 1003), Tokyo, Japan|Toranomon Hospital ( Site 1004), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 1000), Tokyo, Japan|Keio University Hospital ( Site 1002), Tokyo, Japan|National Cancer Center ( Site 1204), Gyeonggi-do, Kyonggi-do, Korea, Republic of|Chungnam National University Hospital ( Site 1205), Daejeon, Taejon-Kwangyokshi, Korea, Republic of|Korea University Anam Hospital ( Site 1203), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1202), Seoul, Korea, Republic of|Asan Medical Center ( Site 1200), Seoul, Korea, Republic of|Samsung Medical Center ( Site 1201), Seoul, Korea, Republic of|Akershus universitetssykehus ( Site 0851), Lorenskog, Akershus, Norway|Helse Bergen HF - Haukeland Universitetssykehus ( Site 0854), Bergen, Hordaland, Norway|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1151), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|SBIH City clinical hospital named after D.D. Pletniov ( Site 1160), Moscow, Moskva, Russian Federation|N.N. Blokhin NMRCO ( Site 1156), Moscow, Moskva, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 1155), Moscow, Moskva, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 1163), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1157), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 1150), Omsk, Omskaya Oblast, Russian Federation|SBHI SPb Clinical Research Centre of specialized types of medical care ( Site 1159), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City clinical oncological dispensary ( Site 1154), Sankt-Petersburg, Sankt-Peterburg, Russian Federation|Instituto Catalan de Oncologia - ICO ( Site 1251), L Hospitalet De Llobregat, Barcelona, Spain|Instituto Valenciano de Oncologia - IVO ( Site 1254), Valencia, Valenciana, Comunitat, Spain|Hospital Universitari Vall d Hebron ( Site 1250), Barcelona, Spain|Hospital Ramon y Cajal ( Site 1253), Madrid, Spain|Hospital General Universitario 12 de Octubre ( Site 1252), Madrid, Spain|National Cheng Kung University Hospital ( Site 1103), Tainan, Taiwan|National Taiwan University Hospital ( Site 1100), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1101), Taipei, Taiwan|Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1302), Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1305), Istanbul, Turkey|Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi ( Site 1303), Istanbul, Turkey|MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 1453), Dnipropetrovsk, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 1452), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Kyiv City Clinical Oncology Center ( Site 1450), Kyiv, Kyivska Oblast, Ukraine|Western General Hospital ( Site 1400), Edinburgh, Edinburgh, City Of, United Kingdom",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,RHABDOMYOSARCOMA,_VINORELBINE,NCT04299113,Phase 1,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,RHABDOMYOSARCOMA,_MOCETINOSTAT,NCT04299113,Phase 1,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",US-20090131367-A1,A61K38/07 ,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,32.7488,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.01,396.454,105.82,6.0,3.0,4.0,42.56,120.32,6.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,LUNG ADENOCARCINOMA,_VINORELBINE,NCT03891173,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Dnipropetrovsk City Multi-field Clinical Hospital #4, Dnipro, Ukraine|Sumy Regional Clinical Oncological Centre, Sumy, Ukraine|Vinnytsya Regional Clinical Oncological Centre, Vinnytsia, Ukraine",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,SMALL CELL LUNG CANCER,_PACLITAXEL,NCT04210037,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Flinders Medical Centre, Bedford Park, South Australia, Australia",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,PANCREATIC ADENOCARCINOMA,_PACLITAXEL,NCT03703063,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia mason medical Center, Seattle, Washington, United States",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,SQUAMOUS CELL CARCINOMA,_PACLITAXEL,NCT03719924,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chu Amiens, Amiens, France|Institut Sainte Catherine, Avignon, France|Hopital Européen, Marseille, France|Ch Le Raincy, Montfermeil, France|Chu Saint Louis, Paris, France|Ch Perpignan, Perpignan, France|Chu de Poitiers, Poitiers, France|Chu Rouen, Rouen, France|Ch Duchenne, Saint-Malo, France",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,NON SMALL CELL LUNG CANCER,_METHYLPREDNISOLONE,NCT03661567,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,METASTATIC MELANOMA,_VANCOMYCIN,NCT03817125,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Angeles Clinic and Research Institute, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",10188697,A61K9/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,LEUKEMIA,_CLADRIBINE,NCT01515527,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7888328.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,LEUKEMIA,_DECITABINE,NCT01515527,Phase 2,Recruiting,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,PANCREATIC ADENOCARCINOMA,_LEUCOVORIN,NCT03193190,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Helen Diller Fam Comp Can Ctr, San Francisco, California, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States|Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Hillman Cancer Center;Medical Oncology, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Charite - Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hosp. G. U Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain",4148999,C07D487/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
O=c1[nH]cc(F)c(=O)[nH]1,PANCREATIC ADENOCARCINOMA,_FLUOROURACIL,NCT03193190,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Helen Diller Fam Comp Can Ctr, San Francisco, California, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States|Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Hillman Cancer Center;Medical Oncology, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center, Germantown, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Charite - Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hosp. G. U Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain",6670335,A61K8/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,OSTEOSARCOMA,_ETOPOSIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=P1(NCCCl)OCCCN1CCCl,OSTEOSARCOMA,_IFOSFAMIDE,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",5252341,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,OSTEOSARCOMA,_LENVATINIB,NCT04154189,Phase 2,Recruiting,All,"2 Years to 25 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's of Alabama, Birmingham, Alabama, United States|Children's National Medical Center, Washington, District of Columbia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Chris O'Brien Lifehouse Hospital, Camperdown, Australia|Perth Childrens Hospital, Nedlands, Australia|Queensland Children's Hospital, South Brisbane, Australia|Children's Hospital at Westmead, Westmead, Australia|St. Anna Kinderspital, Wien, Austria|UZ Gent, Gent, Belgium|Tampereen yliopistollinen sairaala, Tampere, Länsi-Suomen Lääni, Finland|Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Hopitaux de La Timone, Marseille, France|Hôpital de La Mère Et de L'enfant, Nantes, France|Hôpital Armand Trousseau, Paris, France|Institut Curie, Paris, France|Hopital de Hautepierre, Strasbourg, France|Hôpital Des Enfants, Toulouse, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Children's Health Ireland at Crumlin, Dublin, Ireland|Schneider Children's Medical Center of Israel, Petach Tikva, Israel|National Cancer Center, Goyang-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Starship Children's Hospital, Auckland, New Zealand|KK Women's and Children's Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Drottning Silvias Barn Och Ungdomssjukhus, Göteborg, Sweden|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kinderspital Zürich - Eleonorenstiftung, Zürich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|UCL Cancer Institute, London, United Kingdom",7253286,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,ACUTE MYELOBLASTIC LEUKEMIA,_IDARUBICIN,NCT01296178,Not Applicable,Recruiting,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital La Fe, Valencia, Spain",4534971,A61K47/42,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,NEUROFIBROMATOSIS TYPE 1,_SELUMETINIB,NCT04495127,Phase 1,Recruiting,All,"3 Years to 18 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Minato-ku, Japan|Research Site, Setagaya-ku, Japan|Research Site, Yufu-shi, Japan",7425637,C07D401/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CUSHING DISEASE,_DEXAMETHASONE,NCT03974789,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"CHU de Nimes, Nîmes, France",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,SMALL CELL LUNG CANCER,_ACETAZOLAMIDE,NCT03467360,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Antoine Lacassagne, Nice, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,GLIOBLASTOMA,_ANLOTINIB,NCT04119674,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang cancer hospital, Hangzhou, Zhejiang, China",8148532,C07D239/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,GLIOBLASTOMA MULTIFORME,_ASCORBIC_ACID,NCT02344355,Phase 2,"Active, not recruiting",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",7169381.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,GLIOBLASTOMA MULTIFORME,_TEMOZOLOMIDE,NCT02344355,Phase 2,"Active, not recruiting",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,GLIOBLASTOMA MULTIFORME,_PAZOPANIB,NCT02331498,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Antoine Lacassagne, Nice, Cedex 2, France",7105530,C07D231/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,KIDNEY CANCER,_PAZOPANIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",7105530,C07D231/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,KIDNEY CANCER,_SUNITINIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,KIDNEY CANCER,_TEMSIROLIMUS,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",5362718,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,SMALL CELL LUNG CANCER,_TEMOZOLOMIDE,NCT04400188,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital of Sichuan University, Chengdu, Sichuan, China",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Cn1nnc2c(C(N)=O)ncn2c1=O,GLIOMA,_TEMOZOLOMIDE,NCT03257618,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut regional du Cancer - Val d Aurelle, Montpellier, France",5260291,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,OSTEOSARCOMA,_SUNITINIB,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,OSTEOSARCOMA,_LOSARTAN,NCT03900793,Phase 1,Recruiting,All,"10 Years to 40 Years   (Child, Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Children's Hospital of Atlanta, Atlanta, Georgia, United States",5210079,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,RENAL CELL CARCINOMA,_SUNITINIB,NCT02919371,Phase 1|Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,GLIOBLASTOMA,_FLUDEOXYGLUCOSE,NCT04315584,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Virginia, Charlottesville, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,"CARCINOMA, NON-SMALL-CELL LUNG",_TYROSINE,NCT03799094,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clifford Hospital, Guangzhou, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,NSCLC,_TYROSINE,NCT04318938,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,LEUKEMIA,_RUXOLITINIB,NCT02723994,Phase 2,Recruiting,All,"1 Year to 21 Years   (Child, Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Anaheim (Satellite Site), Anaheim, California, United States|Kaiser Permanente Downey (Satellite Site), Downey, California, United States|Kaiser Permanente Fontana (Satellite Site), Fontana, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Miller Children's at Long Beach Medical Center, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucille Packard Child Hospital END, Palo Alto, California, United States|Kaiser Permanente San Diego (Satellite Site), San Diego, California, United States|Rady Children's Hospital, San Diego, California, United States|UCSF Pediatric Hematology/Oncology, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Alfred I. duPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|Adventist Health System/Sunbelt Inc d/b/a/Florida Hospital, Altamonte Springs, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic - of the Nemours Foundation, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic, Pensacola, Florida, United States|All Children's Hospital Johns Hopkins Medicine, Saint Petersburg, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|Saint Mary's Medical Center, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Kapiolani Medical Center for Women and Children/Univ of HI, Honolulu, Hawaii, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|St. Vincent Children's Hospital, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|CS Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Helen Devos Children's Hospital, Grand Rapids, Michigan, United States|Bronson Methodist Hospital Ped, Kalamazoo, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Children's Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Children's Hospital Critical Care, Omaha, Nebraska, United States|Children's Specialty Center of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St Joseph's Regional Medical Center, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, The Children's Hospital at Montefiore, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cohen Children's Medical Center of NY - PRIME, New Hyde Park, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Medical Center - Charlotte, Charlotte, North Carolina, United States|Wake Forest University Health Center, Winston-Salem, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation - Central, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Medical Center of Dayton, Dayton, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Children's Blood and Cancer Center, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Children's Hospital & Regional Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Midwest Children's Cancer Center, Wauwatosa, Wisconsin, United States|Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's & Women's Hospital Center, Vancouver, British Columbia, Canada|McMaster University Health Sciences Center, Hamilton, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada|Montreal Children's Hospital, Montréal, Quebec, Canada|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",7598257,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,RETINOBLASTOMA,_DOXORUBICIN,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5013556,C07F9/5537,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
O=S(=O)(O)CCS,RETINOBLASTOMA,_MESNA,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,RETINOBLASTOMA,_TOPOTECAN,NCT01783535,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5004758,C07D491/22,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,GLIOBLASTOMA,_METFORMIN,NCT03151772,Early Phase 1,Terminated,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sahlgrenska University Hospital, Göteborg, Sweden",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,GLIOBLASTOMA,_DISULFIRAM,NCT03151772,Early Phase 1,Terminated,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sahlgrenska University Hospital, Göteborg, Sweden",3932346,C08F2/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,GLIOBLASTOMA MULTIFORME,_METFORMIN,NCT02780024,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Neurological Institute - McGill University Health Centre, Montréal, Quebec, Canada",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,LUNG NEOPLASMS,_PEMETREXED,NCT03380468,Phase 2|Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fudan University Cancer Center, Shanghai, Shanghai, China",5344932,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,SMALL CELL LUNG CANCER,_IRINOTECAN_HYDROCHLORIDE,NCT04381910,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, Beijing, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,DILATED CARDIOMYOPATHY,_SIMVASTATIN,NCT03775070,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Taipei, Taiwan",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,PHEOCHROMOCYTOMA,_DEXMEDETOMIDINE,NCT04320589,Phase 2,Recruiting,All,"12 Years to 69 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, Egypt",5344840,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,GLIOBLASTOMA MULTIFORME,_VALGANCICLOVIR,NCT04116411,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SE01 Karolinska University Hospital, Solna, Stockholm, Sweden",6083953,C07D473/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,METASTATIC RENAL CELL CARCINOMA,_CABOZANTINIB,NCT03149822,Phase 1|Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States|Memorial Hospital Central, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|UCHealth Lone Tree Medical Center, Lone Tree, Colorado, United States",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"CARCINOMA, RENAL CELL",_CABOZANTINIB,NCT04338269,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, Flagstaff, Arizona, United States|University of Arizona, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Health System, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California Davis, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|New York University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology - Willowbrook, Houston, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists - Gainsville, Gainesville, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Medico Austral OMI, Ciudad Autonoma Buenos Aires, Argentina|Orange Hospital, Orange, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Bendigo Cancer Centre, Bendigo, Victoria, Australia|Box Hill Hospital; Oncology, Box Hill, Victoria, Australia|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut de cancerologie du Gard, Nimes, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie, Frankfurt, Germany|Universitaetsklinikum Freiburg; Urology, Freiburg, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie, Hamburg, Germany|Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie u. Stammzelltransplantation, Hannover, Germany|Universitaetsklinikum Muenster; Urology, Muenster, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Attikon University General Hospital, Athens, Greece|Athens Medical Center; Dept. of Oncology, Athens, Greece|University Hospital of Larissa;Department of Medical Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); SOC Oncologia Medica A, Aviano (PN), Friuli-Venezia Giulia, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS); Day Hospital Oncologico Multidisciplinare, Candiolo (TO), Piemonte, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Kyushu University Hospital, Fukuoka, Japan|Hokkaido University Hospital, Hokkaido, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Yokohama City University Hospital, Kanagawa, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Keio University Hospital, Tokyo, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Wojewódzki Szpital Zespolony im.L.Rydygiera; Oddzial Chemioterapii Nowotworów, Toruń, Poland|Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Warszawa, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wrocław, Poland|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|TSBHI Altai Territorial oncological dispensary, Barnaul, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Medical Center Avicenna; Urology, Novosibirsk, Russian Federation|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Alvaro Cunqueiro; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario de Burgos; Oncología, Burgos, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Royal Blackburn Hospital, Blackburn, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|ROYAL MARSDEN HOSPITAL; DEPT OF MEDICAL ONCOLOGY; The Bob Champion Unit, Sutton, United Kingdom",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,THYROID CANCER,_REGORAFENIB,NCT02657551,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",7351834,C07D209/46,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,METASTATIC MELANOMA,_TRAMETINIB,NCT02392871,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,METASTATIC MELANOMA,_DABRAFENIB,NCT02392871,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,MENINGIOMA,_TRAMETINIB,NCT03631953,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assistance Publique Hôpitaux de Marseille, Marseille, France",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,MENINGIOMA,_ALPELISIB,NCT03631953,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assistance Publique Hôpitaux de Marseille, Marseille, France",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,34.431918519887475,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,441.47,101.21,4.0,2.0,3.0,42.75,105.85,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BRAIN TUMOR,_ABEMACICLIB,NCT03220646,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,GLIOBLASTOMA,_ABEMACICLIB,NCT02977780,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lifespan / Rhode Island Hospital, Providence, Rhode Island, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BLADDER CANCER,_ABEMACICLIB,NCT03837821,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medicine, New York, New York, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,NON SMALL CELL LUNG CANCER,_LORLATINIB,NCT02927340,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts general Hospital, Boston, Massachusetts, United States",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,"CARCINOMA, NON-SMALL-CELL LUNG",_LORLATINIB,NCT03052608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Ocala, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, The Villages, Florida, United States|Florida Cancer Specialists, Winter Park, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute., Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro Medico Austral, Caba, Argentina|Bendigo Day Surgery Collection Centre and Laboratory, Bendigo, Victoria, Australia|Bendigo Medical Imaging, Bendigo Hospital, Bendigo, Victoria, Australia|Melbourne Pathology, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Department of Respiratory,the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Guangdong General Hospital, Guangzhou, China|Fakultni nemocnice Olomouc, Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Hopital Haut-Léveque-Centre François Magendie, Pessac, Aquitaine, France|Hopital de Chevilly Larue, Chevilly Larue, France|Centre Hospitalier du Mans, Le Mans, France|Institut Paoli-Calmettes, Marseille cedex 09, France|Département d'Imagerie Médicale, Marseille cedex 20, France|Hôpital Nord, Marseille cedex 20, France|Service Ophtalmologie, Marseille cedex 20, France|Clinique Monticelli-Paradis-Dr Stephan Fauquier, Marseille, France|Groupe Hospitalier Bichat Claude Bernard, AP-HP, Paris, France|CHU de Rennes Hopital Pontchaillou, Rennes cedex 9, France|CHU de Rennes, Hopital Pontchaillou, Rennes cedex 9, France|Hopital Foch, Suresnes, France|Hopital Larrey, Toulouse Cedex 9, France|Hopital Pierre Paul Riquet, Toulouse cedex 9, France|Hôpital Larrey, Toulouse Cedex 9, France|Department d'imagerie medicale, Villejuif, France|Institut Gustave Roussy, Villejuif, France|Uberortliche Radiologische Gemeinschaftspraxis Dr. med. Marc Amler, Dresden, Germany|Technische Universitat Dresden , Medizinische Fakultat Carl Gustav Carus, Dresden, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Innere Medizin V, Homburg - Saar, Germany|Universitätsklinikum des Saarlandes, Homburg - Saar, Germany|Universitatsklinikum Regensburg, Institut fur Rontgendiagnostik, Regensburg, Germany|Universitatsklinikum Regensburg, Klinik und Poliklinik fur Innere Medizin II, Regensburg, Germany|The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong|The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Artemis Hospital, Gurugram, Haryana, India|Manipal Hospital, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispeciality Hospitals India Pvt Ltd, Bangalore, Karnataka, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|ASST Monza - A.O. San Gerardo, Monza, MB, Italy|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Azienda Ospedaliera di Perugia - Ospedale S. M. Misericordia, Perugia, PG, Italy|Centro di Riferimento Oncologico-IRCCS, Pordenone, PN, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, PR, Italy|AUSL della Romagna - Ospedale degli infermi, Faenza, RA, Italy|AUSL della Romagna - Ospedale ""Umberto I"", Lugo, RA, Italy|UO Farmacia Oncologica, Ravenna, RA, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy|Az.Osp.San Camillo-Forlanini, Roma, RM, Italy|Azienda Ospedaliera Dei Colli Ospedale Monaldi, Napoli, Italy|Istituto Nazionale Tumori di Napoli, Napoli, Italy|Ausl della Romagna- Ravenna, Ravenna, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Department of Pulmonary Medicine and Oncology, Wakayama, Japan|The Catholic University of Korea, St. Vincents Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Division of Medical Oncology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Promotora Medica Aguascalientes SA de CV, Aguascalientes, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Distrito Federal, Mexico|University Medical Center Groningen, Groningen, Netherlands|Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warszawa, Poland|RBHI Kursk Regional Clinical Oncology Dispensary, Kislino, Ryshkovsky Rural Council, Kursk Region, Russian Federation|Budgetary Healthcare Institution Omsk Region ""Clinical Oncological Dispensary"", Omsk, OMSK Region, Russian Federation|LEC at SBIH ""Saint-Petersburg Clinical Research Practical Center of specialized types of, Pesochniy Poselok, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|RBHI Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|FSBI ""N.N.Blokhin Medical Research Center of Oncology"", Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario De Navarra, Pamplona, Navarra, Spain|Hospital Teresa Herrera C.H.U.A.C., A Coruna, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia Girona, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Marmara Univ Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom|Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",8680111,C07D498/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,GLIOBLASTOMA,_IBRUTINIB,NCT03535350,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",7514444,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,METASTATIC RENAL CELL CARCINOMA,_DECITABINE,NCT04049344,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDONE,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",5792477,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,HUNTINGTON'S DISEASE,_RISPERIDON,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,HUNTINGTON'S DISEASE,_COENZYME_Q1,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,HUNTINGTON'S DISEASE,_HALOPERIDOL,NCT04071639,Phase 1,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",3947579,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,21.8813527998521,629.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.7,375.864,40.54,3.0,1.0,3.0,39.15,102.59,6.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,LUNG CANCER,_OSIMERTINIB,NCT03567642,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",8946235,C07D401/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,GLIOBLASTOMA,_APATINIB,NCT03567135,,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Observational Model: Case-Control|Time Perspective: Retrospective,"Fuzhou General Hospital, Fuzhou, Fujian, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,GLIOMA,_APATINIB,NCT03741244,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the Second Hospital of Hebei Medical University, Shijiazhuang, China",US-20040259916-A1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,SMALL CELL LUNG CANCER,_TOPOTECAN,NCT03088813,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sutter Cancer Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Cancer Treatment Centers of America-Georgia, Newnan, Georgia, United States|Illinois Cancer Care, PC, Peoria, Illinois, United States|Southern Maine Health Care, Biddeford, Maine, United States|Maine Research Associates, Lewiston, Maine, United States|University of Maryland Medical Group, Baltimore, Maryland, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Tri County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|OHSU Community Hematology Oncology, Portland, Oregon, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Greenville Hospital System University Medical Center, Greenville, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|MultiCare Health System Institute for Research and Innovation, Spokane, Washington, United States|Summit Cancer Treatment Center, Spokane, Washington, United States|Northwest Cancer Specialists, P.C.-Portland-West, Vancouver, Washington, United States|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|South West Healthcare, Warrnambool, Victoria, Australia|Southern Medical Day Care Centre, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|AZ Klina, Brasschaat, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier de l'Ardenne, Libramont, Belgium|AZ Sint-Maarten, Mechelen, Belgium|Rua Antenor Duarte Villela, 1331, Barretos, Brazil|Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer, Curitiba, Brazil|Hospital de Caridade de Ijuí, Ijuí, Brazil|Oncobio Servicos de Saude, Nova Lima, Brazil|HGB - Hospital Giovanni Battista - Mãe de Deus Center, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil|INCA - Instituto Nacional de Câncer, Rio De Janeiro, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, Brazil|Beijing Cancer Hospital, Beijing, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, China|Jilin Cancer Hospital, Changchun, China|The First Hospital of Jilin University, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Xinmin, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Linyi Cancer Hospital, Linyi, China|Henan Cancer Hospital, Zhengzhou, China|Centre Francois Baclesse, Caen, Calvados, France|CHU Brest - Hôpital Morvan, Brest, France|Hopital Albert Calmette - CHU Lille, lille Cedex, France|Hôpital de la Timone, Marseille, France|Hôpital Nord - CHU Marseille, Marseille, France|Hôpital Saint-Louis, Paris, France|Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France|Centre Hospitalier de Saint-Quentin, Saint-Quentin, France|Hôpital d'Instruction des armées Sainte Anne, Toulon, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Evangelisches Krankenhaus Hamm GmbH, Hamm, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Semmelweis Egyetem, Budapest, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Tudogyogyintezet Torokbalint, Törökbálint, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Universitaria- Università degli Studi della Campania ""Luigi Vanvitelli"", Napoli, Italy|Azienda Socio Sanitaria Territoriale Bergamo Ovest (Ospedale Treviglio Caravaggio di Treviglio), Treviglio, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of|KO-MED Centra Kliniczne Biala Podlaska, Biała Podlaska, Poland|Szpitale Pomorskie spółka z ograniczoną odpowiedzialnością, Gdynia, Poland|SP Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznań, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|S.C Gral Medical S.R.L, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|S.C Medisprof S.R.L, Cluj-Napoca, Romania|S.C Centrul de Oncologie Sf. Nectarie S.R.L, Craiova, Romania|S.C Radiotherapy Center Cluj S.R.L, Floreşti, Romania|S.C Oncocenter Oncologie Clinica S.R.L, Timisoara, Romania|Oncomed SRL, Timişoara, Romania|SBIH of Arkhangelsk region ""Arkhangelsk Clinical Oncological Dispensary"", Arkhangel'sk, Russian Federation|""VitaMed"" LLC, Moscow, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncological Dispensary"", Pyatigorsk, Russian Federation|SBHI of Kaluga Region ""Kaluga regional clinical oncology dispensary"", Saint Petersburg, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", Saint Petersburg, Russian Federation|SBIH ""Samara Regional Clinical Oncological Dispensary"", Samara, Russian Federation|SBIH of Yaroslavl region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation|Clinical Center ""Bezanijska kosa"", Belgrade, Serbia|Oncomed System, Belgrade, Serbia|Military Medical Academy, Belgrad, Serbia|Clinical Center Kragujevac, Belgrad, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|General Hospital Uzice, Užice, Serbia|Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|Baskent University Adana Application and Research Center, Adana, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Medeniyet Uni Goztepe Training&Res Hosp, Istanbul, Turkey|Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Istanbul, Turkey|Inonu Uni. Med. Fac., Malatya, Turkey|Namik Kemal University, Tekirdağ, Turkey|CI Chernivtsi RC Oncological Dispensary, Chernivtsi, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipro, Ukraine|Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, Ukraine|CI Kryvyi Rih Oncological Dispensary of DRC, Kryvyi Rih, Ukraine|Treatment and Diagnostic Center of LLC Specialized clinic Dobryi Prognoz, Kyiv, Ukraine|Treatment-Prevention Institution Volyn Regional Oncological Dispensary, Luts'k, Ukraine|Odesa Regional Oncologic Dispensary, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|CCCH City Oncological Center SHEI Uzhgorod NU, Uzhgorod, Ukraine|Medical Clinic Innovacia, LLC, Vyshhorod, Ukraine",5004758,C07D491/22,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CC)C(=S)SSC(=S)N(CC)CC,GLIOBLASTOMA MULTIFORME,_DISULFIRAM,NCT02715609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",3932346,C08F2/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],GLIOBLASTOMA MULTIFORME,_COPPER_GLUCONATE,NCT02715609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",4112066,A61Q11/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,MULTIPLE MYELOMA,_FOSAPREPITANT,NCT02780609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",5691336,C07D413/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F,METASTATIC COLORECTAL CANCER,_TRIFLURIDINE,NCT04166604,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Amiens, Amiens, France|Institut de cancérologie de l'Ouest, Angers, France|CHRU Jean Minjoz, Besançon, France|centre Pierre Curie, Beuvry, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre hospitalier de Chauny, Chauny, France|Polyclinique Sainte Côme, Compiègne, France|Clinique de Flandre, Coudekerque-Branche, France|Hôpital Henri Mondor, Créteil, France|Centre Georges François Leclerc, Dijon, France|CHD Vendée, La Roche-sur-Yon, France|Hôpital Franco-Britannique, Levallois-Perret, France|Hôpital Privé Jean Mermoz, Lyon, France|Hôpital Européen, Marseille, France|Hôpital Layne, Mont-de-Marsan, France|Hôpital Nord Franche Comté, Montbéliard, France|Groupe Hospitalier Pitié Sapêtrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Haut Lévêque, Pessac, France|CHU Poitiers, Poitiers, France|CHU Robert Debré, Reims, France",5744475,C07D239/553,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.183104375859802,772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.45,296.1999,99.1,5.0,3.0,2.0,23.07,56.34,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,LYMPHOMA,_PARSACLISIB,NCT03235544,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama At Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Rocky Mountain Cancer Center-Aurora, Aurora, Colorado, United States|Asclepes Research Centers, Brooksville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Bond & Steele Clinic, P.A., Winter Haven, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States|Clinical Research Alliance, Inc., New Hyde Park, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Willamette Valley Cancer Institute, Eugene, Oregon, United States|Kaiser Permanente - Northwest, Portland, Oregon, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology San Antonio, San Antonio, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|Yakima Valley Memorial Hospital/North Star, Yakima, Washington, United States|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium|Institut Jules Bordet, Brussels, Belgium|Hopital de Jolimont, La Louviere, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Prague 10, Czechia|Charles University General Hospital, Prague 2, Czechia|Fakultni Nemocnice Kralovske Vinohadry, Interni Hematologicka Klinika, Prague, Czechia|Aalborg University Hospital, Aalborg, Denmark|Aarhus Universitets Hospital, Aarhus, Denmark|Odense Universitetshospital (Ouh) (Odense University Hospital), Odense C, Denmark|Zealand University Hospital, Roskilde, Denmark|Avicenne Hospital, Bobigny, France|Chu de Clermont - Ferrand- Hospital Estaing, Clermont-ferrand, France|Centre Hospitalier Universitaire Henri Mondor, Creteil, France|University Hospital Grenoble, Grenoble, France|Centre Hospitalier Departemental - La-Roche-Sur-Yon - Les Oudairies, La Roche Sur Yon, France|Centre Hospitalier Universitaire de Grenoble, La Tronche, France|Centre Hospitalier de Versailles, Le Chesnay, France|Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Lyon, France|Centre Antoine Lacassagne, Nice, France|Hopital Saint-Louis, Paris, France|H�Pital Universitaire Piti�-Salp�Tri�Re, Paris, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite Cedex, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Centre Henri Becquerel, Rouen, France|Chru Hopitaux de Tours, Hospital Bretonneau, Tours, France|Institute Gustave Roussy (Igr), Villejuif Cedex, France|Praxis Brudler, Heinrich, Bangerter, Augsburg, Germany|Universitaetsklinikum Essen, Essen, Germany|Universit�Tsklinikum Essen, Essen, Germany|Justus-Liebig University, Giessen, Germany|Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii, Mainz, Germany|Kliniken Maria Hilf, Moenchengladbach, Germany|Rotkreuzklinikum Munich, Munchen, Germany|Universit�Tsklinikum Ulm, ULM, Germany|Rambam Medical Center, Haifa, Israel|Hadassah Hebrew University Medical Center, Jerusalem, Israel|Hadassah Hebrew University Medical Center Ein Karem Hadassah, Jerusalem, Israel|Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, MI, Italy|Centro Ricerche Cliniche, Bologna, Italy|Azienda Policlinico Vittorio Emanuele, Catania, Italy|Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale Niguarda Ca Granda, Milano, Italy|A.O.U. Di Modena - Policlinico, Modena, Italy|A.O.U. Federico Ii, Napoli, Italy|Aou Maggiore Della Carita, Novara, Italy|Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy|Sapienza University, Rome, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena, Italy|Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza, Torino, Italy|Beskidzkie Centrum Onkologii Im.Jana Pawla Ii, Bielsko-biala, Poland|Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozow, Poland|University Clinical Center, Gdansk, Poland|Pratia McM Krakow, Krakow, Poland|Nu-Med Centrum Diagnostykii I Terapii Onkologicznej, Tomaszow Mazowiecki, Poland|Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warszawa, Poland|Hospital Del Mar, Barcelona, Spain|Hospital General Universitari Vall D Hebron, Barcelona, Spain|Hospital Universitari Mutua Terrassa, Barcelona, Spain|Institut Catala D Oncologia, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Md Anderson Cancer Centre Madrid, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Fundacion Jimenez Diaz University Hospital, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de La Paz, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario Y Politecnic La Fe, Valencia, Spain|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|University College London Hospitals (Uclh), London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.67,432.88,107.95,6.0,2.0,4.0,42.87,123.54,5.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,HUNTINGTON'S DISEASE,_NILOTINIB,NCT03764215,Phase 1,Recruiting,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Medical Center, Washington, District of Columbia, United States",7169791,C07D405/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0
FC(F)(F)C(F)(F)C(F)(F)F,KIDNEY CANCER,_PERFLUTREN,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",6723303,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
FS(F)(F)(F)(F)F,KIDNEY CANCER,_SULFUR_HEXAFLUORIDE,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5686060,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,31.0150105751658,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,146.05,0.0,0.0,0.0,0.0,7.11,18.44,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=[As]O[As]=O,AML,_ARSENIC_TRIOXIDE,NCT03031249,Phase 1|Phase 2,Recruiting,All,"14 Years to 55 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",6723351,5,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],GLIOBLASTOMA,_GADOTERIDOL,NCT02359097,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",5474756,C07F9/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,3.0,11.7291936179387,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.36,558.68,153.58,11.0,1.0,1.0,39.42,133.55,8.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],GLIOBLASTOMA,_FERUMOXYTOL,NCT02359097,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],BRAIN NEOPLASM,_FERUMOXYTOL,NCT03234309,Phase 2,Recruiting,All,"5 Years to 18 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"OHSU Knight Cancer Institute, Portland, Oregon, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
N[C@]1(C(=O)O)C[C@@H](F)C1,GLIOBLASTOMA,_FLUCICLOVINE,NCT03926507,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"M D Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,GLIOBLASTOMA,_FLUCICLOVINE_F18,NCT03926507,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"M D Anderson Cancer Center, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)C(=O)O,GLIOMA,_PYRUVATE,NCT03739411,Phase 1,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CC(=O)C(=O)O,PANCREATIC DUCTAL ADENOCARCINOMA,_PYRUVATE,NCT04565327,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,DILATED CARDIOMYOPATHY,_RESVERATROL,NCT01914081,Phase 3,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Boniface General Hospital, Winnipeg, Manitoba, Canada",5747536,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C,MULTIPLE MYELOMA,_TASQUINIMOD,NCT04405167,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",6133285,C07D215/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,41.0,15.146101562660403,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.26,406.361,70.08,4.0,1.0,3.0,36.89,100.19,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,CUSHING DISEASE,_SELICICLIB,NCT03774446,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cedars-Sinai Medical Center, Los Angeles, California, United States",US-20020049218-A1,A61P17/00 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,CHRONIC LYMPHOCYTIC LEUKEMIA,_BNC105,NCT03454165,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.13,452.352,133.89,8.0,2.0,3.0,43.41,109.33,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_ENZASTAURIN,NCT03263026,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States|Cedars Sinai Hospital, Beverly Hills, California, United States|Desert Hematology, Rancho Mirage, California, United States|Centura Health Corporation, Denver, Colorado, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Christiana Care Health Services, Newark, Delaware, United States|Watson Clinic, Lakeland, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Aurora-Advocate Health, Park Ridge, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville, Kentucky, United States|Regional Cancer Care Associates, MD, Bethesda, Maryland, United States|Minnesota Oncology Hematology Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System/ Morristown Meeical Center, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Comprehensive Cancer Cente, Buffalo, New York, United States|New York Medical College, Hawthorne, New York, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Baylor Scott and White University Medical Center, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Oncology Consultants: Memorial City, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Clinic, Houston, Texas, United States|Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee, Wisconsin, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital (Hematology Dept), Beijing, China|JiLin Cancer Hospital（Lymphoma hematology Dept), Changchun, China|West China Hospital of Sichuan University (Hematology Dept), Chengdu, China|Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Medical University Union Hospital, Fuzhou, China|GuangDong General Hospital, Guangzhou, China|ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou, China|Harbin Medical University Cancer Hospital (Oncology Internal), Harbin, China|Fudan University Shanghai Cancer Hospital, Shanghai, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The First Affiliated Hospital of Medical School of Zhejiang University (Hematology Dept), Zhejiang, China|HeNan Cancer Hospital (Hematology Dept), Zhengzhou, China|The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou, China",EP-0817627-B1,C07D335/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,27.0,122.811556705476,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.86,515.617,72.16,4.0,1.0,7.0,56.74,151.61,5.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,DIFFUSE LARGE B-CELL LYMPHOMA,_ENZASTAURIN_HYDROCHLORIDE,NCT03263026,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Oncology Specialties: Clearview Cancer Institute, Huntsville, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, United States|Cedars Sinai Hospital, Beverly Hills, California, United States|Desert Hematology, Rancho Mirage, California, United States|Centura Health Corporation, Denver, Colorado, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Christiana Care Health Services, Newark, Delaware, United States|Watson Clinic, Lakeland, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Aurora-Advocate Health, Park Ridge, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville, Kentucky, United States|Regional Cancer Care Associates, MD, Bethesda, Maryland, United States|Minnesota Oncology Hematology Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System/ Morristown Meeical Center, Morristown, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Comprehensive Cancer Cente, Buffalo, New York, United States|New York Medical College, Hawthorne, New York, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Hematology & Oncology Associates, Inc., Canton, Ohio, United States|Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc., Massillon, Ohio, United States|Toledo Clinic Cancer Centers, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Baylor Scott and White University Medical Center, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Oncology Consultants: Memorial City, Houston, Texas, United States|Baylor College of Medicine (BCM) - Baylor Clinic, Houston, Texas, United States|Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee, Wisconsin, United States|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital (Hematology Dept), Beijing, China|JiLin Cancer Hospital（Lymphoma hematology Dept), Changchun, China|West China Hospital of Sichuan University (Hematology Dept), Chengdu, China|Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Medical University Union Hospital, Fuzhou, China|GuangDong General Hospital, Guangzhou, China|ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou, China|Harbin Medical University Cancer Hospital (Oncology Internal), Harbin, China|Fudan University Shanghai Cancer Hospital, Shanghai, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|The First Affiliated Hospital of Medical School of Zhejiang University (Hematology Dept), Zhejiang, China|HeNan Cancer Hospital (Hematology Dept), Zhengzhou, China|The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,NEUROENDOCRINE TUMORS,_DOTATATE,NCT04318561,Phase 1|Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Peking Union Medical College Hospital, Beijing, Beijing, China",9375498,C07B59/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,46.5882256309164,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.85,1435.63,497.46,24.0,17.0,6.0,144.3,364.83,26.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1,MYELODYSPLASTIC SYNDROME,_LB-100,NCT03886662,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.97,268.313,70.08,5.0,1.0,3.0,27.89,67.27,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,IDIOPATHIC MEMBRANOUS NEPHROPATHY,_PREDNISONE,NCT03549663,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,IDIOPATHIC MEMBRANOUS NEPHROPATHY,_TACROLIMUS,NCT03549663,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China",5260301,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,AIRWAY INFLAMMATION,_PREDNISONE,NCT03861390,Phase 1|Phase 2,Recruiting,All,18 Years to 45 Years   (Adult),Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Center for Environmental Medicine, Asthma and Lung Biology at UNC Chapel Hill, Chapel Hill, North Carolina, United States",6488960,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,EPIDERMOLYSIS BULLOSA,_CYCLOPHOSPHAMIDE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,EPIDERMOLYSIS BULLOSA,_FLUDARABINE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,EPIDERMOLYSIS BULLOSA,_CYCLOSPORINE,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",4839342.0,A61K38/13,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,EPIDERMOLYSIS BULLOSA,_MYCOPHENOLATE_MOFETIL,NCT01033552,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5543408,C07D307/88,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,UVEITIS|MACULAR EDEMA,_METHOTREXATE,NCT02623426,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Jules Stein Eye Institute, UCLA, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Duke Eye Center, Duke University, Durham, North Carolina, United States|Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States|MidAtlanitc Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|Retinal Consultants of Houston, Houston, Texas, United States|John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States|Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia|McGill University, Montreal, Quebec, Canada|LV Prasad Eye Institute - Bhubaneswar, Bhubaneswar, Odisha, India|Medical and Vision Research Foundation, Chennai, Tamil Nadu, India|LV Prasad Eye Institute - Hyderabad, Hyderabad, Telangana, India|Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India|University Hospitals Bristol NHS Foundation Trust, Bristol, England, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom|Liverpool University Hospitals NHS Foundation Trust, Liverpool, England, United Kingdom|Moorfields Eye Hospital NHS Foundation Trust, London, England, United Kingdom|Manchester University NHS Foundation Trust, Manchester, England, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Moorfields Eye Hospital, London, United Kingdom",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,UVEITIS|MACULAR EDEMA,_DEXAMETHASONE,NCT02623426,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Jules Stein Eye Institute, UCLA, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Duke Eye Center, Duke University, Durham, North Carolina, United States|Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States|MidAtlanitc Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|Retinal Consultants of Houston, Houston, Texas, United States|John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States|Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia|McGill University, Montreal, Quebec, Canada|LV Prasad Eye Institute - Bhubaneswar, Bhubaneswar, Odisha, India|Medical and Vision Research Foundation, Chennai, Tamil Nadu, India|LV Prasad Eye Institute - Hyderabad, Hyderabad, Telangana, India|Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India|University Hospitals Bristol NHS Foundation Trust, Bristol, England, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom|Liverpool University Hospitals NHS Foundation Trust, Liverpool, England, United Kingdom|Moorfields Eye Hospital NHS Foundation Trust, London, England, United Kingdom|Manchester University NHS Foundation Trust, Manchester, England, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Moorfields Eye Hospital, London, United Kingdom",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,PROLIFERATIVE VITREORETINOPATHY,_METHOTREXATE,NCT04482543,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Ophthalmic Research Center, Tehran, Iran, Islamic Republic of",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,EPIDERMOLYSIS BULLOSA,_TACROLIMUS,NCT02582775,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5260301,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,EPIDERMOLYSIS BULLOSA,_BUSULFAN,NCT02582775,Phase 2,Recruiting,All,"up to 25 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",5430057,2,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.302,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,PULMONARY ARTERIAL HYPERTENSION,_ANASTROZOLE,NCT03229499,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",RE36617,C07D239/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PULMONARY ARTERIAL HYPERTENSION,_OLAPARIB,NCT03782818,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alberta Hospital, Edmonton, Alberta, Canada|UHN-Toronto General Hospital, Toronto, Ontario, Canada|IUCPQ-UL, Quebec City, Quebec, Canada",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,UVEITIS,_ACYCLOVIR,NCT03389191,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China",RE39264,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,27.0,127.082691636378,2362.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.95,225.2046,114.76,7.0,3.0,2.0,21.51,54.63,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,POLYMYALGIA RHEUMATICA,_PREDNISOLONE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,POLYMYALGIA RHEUMATICA,_LEFLUNOMIDE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5504084,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_TARTRATE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BRIMONIDINE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",5424078.0,A61K47/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BRIMONIDINE_TARTRATE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",WO-1995003798-A2,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,"POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT",_TOLVAPTAN,NCT02847624,,Recruiting,All,"Child, Adult, Older Adult",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan",5753677,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,PRIMARY SCLEROSING CHOLANGITIS,_SULFASALAZINE,NCT03561584,Phase 2,Recruiting,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of California, Davis, Davis, California, United States|University of Miami, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Washington Medical Center, Seattle, Washington, United States",4849416,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.92,398.393,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,"HYPOXIA, ALTITUDE",_ACETAZOLAMIDE,NCT04251364,Not Applicable,Recruiting,Male,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France",,,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,"HYPOXIA, ALTITUDE",_ATORVASTATIN,NCT04251364,Not Applicable,Recruiting,Male,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France",4681893,C07D405/06,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC12CC3CC(C)(C1)CC(N)(C3)C2,SICKLE CELL DISEASE,_MEMANTINE,NCT03247218,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emek Medical Centre, Afula, Israel",5061703,1,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,SICKLE CELL DISEASE,_MEMANTINE_HYDROCHLORIDE,NCT03247218,Phase 2,Recruiting,All,"10 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emek Medical Centre, Afula, Israel",5955434,C07K5/0808,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,37.388858087435004,112.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
c1ccc([C@H]2CN3CCSC3=N2)cc1,APLASTIC ANEMIA,_LEVAMISOLE,NCT03218657,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Zhejiang Province Traditional Chinese Medical Hospital, Hangzhou, Zhejiang, China",3978060,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,23.1298383950389,791.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,204.291,15.6,2.0,0.0,3.0,22.35,60.08,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)N[C@@H](CS)C(=O)O,IDIOPATHIC PULMONARY FIBROSIS,_ACETYLCYSTEINE,NCT04312594,Phase 2,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",8148356,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=N)NC(=N)N,FRAGILE X SYNDROME,_METFORMIN,NCT04141163,Phase 1|Phase 2,Recruiting,Male,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rowan University School of Osteopathic Medicine, Stratford, New Jersey, United States",6288095.0,4,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,PRIMARY OPEN ANGLE GLAUCOMA,_METFORMIN,NCT04155164,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,ABDOMINAL AORTIC ANEURYSM,_METFORMIN,NCT03507413,Phase 2|Phase 3,Enrolling by invitation,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University of Vienna, Department of Surgery, Division of Vascular Surgery, Vienna, Austria",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,AORTIC STENOSIS,_ASPIRIN,NCT03557242,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Foundation for Cardiovascular Medicine, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Stony Brook Hospital, Stony Brook, New York, United States|St. John Health System, Tulsa, Oklahoma, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Henrico Doctors' Hospital, Richmond, Virginia, United States",6015577,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,AORTIC STENOSIS,_WARFARIN,NCT03557242,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Foundation for Cardiovascular Medicine, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Stony Brook Hospital, Stony Brook, New York, United States|St. John Health System, Tulsa, Oklahoma, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Henrico Doctors' Hospital, Richmond, Virginia, United States",3932656,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,_PRAVASTATIN,NCT04284657,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keck School of Medicine of University of Southern California, Los Angeles, California, United States",5622985.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,_SODIUM_CITRATE,NCT04284657,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keck School of Medicine of University of Southern California, Los Angeles, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.55,258.068,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,FRAGILE X SYNDROME,_LOVASTATIN,NCT02998151,Phase 2,Enrolling by invitation,All,"15 Years to 55 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",6080428.0,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,FRAGILE X SYNDROME,_MINOCYCLINE,NCT02998151,Phase 2,Enrolling by invitation,All,"15 Years to 55 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",5908838,6,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(=O)NCCCS(=O)(=O)O,FRAGILE X SYNDROME,_ACAMPROSATE,NCT02998151,Phase 2,Enrolling by invitation,All,"15 Years to 55 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.8,181.21,83.47,4.0,2.0,0.0,17.17,38.91,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,HYPERTROPHIC CARDIOMYOPATHY,_SACUBITRIL,NCT03832660,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Regensburg, Regensburg, Germany|Azienda Ospedaliero Universitaria Careggi Florence, Florence, Italy|University of Belgrade Faculty of Medicine, Belgrade, Serbia|Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|Newcastle University, Faculty of Medical Sciences, Clinical Research Facility, Royal Victoria Infirmary; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, England, United Kingdom",7468390,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,_IRBESARTAN,NCT03493685,Phase 3,Recruiting,All,"8 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Retrophin Investigational Site, Florence, Alabama, United States|Retrophin Investigational Site, Homewood, Alabama, United States|Retrophin Investigational Site, Mesa, Arizona, United States|Retrophin Investigational Site, Phoenix, Arizona, United States|Retrophin Investigational Site, Los Angeles, California, United States|Retrophin Investigational Site, Northridge, California, United States|Retrophin Investigational Site, Palo Alto, California, United States|Retrophin Investigational Site, San Diego, California, United States|Retrophin Investigational Site, San Dimas, California, United States|Retrophin Investigational Site, San Francisco, California, United States|Retrophin Investigational Site, Santa Clarita, California, United States|Retrophin Investigational Site, Torrance, California, United States|Retrophin Investigational Site, Victorville, California, United States|Retrophin Investigational Site, Whittier, California, United States|Retrophin Investigational Site, Aurora, Colorado, United States|Retrophin Investigational Site, Denver, Colorado, United States|Retrophin Investigational Site, Denver, Colorado, United States|Retrophin Investigational Site, Norwich, Connecticut, United States|Retrophin Investigational Site, Wilmington, Delaware, United States|Retrophin Investigational Site, Washington, District of Columbia, United States|Retrophin Investigational Site, Coral Springs, Florida, United States|Retrophin Investigational Site, Fort Lauderdale, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Ocala, Florida, United States|Retrophin Investigational Site, Orlando, Florida, United States|Retrophin Investigational Site, Port Charlotte, Florida, United States|Retrophin Investigational Site, Tampa, Florida, United States|Retrophin Investigational Site, Temple Terrace, Florida, United States|Retrophin Investigational Site, Winter Park, Florida, United States|Retrophin Investigational Site, Atlanta, Georgia, United States|Retrophin Investigational Site, Columbus, Georgia, United States|Retrophin Investigational Site, Lawrenceville, Georgia, United States|Meridian ID, Meridian, Idaho, United States|Retrophin Investigational Site, Chicago, Illinois, United States|Retrophin Investigational Site, Merrillville, Indiana, United States|Retrophin Investigational Site, Iowa City, Iowa, United States|Retrophin Investigational Site, Kansas City, Kansas, United States|Retrophin Investigational Site, Wichita, Kansas, United States|Retrophin Investigational Site, Louisville, Kentucky, United States|Retrophin Investigational Site, Monroe, Louisiana, United States|Retrophin Investigational Site, New Orleans, Louisiana, United States|Retrophin Investigational Site, Shreveport, Louisiana, United States|Retrophin Investigational Site, Portland, Maine, United States|Retrophin Investigational Site, Baltimore, Maryland, United States|Retrophin Investigational Site, Boston, Massachusetts, United States|Retrophin Investigational Site, Boston, Massachusetts, United States|Retrophin Investigational Site, Springfield, Massachusetts, United States|Retrophin Investigational Site, Ann Arbor, Michigan, United States|Retrophin Investigational Site, Minneapolis, Minnesota, United States|Retrophin Investigational Site, Minneapolis, Minnesota, United States|Retrophin Investigational Site, Kansas City, Missouri, United States|Retrophin Investigational Site, Kansas City, Missouri, United States|Retrophin Investigational Site, Saint Louis, Missouri, United States|Retrophin Investigational Site, Lincoln, Nebraska, United States|Retrophin Investigational Site, Las Vegas, Nevada, United States|Retrophin Investigational Site, Reno, Nevada, United States|Retrophin Investigational Site, Hackensack, New Jersey, United States|Retrophin Investigational Site, Bronx, New York, United States|Retrophin Investigational Site, Flushing, New York, United States|Retrophin Investigational Site, New Hyde Park, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, Stony Brook, New York, United States|Retrophin Investigational Site, Chapel Hill, North Carolina, United States|Retrophin Investigational Site, Greenville, North Carolina, United States|Retrophin Investigational Site, Raleigh, North Carolina, United States|Retrophin Investigational Site, Winston-Salem, North Carolina, United States|Retrophin Investigational Site, Akron, Ohio, United States|Retrophin Investigational Site, Cleveland, Ohio, United States|Retrophin Investigational Site, Columbus, Ohio, United States|Retrophin Investigational Site, Oklahoma City, Oklahoma, United States|Retrophin Investigational Site, Bend, Oregon, United States|Retrophin Investigational Site, Roseburg, Oregon, United States|Retrophin Investigational Site, Bethlehem, Pennsylvania, United States|Retrophin Investigational Site, Camp Hill, Pennsylvania, United States|Retrophin Investigational Site, Philadelphia, Pennsylvania, United States|Retrophin Investigational Site, Upland, Pennsylvania, United States|Retrophin Investigational Site, Columbia, South Carolina, United States|Retrophin Investigational Site, Memphis, Tennessee, United States|Retrophin Investigational Site, Nashville, Tennessee, United States|Retrophin Investigational Site, Amarillo, Texas, United States|Retrophin Investigational Site, Corpus Christi, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, El Paso, Texas, United States|Retrophin Investigational Site, Fort Worth, Texas, United States|Retrophin Investigational Site, Houston, Texas, United States|Retrophin Investigational Site, Houston, Texas, United States|Retrophin Investigational Site, Lewisville, Texas, United States|Retrophin Investigational Site, Sherman, Texas, United States|Retrophin Investigational Site, Webster, Texas, United States|Retrophin Investigational Site, Saint George, Utah, United States|Retrophin Investigational Site, Salt Lake City, Utah, United States|Retrophin Investigational Site, Salt Lake City, Utah, United States|Retrophin Investigational Site, Alexandria, Virginia, United States|Retrophin Investigational Site, Fairfax, Virginia, United States|Retrophin Investigational Site, Hampton, Virginia, United States|Retrophin Investigational SIte, Lansdowne Town Center, Virginia, United States|Retrophin Investigational Site, Norfolk, Virginia, United States|Retrophin Investigational Site, Spokane, Washington, United States|Retrophin Investigational Site, Tacoma, Washington, United States|Retrophin Investigational Site, Morgantown, West Virginia, United States|Retrophin Investigational Site, Marshfield, Wisconsin, United States|Retrophin Investigational Site, Milwaukee, Wisconsin, United States|Retrophin Investigational Site, Wauwatosa, Wisconsin, United States|Retrophin Investigational Site, Buenos Aires, Argentina|Retrophin Investigational Site, Córdoba, Argentina|Retrophin Investigational Site, Santa Fe, Argentina|Retrophin Investigational Site, Concord, New South Wales, Australia|Retrophin Investigational Site, New Lambton, New South Wales, Australia|Retrophin Investigational Site, Saint Leonards, New South Wales, Australia|Retrophin Investigational Site, Wollongong, New South Wales, Australia|Retrophin Investigational Site, Birtinya, Queensland, Australia|Retrophin Investigational Site, Woolloongabba, Queensland, Australia|Retrophin Investigational Site, Adelaide, South Australia, Australia|Retrophin Investigational Site, Parkville, Victoria, Australia|Retrophin Investigational Site, Nedlands, Western Australia, Australia|Retrophin Investigational Site, Bruxelles, Belgium|Retrophin Investigational Site, Kortrijk, Belgium|Retrophin Investigational Site, Leuven, Belgium|Retrophin Investigational Site, Liège, Belgium|Retrophin Investigational Site, Roeselare, Belgium|Retrophin Investigational Site, Botucatu, Brazil|Retrophin Investigational Site, Itaquera, Brazil|Retrophin Investigational Site, Porto Alegre, Brazil|Retrophin Investigational Site, São Paulo, Brazil|Retrophin Investigational Site, São Paulo, Brazil|Retrophin Investigational Site, Edmonton, Alberta, Canada|Retrophin Investigational Site, London, Ontario, Canada|Retrophin Investigational Site, Greenfield Park, Quebec, Canada|Retrophin Investigational Site, Montréal, Quebec, Canada|Retrophin Investigational Site, Montréal, Quebec, Canada|Retrophin Investigational Site, Osijek, Croatia|Retrophin Investigational Site, Zagreb, Croatia|Retrophin Investigational Site, Praha 10, Praha, Czechia|Retrophin Investigational Site, Praha 2, Praha, Czechia|Retrophin Investigational Site, Nový Jičín, Czechia|Retrophin Investigational Site, Aarhus, Region Midtjylland, Denmark|Retrophin Investigational Site, Kolding, Southern Denmark, Denmark|Retrophin Investigational Site, Tallinn, Estonia|Retrophin Investigational Site, Tallin, Estonia|Retrophin Investigational Site, Tartu, Estonia|Retrophin Investigational Site, Amiens, France|Retrophin Investigational Site, Bordeaux, France|Retrophin Investigational Site, Brest, France|Retrophin Investigational Site, Clermont-Ferrand, France|Retrophin Investigational Site, Créteil, France|Retrophin Investigational Site, Grenoble Cedex 9, France|Retrophin Investigational Site, Le Kremlin-Bicêtre cedex, France|Retrophin Investigational Site, Le Kremlin-Bicêtre, France|Retrophin Investigational Site, Lille, France|Retrophin Investigational Site, Marseille, France|Retrophin Investigational Site, Nice, France|Retrophin Investigational Site, Paris Cedex 15, France|Retrophin Investigational Site, Paris cedex 15, France|Retrophin Investigational Site, Paris, France|Retrophin Investigational Site, Paris, France|Retrophin Investigational Site, Saint-Priest-en-Jarez, France|Retrophin Investigational Site, Strasbourg, France|Retrophin Investigational Site, Toulouse, France|Retrophin Investigational Site, Valenciennes, France|Retrophin Investigational Site, Düsseldorf, Westfalen, Germany|Retrophin Investigational Site, Aachen, Germany|Retrophin Investigational Site, Berlin, Germany|Retrophin Investigational Site, Heidelberg, Germany|Retrophin Investigational Site, Stuttgart, Germany|Retrophin Investigational Site, Villingen-Schwenningen, Germany|Retrophin Investigational Site, Hong Kong, Hong Kong|Retrophin Investigational Site, Baja, Hungary|Retrophin Investigational Site, Bari, Italy|Retrophin Investigational Site, Bergamo, Italy|Retrophin Investigational Site, Firenze, Italy|Retrophin Investigational Site, Genova, Italy|Retrophin Investigational Site, Lecco, Italy|Retrophin Investigational Site, Milano, Italy|Retrophin Investigational Site, Monza, Italy|Retrophin Investigational Site, Pavia, Italy|Retrophin Investigational Site, Roma, Italy|Retrophin Investigational Site, Verona, Italy|Retrophin Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Busan, Korea, Republic of|Retrophin Investigational Site, Daejeon, Korea, Republic of|Retrophin Investigational Site, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Auckland, New Zealand|Retrophin Investigational Site, Hamilton, New Zealand|Retrophin Investigational Site, Olsztyn, Poland|Retrophin Investigational Site, Olsztyn, Poland|Retrophin Investigational Site, Piotrków Trybunalski, Poland|Retrophin Investigational Site, Warsaw, Poland|Retrophin Investigational Site, Warsaw, Poland|Retrophin Investigational Site, Wrocław, Poland|Retrophin Investigational Site, Wrocław, Poland|Retrophin Investigational Site, Łódź, Poland|Retrophin Investigational Site, Amadora, Portugal|Retrophin Investigational Site, Carnaxide, Portugal|Retrophin Investigational Site, Coimbra, Portugal|Retrophin Investigational Site, Lisboa, Portugal|Retrophin Investigational Site, Lisbon, Portugal|Retrophin Investigational Site, Loures, Portugal|Retrophin Investigational Site, Porto, Portugal|Retrophin Investigational Site, Setúbal, Portugal|Retrophin Investigational Site, Vila Nova De Gaia, Portugal|Retrophin Investigational Site, Palma De Mallorca, Baleares, Spain|Retrophin Investigational Site, Lugo, Burela, Spain|Retrophin Investigational Site, Sagunto, Valencia, Spain|Retrophin Investigational Site, Badalona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Ciudad Real, Spain|Retrophin Investigational Site, Córdoba, Spain|Retrophin Investigational Site, Madrid, Spain|Retrophin Investigational Site, Madrid, Spain|Retrophin Investigational Site, Majadahonda, Spain|Retrophin Investigational Site, Málaga, Spain|Retrophin Investigational Site, Sevilla, Spain|Retrophin Investigational Site, Sevilla, Spain|Retrophin Investigational Site, Valencia, Spain|Retrophin Investigational Site, Valencia, Spain|Retrophin Investigational Site, Zaragoza, Spain|Retrophin Investigational Site, Göteborg, Sweden|Retrophin Investigational Site, Solna, Sweden|Retrophin Investigational Site, Uppsala, Sweden|Retrophin Investigational Site, Hualien City, Taiwan|Retrophin Investigational Site, Kaohsiung City, Taiwan|Retrophin Investigational Site, Kaohsiung, Taiwan|Retrophin Investigational Site, New Taipei City, Taiwan|Retrophin Investigational Site, Taichung, Taiwan|Retrophin Investigational Site, Taichung, Taiwan|Retrophin Investigational Site, Tainan City, Taiwan|Retrophin Investigational Site, Taipei City, Taiwan|Retrophin Investigational Site, Taipei City, Taiwan|Retrophin Investigational Site, Taipei, Taiwan|Retrophin Investigational Site, Taoyuan, Taiwan|Retrophin Investigational Site, Brighton, East Sussex, United Kingdom|Retrophin Investigational Site, Manchester, Greater Manchester, United Kingdom|Retrophin Investigational Site, Leicester, Leicestershire, United Kingdom|Retrophin Investigational Site, Carshalton, London, United Kingdom|Retrophin Investigational Site, Hampstead, London, United Kingdom|Retrophin Investigational Site, Whitechapel, London, United Kingdom|Retrophin Investigational Site, Fulwood, Preston, United Kingdom|Retrophin Investigational Site, Brighton, United Kingdom|Retrophin Investigational Site, Cambridge, United Kingdom|Retrophin Investigational Site, Cardiff, United Kingdom|Retrophin Investigational Site, Glasgow, United Kingdom|Retrophin Investigational Site, Leicester, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, Manchester, United Kingdom|Retrophin Investigational Site, Newcastle, United Kingdom|Retrophin Investigational Site, Reading, United Kingdom|Retrophin Investigational Site, Salford, United Kingdom|Retrophin Investigational Site, Swansea, United Kingdom|Retrophin Investigational Site, York, United Kingdom",5270317,C07D231/12,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
[C-]#[O+],ACUTE RESPIRATORY DISTRESS SYNDROME,_CARBON_MONOXIDE,NCT03799874,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,SMALL CELL LUNG CANCER,_VENETOCLAX,NCT04422210,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke Cancer Institute, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO, L'Hospitalet de Llobregat, Barcelona, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain",8546399,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,GLIOBLASTOMA MULTIFORME,_SELINEXOR,NCT04421378,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami, Florida, United States|Hackensack Meridian Health, 92 Second Street, Hackensack, New Jersey, United States|Columbia University Irving Medical Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=NN(CCCl)C(=O)NC1CCCCC1,GLIOBLASTOMA MULTIFORME,_LOMUSTINE,NCT04421378,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami, Florida, United States|Hackensack Meridian Health, 92 Second Street, Hackensack, New Jersey, United States|Columbia University Irving Medical Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",4631289,C07D233/91,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,42.9084786135238,262.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.62,233.695,61.77,2.0,1.0,1.0,23.61,58.65,4.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,CORONAVIRUS INFECTION,_SELINEXOR,NCT04349098,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom",9079865,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BIRTH ASPHYXIA,_SILDENAFIL,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,BIRTH ASPHYXIA,_SILDENAFIL_CITRATE,NCT04169191,Phase 1,Recruiting,All,up to 2 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Children's Hospital, Montréal, Quebec, Canada",WO-1999030688-A1,A61K9/19,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BRONCHOPULMONARY DYSPLASIA,_SILDENAFIL,NCT03142568,Phase 2,Recruiting,All,up to 28 Days   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Children's Hospital of Nevada at UMC, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Kings County Hospital Center, Brooklyn, New York, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Golisano Children's Hospital - University of Rochester Medical Center, Rochester, New York, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,INFECTIVE ENDOCARDITIS,_RIFAMPIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",3963705,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,INFECTIVE ENDOCARDITIS,_LEVOFLOXACIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",5053407,C07D413/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,INFECTIVE ENDOCARDITIS,_OXACILLIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",4199566,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,1121.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.436,112.74,5.0,2.0,4.0,39.61,101.83,4.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
NC(=O)N1c2ccccc2C=Cc2ccccc21,TRIGEMINAL NEURALGIA,_CARBAMAZEPINE,NCT03580317,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","the Third affiliated hospital of Zhejiang Chinese Medical university, Hangzhou, Zhejiang, China",5284662,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,25.7910840058317,220.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1,236.2686,46.33,1.0,1.0,3.0,25.0,71.89,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,LENNOX-GASTAUT SYNDROME,_RUFINAMIDE,NCT02175173,,Recruiting,All,"Child, Adult, Older Adult",Industry,Observational Model: Other|Time Perspective: Retrospective,"Osaka, Japan|Tokyo, Japan",6740669,C07D249/04,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,AMYOTROPHIC LATERAL SCLEROSIS,_PERAMPANEL,NCT03793868,Early Phase 1,Completed,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Mayo Clinic, Jacksonville, Florida, United States",6949571,C07D409/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,51.6478777798312,55.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.54,349.39300000000014,56.99,3.0,0.0,4.0,38.03,104.74,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,ESOPHAGEAL VARICES,_CARVEDILOL,NCT04499898,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sherief Abd-Elsalam, Tanta, Egypt",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,TRIGEMINAL NEURALGIA,_GUANFACINE,NCT03865940,Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",5854290,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,39.2615864802152,71.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.28,246.093,78.97,3.0,3.0,1.0,21.75,69.63,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,PRIMARY OPEN ANGLE GLAUCOMA,_TIMOLOL,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,PRIMARY OPEN ANGLE GLAUCOMA,_DORZOLAMIDE,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12,PRIMARY OPEN ANGLE GLAUCOMA,_BRIMONIDINE,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",5424078.0,A61K47/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",_TIMOLOL,NCT04149899,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Eye Research Foundation, Newport Beach, California, United States",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,OPEN ANGLE GLAUCOMA,_LATANOPROST,NCT04060758,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bendigo Eye Clinic, Bendigo, Victoria, Australia|Essendon Eye Clinic, Essendon, Victoria, Australia|Melbourne Eye Specialists, Fitzroy, Victoria, Australia|PersonalEYES, Parramatta, Victoria, Australia|Eyes First, Springvale, Victoria, Australia",5296504,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BIMATOPROST,NCT04285580,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eye Center South, Dothan, Alabama, United States|Eye Research Foundation, Newport Beach, California, United States|Scott & Christie and Associates, Cranberry Township, Pennsylvania, United States|Keystone Research LTD, Austin, Texas, United States",6403649,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,LYMPHOMA,_FAMOTIDINE,NCT03647072,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Cairo, Egypt",5075114,A61K9/5047,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,PERIPARTUM CARDIOMYOPATHY,_BROMOCRIPTINE,NCT02590601,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Heart Institute, Monteal, Quebec, Canada",5468755,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,ACUTE MYELOID LEUKEMIA,_TALAZOPARIB,NCT02878785,Phase 1|Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States",8012976,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.93,380.359,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,PULMONARY HYPERTENSION,_ALBUTEROL,NCT03270332,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",5775321,B65D83/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,SMALL CELL LUNG CANCER,_RUCAPARIB,NCT03958045,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States",6495541,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,OSTEO ARTHRITIS OF THE KNEES,_TRIAMCINOLONE_HEXACETONIDE,NCT04231318,Phase 3,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Tucson Orthopaedic Institute, Tucson, Arizona, United States|Ascension Research LLC, Pinellas Park, Florida, United States",4279900,C07J71/0031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,67.0,23.8197909608,351.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,ACUTE MYELOID LEUKEMIA,_ATOVAQUONE,NCT03568994,Early Phase 1,Recruiting,All,"1 Month to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Medicine, Baltimore, Maryland, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",5998449,1,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,25.199696092322196,296.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.74,366.837,54.37,3.0,1.0,4.0,39.64,103.11,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,GLAUCOMA,_HYALURONATE,NCT03758859,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Western Eye Hospital, London, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,"RESPIRATORY DISTRESS SYNDROME, ADULT",_ILOPROST,NCT03111212,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Tuebingen, Tuebingen, Germany",EP-1089970-B1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,OVARIAN CANCER,_FOSTAMATINIB,NCT03246074,Phase 1,Recruiting,Female,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",7449458,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,AMYOTROPHIC LATERAL SCLEROSIS,_CLENBUTEROL,NCT04245709,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical center, Durham, North Carolina, United States",4386062,A61K49/0006,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,511.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,277.19,58.28,3.0,3.0,1.0,28.81,73.38,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,"HYPERTENSION, PULMONARY",_SELEXIPAG,NCT04175600,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA Medical Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Congenital Heart Center of the University of Florida, Gainesville, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Detroit Medical Center, Detroit, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Virginia Division of Pediatric Cardiology, Charlottesville, Virginia, United States|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao, Blumenau, Brazil|Hospital Pequeno Principe, Curitiba, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|Hospital São Paulo-UNIFESP, Sao Paulo, Brazil|Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead, Sofia, Bulgaria|Hospital For Sick Children, Toronto, Ontario, Canada|Stollery Children's Hospital, Edmonton, Canada|Centre Hospitalier Sainte Justine, Montreal, Canada|Beijing Anzhen Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Guangzhou Women And Children's Medical Center, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Children's Hospital of Fudan University, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China|Clinica San Rafael, Bogota, Colombia|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Colombia|Clinica Vascular las Americas, Medellin, Colombia|Hospital Universidad del Norte, Soledad, Colombia|Rigshospitalet, Copenhagen Ø, Denmark|New Children's Hospital of the Helsinki University Hospital (HUS), Helsinki, Finland|Hôpital Cardiologique - Chru Lille, Lille Cedex, France|Hopital de la Timone, Marseille Cedex 5, France|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|Universtà Degli Studi Di Padova, Padova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita, Torino, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania|National Heart Institute, Kuala Lumpur, Malaysia|CICUM San Miguel, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Slaskie Centrum Chorob Serca, Zabrze, Poland|Hospital De Santa Marta, Lisboa, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Kazan State Medical University, Kazan, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Children's City Clinical Hospital n.a. Baslyaeva, Moscow, Russian Federation|Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU, Moscow, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Tyumen Regional Hospital #1, Tyumen, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Drottning Silvias barn- och ungdomssjukhus, Gothenburg, Sweden|Skanes universitetssjukhus, Lund, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chiang Mai University Hospital, Chiang Mai, Thailand|Cukurova Balcali Hospital Application and Research Center, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|CAPA Istanbul University Medical Faculty, Istanbul, Turkey|Mehmet Akif Ersoy Training and Research Hospital, Istanbul, Turkey|Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital, Izmir, Turkey|Izmir Tepecik Training and Research Hospital, Izmir, Turkey|Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev, Dnipro, Ukraine|MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery', Dnipro, Ukraine|Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH, Kyiv, Ukraine|Communal Non-commercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|MI Zaporizhzhia Regional Clinical Children's Hospital of Zaporizhzhia Regional Council, Zaporizhzhya, Ukraine|Hanoi Medical University Hospital, Hanoi, Vietnam|Tam Duc Cardiology Hospital, Ho Chi Minh, Vietnam|Children's Hospital 1, Ho Chi Minh, Vietnam",7205302,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,59.7301792644612,38.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.4,496.63,101.49,7.0,1.0,3.0,54.98,136.81,11.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Cc1ncc(CO)c(CN)c1O,ABDOMINAL OBESITY METABOLIC SYNDROME,_PYRIDOXAMINE,NCT02954588,Not Applicable,Completed,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Maastricht University Medical Center, Maastricht, Netherlands",4046879,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,18.201605782459602,128.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.2,168.1931,79.37,4.0,3.0,1.0,17.53,45.76,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
C[S@@](=O)CCCCN=C=S,ALZHEIMER DISEASE,_SULFORAPHANE,NCT04213391,Not Applicable,Recruiting,All,"50 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Second Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",5411986,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,25.659664469496196,283.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.24,177.28,29.43,2.0,0.0,0.0,19.12,49.57,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,EPIDERMOLYSIS BULLOSA,_SERLOPITANT,NCT03836001,Phase 2,Recruiting,All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Redwood City, California, United States",US-20100209496-A1,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.29,555.5369999999998,29.54,3.0,0.0,5.0,51.54,134.58,7.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
CN1CC[C@]2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)[C@H]12,ALZHEIMER DISEASE,_POSIPHEN,NCT02925650,Phase 1|Phase 2,Recruiting,All,"55 Years to 85 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSD Alzheimer's Disease Research Center, La Jolla, California, United States|IU Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington University Sleep Medicine Center, Brentwood, Missouri, United States|Columbia University Medical Center Sergievsky Center Taub Institute, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.38,337.423,44.81,4.0,1.0,4.0,37.5,99.96,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,FRAGILE X SYNDROME,_AZD7325,NCT03140813,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",US-20070142328-A1,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,TRIGEMINAL NEURALGIA,_RIMEGEPANT,NCT03941834,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins University, Baltimore, Maryland, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,25.298260744573806,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.68,534.568,113.68,5.0,2.0,6.0,54.23,139.58,4.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,JUVENILE IDIOPATHIC ARTHRITIS,_BARICITINIB,NCT03773978,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto CAICI SRL, Rosario, Santa Fe, Argentina|Centro Medico Privado de Reumatologia, SAN M. DE Tucuman, Tucuman, Argentina|Hospital General de Niños Dr. Pedro de Elizalde, Buenos Aires, Argentina|The Sydney Children's Hospitals Network, Westmead, New South Wales, Australia|Royal Childrens Hospital Melbourne, Parkville, Victoria, Australia|Perth Children's Hospital, Nedlands, Western Australia, Australia|LKH Bregenz, Bregenz, Vorarlberg, Austria|AKH, Wien, Austria|UCL- Saint Luc, Brussels, Brussels-Capital, Belgium|UZ Gent-Reuma, Gent, East Flanders, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, Minas Gerais, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo, Brazil|Faculdade de Ciências Médicas - UNICAMP, Campinas, Sao Paulo, Brazil|Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil|Children's hospital of Nanjing, Nanjing, Jiangsu, China|Children's Hospital of Chongqing Medical University, Chongqing, Tianjin City, China|Capitol Institute of Pediatrics Children'S Hospital, Beijing, China|Beijing Children's hospital, Capital Medical University, Beijing, China|Children's Hospital of Soochow University, Suzhou, China|Centrum detske revmatologie VFN, Klinika detskeho a dorostoveho lekarstvi 1.LFUK a VFN v Praze, Prague, Czechia|Fakultni Nemocnice v Motole, Praha 5, Czechia|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Paediatric rheumatology Unit, København Ø, Denmark|Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Bron, France|Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France|Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France|GH Necker - Enfants Malades, Paris Cedex 15, France|CHU la Miletrie, Poitiers, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Asklepios Klinik Sankt Augustin, Saint Augustin, Nordrhein-Westfalen, Germany|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Schön Klinik Hamburg Eilbek, Hamburg, Germany|Sri Ramachandra MedicaL College & Research Institute, Porur, Chennai, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Christian Medical College Vellore, Vellore, Tamil Nadu, India|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India|Rambam Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Schneider Children's Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Ramat Gan, Israel|A.O.U. Ospedali Riuniti- Presidio ""G. Salesi"" -Reumatologia Pediatrica, Ancona, Italy|ASST Spedali Civili - Università degli Studi, Brescia, Italy|Ospedale SS. Annunziata, Chieti, Italy|Azienda Ospedaliero Universitaria Meyer, Firenze, Italy|Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliera - Universitaria Pisana, Pisa, Italy|Ospedale Infantile Burlo Garofolo, Trieste, Italy|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Miyagi Children's Hospital, Sendai, Miyagi, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Saitama Children's Medical Center, Saitama-shi, Saitama, Japan|Tokyo Medical And Dental University Medical Hospital, Bunkyō, Tokyo, Japan|St. Lukes International Hospital, Chuo-Ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Kagoshima University Hospital, Kagoshima, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Clinstile, S.A. de C.V., Cuauhtemoc, Federal District, Mexico|CREA de Guadalajara, S.C., Guadalajara, Jalisco, Mexico|Hospital Univ. ""Dr. José Eleuterio González"", Monterrey, Nuevo León, Mexico|Investigacion y Biomedicina de Chihuahua, Chihuahua, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C, Durango, Mexico|Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie, Krakow, Poland|CSK, Uniwersyteckie Centrum Pediatrii im.M.Konopnickiej,Klinika Kardiologii i Reumatologii Dzieciecej, Lodz, Poland|Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji, Warszawa, Poland|V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation|Morozovsky Children's City Clinical Hospital, Moscow, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Scientific Center of Children's Health, Moscow, Russian Federation|Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Cataluna, Spain|Complexo Hospitalario Universitario A Coruña, CHUAC, La Coruña, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Dokuz Eylul University Hospital, Izmir, Turkey|University College Hospital - London, London, Greater London, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, Bloomsbury, London, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Bristol Royal Hospital for Children, Bristol, United Kingdom|Alder Hey Children's Hospital, Liverpool, United Kingdom",8158616,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
COc1cc(CC(C)N)c(OC)cc1C,FUCHS' ENDOTHELIAL DYSTROPHY,_DOM,NCT02542644,Not Applicable,Recruiting,All,"18 Years to 98 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria|Vienna Institute for Research in Ocular Surgery (VIROS), Vienna, Austria",WO-1998042331-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,GASTROPARESIS,_BUSPIRONE,NCT03587142,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Louisville, Louisville, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|Texas Tech University Health Science Center, El Paso, Texas, United States",3976776.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
FCOC(C(F)(F)F)C(F)(F)F,HEART DISEASE,_SEVOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",5990176,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
FC(F)OC(Cl)C(F)(F)F,HEART DISEASE,_ISOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,AORTIC VALVE STENOSIS,_EDOXABAN,NCT04171726,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",7365205,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,CANCER,_CYCLOPHOSPHAMIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CANCER,_SIROLIMUS,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5212155,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,CANCER,_ETOPOSIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CANCER,_CELECOXIB,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,CANCER,_GEMCITABINE,NCT03507491,Phase 1,Recruiting,All,"6 Months to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,ALZHEIMER DISEASE,_BREXPIPRAZOLE,NCT03594123,Phase 3,Recruiting,All,"55 Years to 91 Years   (Adult, Older Adult)",Industry,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding sites, contact 844-687-8522, Miami, Florida, United States",7888362,C07D409/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,58.1531448284359,25.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.38,433.57,44.81,4.0,1.0,5.0,49.48,129.16,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,CANCER,_GEFITINIB,NCT02929693,Phase 3,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5457105.0,C07D239/94,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,OBSESSIVE COMPULSIVE DISORDER,_TOLCAPONE,NCT03348930,Phase 2|Phase 3,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",5236952.0,C07D265/36,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,28.0580710076182,226.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.63,273.2408,103.35,5.0,2.0,2.0,26.44,72.96,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,TRAUMATIC BRAIN INJURY,_BIPERIDEN,NCT01048138,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of São Paulo, Sao Paulo, Brazil",4863738,A61K9/7053,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,21.421384422678003,236.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.28,311.4611,23.47,2.0,1.0,4.0,36.88,97.02,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,TRIGEMINAL NEURALGIA,_FOSPHENYTOIN,NCT03712254,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Danish Headache Center, Rigshospitalet - Glostrup, Glostrup, Denmark",4260769,C07D233/72,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,23.425532351793603,147.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.08,362.2739,116.17,5.0,3.0,3.0,33.23,87.05,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
